UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2019~~

2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission file number:

001-36167

Karyopharm Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware		26-3931704
~~Delaware~~		~~26-3931704~~
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

85 Wells Avenue, 2nd Floor Newton, , MA		02459
(Address of principal executive offices)		(Zip Code)

(

~~617~~

)

(617) 658-0600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, , $0.0001 par value	KPTI	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such ~~~~reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

☒

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§ (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

☒

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule

12b-2

of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act). Yes

☐

☒

As of ~~October 29, 2019,~~July 30, 2020, there were ~~62,790,043~~73,478,203 shares of Common Stock, $0.0001 par value per share, outstanding.

~~Table of Contents~~

TABLE OF CONTENTS

	PART I - FINANCIAL INFORMATION
	~~PART I—FINANCIAL INFORMATION~~

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Operations	4
	Condensed Consolidated Statements of Comprehensive Loss	5
	Condensed Consolidated Statements of Cash Flows	6
	Condensed Consolidated Statements of Stockholders’ Equity	7
	Notes to Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36	27
Item 4.	Controls and Procedures	36	28

	PART ~~II—~~II - OTHER INFORMATION

Item 1.	Legal Proceedings	37	29
Item ~~1.A.~~ 1A.	Risk Factors	37	29
Item 6.	Exhibits	78	73
	Signatures	79	74

~~Table of Contents~~

PART I—I - FINANCIAL INFORMATION

~~Item 1.~~

~~Condensed Consolidated Financial Statements (Unaudited).~~

~~Karyopharm Therapeutics Inc.~~

Item 1. Condensed Consolidated Financial Statements (Unaudited).

KARYOPHARM THERAPEUTICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except ~~share and~~ per share amounts)

	June 30, 2020			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	103,102		$	128,858
Short-term investments		193,615			133,098
Accounts receivable		9,581			7,862
Inventory		1,652			346
Prepaid expenses and other current assets		7,971			7,289
Restricted cash		1,915			1,117
Total current assets		317,836			278,570
Property and equipment, net		2,592			3,046
Operating lease right-of-use assets		10,013			10,617
Long-term investments		48,856			2,016
Restricted cash		714			714
Total assets	$	380,011		$	294,963
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,888		$	985
Accrued expenses		45,979			40,878
Deferred revenue		297			2,341
Operating lease liabilities		1,778			1,646
Other current liabilities		628			500
Total current liabilities		50,570			46,350
Convertible senior notes		113,776			109,857
Deferred royalty obligation		73,588			73,588
Operating lease liabilities, net of current portion		12,278			13,202
Deferred revenue, net of current portion		—			2,192
Total liabilities		250,212			245,189
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000 shares authorized; NaN issued and outstanding		—			—
Common stock, $0.0001 par value; 200,000 shares authorized; 73,366 and 65,370 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively		7			7
Additional paid-in capital		1,101,596			923,142
Accumulated other comprehensive income (loss)		891			(37	)
Accumulated deficit		(972,695	)		(873,338	)
Total stockholders’ equity		129,799			49,774
Total liabilities and stockholders’ equity	$	380,011		$	294,963

September 30,
2019

December 31,
2018

Assets









Current assets:

Cash and cash equivalents
$
168,004
$
118,021

Short-term investments

99,525

210,178

Accounts receivable

7,928

—

Inventory

100

—

Prepaid expenses and other current assets

5,310

6,413

Total current assets

280,867

334,612

Property and equipment, net

3,240

3,863

Operating lease
right-of-use
assets

10,904

—

Long-term investments

2,022

2,001

Restricted cash

712

716

Total assets
$
297,745
$
341,192

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable
$
3,068
$
4,332

Accrued expenses

32,421

32,493

Deferred revenue

1,053

9,362

Operating lease liabilities

1,583

—

Deferred rent

—

390

Other current liabilities

1,077

327

Total current liabilities

39,202

46,904

Convertible senior notes

107,962

102,664

Deferred royalty obligation

73,589

—

Operating lease liabilities, net of current portion

13,643

—

Deferred revenue, net of current portion

3,479

4,532

Deferred rent, net of current portion

—

3,922

Total liabilities

237,875

158,022

Stockholders’ equity:

Preferred stock, $0.0001 par value; 5,000,000 shares authorized;
NaN
issued and outstanding

—

—

Common stock, $0.0001 par value; 200,000,000 shares authorized; 62,705,481 shares issued and outstanding at September 30, 2019; 100,000,000 shares authorized; 60,829,308 shares issued and outstanding at December 31, 2018

6

6

Additional
paid-in
capital

884,585

857,156

Accumulated other comprehensive loss

(30
)
(244
)
Accumulated deficit

(824,691
)
(673,748
)

Total stockholders’ equity

59,870

183,170

Total liabilities and stockholders’ equity
$
297,745
$
341,192

See accompanying notes to condensed consolidated financial statements.

~~Table of Contents~~

~~Karyopharm Therapeutics Inc.~~

KARYOPHARM THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except ~~share and~~ per share amounts)

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Revenues:
Product revenue, net	$	18,601		$	—		$	34,662		$	—
License and other revenue		14,913			9,493			16,990			9,648
Total revenues		33,514			9,493			51,652			9,648
Operating expenses:
Cost of sales		396			—			1,215			—
Research and development		42,594			26,517			76,591			64,491
Selling, general and administrative		30,843			24,662			61,521			51,765
Total operating expenses		73,833			51,179			139,327			116,256
Loss from operations		(40,319	)		(41,686	)		(87,675	)		(106,608	)
Other income (expense):
Interest income		849			1,412			1,824			3,183
Interest expense		(6,758	)		(3,089	)		(13,267	)		(6,087	)
Other expense, net		(61	)		(44	)		(36	)		(46	)
Total other expense, net		(5,970	)		(1,721	)		(11,479	)		(2,950	)
Loss before income taxes		(46,289	)		(43,407	)		(99,154	)		(109,558	)
Income tax provision		(137	)		(8	)		(203	)		(18	)
Net loss	$	(46,426	)	$	(43,415	)	$	(99,357	)	$	(109,576	)
Net loss per share—basic and diluted	$	(0.63	)	$	(0.71	)	$	(1.41	)	$	(1.80	)
Weighted-average number of common shares outstanding used in net loss per share—basic and diluted		73,237			60,929			70,475			60,893

Three Months Ended,
September 30,

Nine Months Ended
September 30,

2019

2018

2019

2018
Revenues:
















Product revenue, net
$
12,821
$
—
$
12,821
$
—

License and other revenue

328

239

9,976

30,130

Total revenues

13,149

239

22,797

30,130

Operating expenses:

Cost of sales

1,013

—

1,013

—

Research and development

26,270

36,427

90,761

122,482

Selling, general and administrative

25,267

12,966

77,032

30,076

Total operating expenses

52,550

49,393

168,806

152,558

Loss from operations

(39,401
)
(49,154
)
(146,009
)
(122,428
)
Other income (expense):

Interest income

1,137

1,098

4,320

2,260

Interest expense

(3,093
)
—

(9,180
)
—

Other income (expense)

10

(13
)
(36
)
(20
)

Total other (expense) income, net

(1,946
)
1,085

(4,896
)
2,240

Loss before income taxes

(41,347
)
(48,069
)
(150,905
)
(120,188
)
Income tax provision

(20
)
(14
)
(38
)
(9
)
��
Net loss
$
(41,367
) $
(48,083
) $
(150,943
) $
(120,197
)

Net loss per share—basic and diluted
$
(0.67
) $
(0.79
) $
(2.46
) $
(2.17
)

Weighted-average number of common shares outstanding used in net loss per share—basic and diluted

62,092,841

60,586,511

61,297,249

55,465,261

See accompanying notes to condensed consolidated financial statements.

~~Table of Contents~~

~~Karyopharm Therapeutics Inc.~~

KARYOPHARM THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)

(in thousands)

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Net loss	$	(46,426	)	$	(43,415	)	$	(99,357	)	$	(109,576	)
Comprehensive income (loss)
Unrealized gain on investments		1,273			52			959			309
Foreign currency translation adjustment		38			37			(31	)		(4	)
Comprehensive loss	$	(45,115	)	$	(43,326	)	$	(98,429	)	$	(109,271	)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2019

2018

2019

2018
Net loss


$
(41,367
)



$
(48,083
)



$

(150,943
)



$
(120,197
)


Comprehensive income (loss)

Unrealized (loss) gain on investments

(59
)
110

250

105

Foreign currency translation adjustments

(32
)
(3
)
(36
)
(41
)

Comprehensive loss
$
(41,458
) $
(47,976
) $
(150,729
) $

(120,133
)

See accompanying notes to condensed consolidated financial statements.

~~Table of Contents~~

~~Karyopharm Therapeutics Inc.~~

KARYOPHARM THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

	Six Months Ended June 30,
	2020			2019
Operating activities
Net loss	$	(99,357	)	$	(109,576	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		480			487
Net amortization of premiums and discounts on investments		89			(968	)
Amortization of debt discount and issuance costs		3,919			3,493
Stock-based compensation expense		11,580			8,023
Changes in operating assets and liabilities:
Accounts receivable		(1,719	)	—
Inventory		(1,306	)	—
Prepaid expenses and other current assets		(682	)		742
Operating lease right-of-use assets		605			531
Accounts payable		903			(3,171	)
Accrued expenses and other liabilities		5,228			(4,580	)
Deferred revenue		(4,236	)		(9,362	)
Operating lease liabilities		(792	)		(446	)
Net cash used in operating activities		(85,288	)		(114,827	)
Investing activities
Purchases of property and equipment		(26	)		(49	)
Proceeds from maturities of investments		99,286			118,511
Purchases of investments		(205,773	)		(46,668	)
Net cash (used in) provided by investing activities		(106,513	)		71,794
Financing activities
Proceeds from issuance of common stock, net of issuance costs		161,803		—
Proceeds from the exercise of stock options and shares issued under employee stock purchase plan		5,072			547
Net cash provided by financing activities		166,875			547
Effect of exchange rate on cash, cash equivalents and restricted cash		(32	)		9
Net decrease in cash, cash equivalents and restricted cash		(24,958	)		(42,477	)
Cash, cash equivalents and restricted cash at beginning of period		130,689			118,737
Cash, cash equivalents and restricted cash at end of period	$	105,731		$	76,260
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets
Cash and cash equivalents	$	103,102		$	75,545
Short-term restricted cash		1,915			—
Long-term restricted cash		714			715
Total cash, cash equivalents and restricted cash	$	105,731		$	76,260
Supplemental disclosures:
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$	—		$	11,711
Cash paid for amounts included in the measurement of operating lease liabilities	$	1,592		$	1,319
Cash paid for interest on deferred royalty obligation	$	2,400		$	—

Nine Months Ended
September 30,

2019

2018
Operating activities

Net loss


$
(150,943
)



$
(120,197
)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

730

541

Net amortization of premiums and discounts on investments

(1,242
)
280

Amortization of debt discount and issuance costs

5,298

—

Stock-based compensation expense

11,742

13,378

Changes in operating assets and liabilities:

Accounts
r
eceivable

(7,928
)
—

Inventory

(100
)
—

Prepaid expenses and other current assets

1,108

(3,039
)
Operating lease
right-of-use
assets

807

—

Accounts payable

(1,215
)
(3,425
)
Accrued expenses and other liabilities

569

8,139

Operating lease liabilities

(797
)
—

Deferred revenue

(9,362
)
(8,027
)
Deferred rent

—

1,405

Net cash used in operating activities

(151,333
)
(110,945
)
Investing activities

Purchases of property and equipment

(156
)
(1,270
)
Proceeds from maturities of investments

202,454

94,378

Purchases of investments

(90,329
)
(97,662
)

Net cash provided by (used in) investing activities

111,969

(4,554
)
Financing activities

Proceeds from the issuance of common stock, net of issuance costs

14,563

145,706

Proceeds from the exercise of stock options and shares issued under employee stock purchase plan

1,124

2,627

Proceeds from deferred royalty obligation, net

73,682

—

Net cash provided by financing activities

89,369

148,333

Effect of exchange rate on cash, cash equivalents and restricted cash

(26
)
(9
)

Net increase in cash, cash equivalents and restricted cash

49,979

32,825

Cash, cash equivalents and restricted cash at beginning of period

118,737

69,487

Cash, cash equivalents and restricted cash at end of period
$
168,716
$
102,312

Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets

Cash and cash equivalents
$
168,004
$
101,600

Long-term restricted cash

712

712

Total cash, cash equivalents and restricted cash
$
168,716
$
102,312

Supplemental disclosures:

Deferred financing costs in
a
ccrued expenses at period end
$
93
$
—

Operating lease
right-of-use
assets obtained in exchange for operating lease liabilities
$
11,711
$
—

Cash paid for amounts included in the measurement of operating lease liabilities
$
2,096
$
—

See accompanying notes to condensed consolidated financial statements.

~~Table of Contents~~

~~Karyopharm Therapeutics Inc.~~

KARYOPHARM THERAPEUTICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in ~~thousands, except share amounts)~~thousands)

	Common Shares
	Shares		Amount		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit			Total Stockholders’ Equity
Balance at March 31, 2020		73,095	$	7	$	1,092,829	$	(420	)	$	(926,269	)	$	166,147
Vesting of restricted stock		—		—		—		—			—			—
Exercise of stock options and shares issued under the employee stock purchase plan		271		—		2,339		—			—			2,339
Stock-based compensation expense		—		—		6,428		—			—			6,428
Unrealized gain on investments		—		—		—		1,273			—			1,273
Foreign currency translation adjustment		—		—		—		38			—			38
Net loss		—		—		—		—			(46,426	)		(46,426	)
Balance at June 30, 2020		73,366	$	7	$	1,101,596	$	891		$	(972,695	)	$	129,799

Balance at March 31, 2019		60,864	$	6	$	861,215	$	(28	)	$	(739,909	)	$	121,284
Vesting of restricted stock		—		—		—		—			—			—
Exercise of stock options and shares issued under the employee stock purchase plan		101		—		395		—			—			395
Stock-based compensation expense		—		—		4,116		—			—			4,116
Unrealized gain on investments		—		—		—		52			—			52
Foreign currency translation adjustment		—		—		—		37			—			37
Net loss		—		—		—		—			(43,415	)		(43,415	)
Balance at June 30, 2019		60,965	$	6	$	865,726	$	61		$	(783,324	)	$	82,469

Balance at December 31, 2019		65,370	$	7	$	923,142	$	(37	)	$	(873,338	)	$	49,774
Vesting of restricted stock		189		—		—		—			—			—
Exercise of stock options and shares issued under the employee stock purchase plan		619		—		5,072		—			—			5,072
Stock-based compensation expense		—		—		11,580		—			—			11,580
Issuance of common stock, net of issuance costs		7,188		—		161,802		—			—			161,802
Unrealized gain on investments		—		—		—		959			—			959
Foreign currency translation adjustment		—		—		—		(31	)		—			(31	)
Net loss		—		—		—		—			(99,357	)		(99,357	)
Balance at June 30, 2020		73,366	$	7	$	1,101,596	$	891		$	(972,695	)	$	129,799

Balance at December 31, 2018		60,829	$	6	$	857,156	$	(244	)	$	(673,748	)	$	183,170
Vesting of restricted stock		5		—		—		—			—			—
Exercise of stock options and shares issued under the employee stock purchase plan		131		—		547		—			—			547
Stock-based compensation expense		—		—		8,023		—			—			8,023
Unrealized gain on investments		—		—		—		309			—			309
Foreign currency translation adjustment		—		—		—		(4	)		—			(4	)
Net loss		—		—		—		—			(109,576	)		(109,576	)
Balance at June 30, 2019		60,965	$	6	$	865,726	$	61		$	(783,324	)	$	82,469

Common Shares

Shares

Amount

Additional
Paid-In
Capital

Accumulated
Other
Comprehensive
Income
(Loss)

Accumulated
Deficit

Total
Stockholders’
Equity
Balance at June 30, 2019



60,965,505




$
6




$
865,726




$
61





$
(783,324
)




$
82,469


Vesting of restricted stock

5,000

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

100,525

—

577

—

—

577

Issuance of common stock, net of issuance costs of $0.3 million

1,634,451

—

14,563

—

—

14,563

Stock-based compensation expense

—

—

3,719

—

—

3,719

Unrealized loss on investments

—

—

—

(59
)
—

(59
)
Foreign currency translation adjustment

—

—

—

(32
)
—

(32
)
Net loss

—

—

—

—

(41,367
)
(41,367
)

Balance at September 30, 2019

62,705,481
$
6
$
884,585
$
(30
) $
(824,691
) $
59,870

Balance at June 30, 2018

60,501,260
$
6
$
781,176
$
(260
) $
(567,455
) $
213,467

Vesting of restricted stock

—

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

163,597

—

812

—

—

812

Stock-based compensation expense

—

—

4,775

—

—

4,775

Unrealized gain on investments

—

—

—

110

—

110

Foreign currency translation adjustment

—

—

—

(3
)
—

(3
)
Net loss

—

—

—

—

(48,083
)
(48,083
)

Balance at September 30, 2018

60,664,857
$
6
$
786,763
$
(153
) $
(615,538
) $
171,078

Balance at December 31, 2018

60,829,308
$
6

857,156
$
(244
) $
(673,748
) $
183,170

Vesting of restricted stock

10,000

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

231,722

—

1,124

—

—

1,124

Issuance of common stock, net of issuance costs of $0.3 million

1,634,451

—

14,563

—

—

14,563

Stock-based compensation expense

—

—

11,742

—

—

11,742

Unrealized gain on investments

—

—

—

250

—

250

Foreign currency translation adjustment

—

—

—

(36
)
—

(36
)
Net loss

—

—

—

—

(150,943
)
(150,943
)

Balance at September 30, 2019

62,705,481
$
6
$
884,585
$
(30
) $
(824,691
) $
59,870

Balance at December 31, 2017

49,533,150
$
5
$
625,053
$
(217
) $
(495,341
) $
129,500

Vesting of restricted stock

103,800

—

—

—

—

—

Exercise of stock options and shares issued under the employee stock purchase plan

502,483

—

2,627

—

—

2,627

Issuance of common stock, net of issuance costs of $0.2 million

10,525,424

1

145,705

—

—

145,706

Stock-based compensation expense

—

—

13,378

—

—

13,378

Unrealized gain on investments

—

—

—

105

—

105

Foreign currency translation adjustment

—

—

—

(41
)
—

(41
)
Net loss

—

—

—

—

(120,197
)
(120,197
)

Balance at September 30, 2018

60,664,857
$
6
$
786,763
$
(153
) $
(615,538
) $
171,078

See accompanying notes to condensed consolidated financial statements.

~~Table of Contents~~

~~Karyopharm Therapeutics Inc.~~

KARYOPHARM THERAPEUTICS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. ~~Summary~~Nature of ~~Significant Accounting Policies~~

Business and Basis of Presentation

Nature of Business

Karyopharm Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the “Company,” “we,” “us,” or “our”), is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of novel, first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. We were incorporated in Delaware on December 22, 2008 and have a principal place of business in Newton, Massachusetts. Our Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein exportin 1 (“XPO1”). Our initial focus has been on seeking the regulatory approval and commercialization of our lead SINE compound, selinexor, as an oral agent in cancer indications with significant unmet clinical need. In July 2019, the U.S. Food and Drug Administration (“FDA”) approved XPOVIO^®(selinexor) tablets in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. XPOVIO became commercially available in the U.S. in July 2019. In June 2020, the FDA approved XPOVIO for a second indication to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. We began commercialization of XPOVIO for this indication in June 2020.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of ~~Karyopharm Therapeutics Inc., a Delaware corporation,~~the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation

S-X,

Rule

10-01.

Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In ~~our~~the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, ~~2019.~~2020. For further information, refer to the financial statements and footnotes included in our Annual Report on Form

10-K

for the year ended December 31, ~~2018~~2019 as filed with the Securities and Exchange Commission (“SEC”) on February ~~28, 2019.~~

~~In July 2019, the U.S. Food and Drug Administration~~26, 2020 (“~~FDA”~~Annual Report”) ~~approved XPOVIO~~

(selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (“RRMM”) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Following accelerated approval by the FDA, XPOVIO became commercially available in the United States in July 2019.

Basis of Consolidation

The condensed consolidated financial statements at ~~September~~June 30, ~~2019~~2020 include the accounts of Karyopharm Therapeutics Inc. and ~~our~~its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The significant accounting policies used in preparation of these condensed consolidated financial statements on Form

10-Q

~~for the nine months ended September 30, 2019~~ are consistent with those discussed in Note 2, ~~to the financial statements~~“Summary of Significant Accounting Policies,” in our Annual ~~Report on Form~~

~~10-K~~

~~for the year ended December 31, 2018, except as it relates to product revenue recognition, accounts receivable, inventory, cost of sales,~~Report.

2. Recent Accounting Pronouncements and deferred royalty obligations, as discussed below, and the adoption of new accounting standards during the nine months ended September 30, 2019, as discussed in Note 2. There were no changes to our accounting policy for license and asset sale agreements, as disclosed in our

~~evenue~~

~~ecognition policy in Note 2 to the financial statements in our Annual Report on Form~~

~~10-K~~

~~for the year ended December 31, 2018, during the nine months ended September 30, 2019.~~

~~Product Revenue Recognition~~

~~We adopted~~CARES Act Provisions

Recently Adopted Accounting Standards ~~Update~~

~~(“ASU”)~~

~~2014-09,~~

~~Revenue from Contracts with Customers~~

~~, as well as subsequent amendments, which were codified in~~

In June 2016, the Financial Accounting Standards Board

(“FASB”)

issued Accounting Standards ~~Codification~~Update (“~~ASC”~~ASU”) ~~606,~~No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on ~~January 1, 2018, using~~Financial Instruments (“ASU 2016-13”). Certain amendments thereto were also issued by the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have a material impact on our consolidated financial position, results of operations, stockholder’s equity or cash flows as of the adoption date, as no transition adjustment for any of our contracts with customers was required.

~~ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements,~~FASB. ASU 2016-13 and financial instruments. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assesses whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients.

~~Table of Contents~~

In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or less. However, no such costs have been incurred to date. In addition to distribution agreements with our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of our products.

In the context of ASC 606, each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the product is transferred to the customer. Accordingly, we recognize product revenue when the customer obtains control of our product, which occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue.

Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related ~~sales, and are classified~~amendments require that credit losses be reported as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contracts with our customers will not occur in a future period.

~~The following are the components of variable consideration related to product revenue:~~

~~Cash discounts and distributor fees:~~

We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).

~~Product returns:~~

Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product’s expiration date and ending twelve months after the product’s expiration date). We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel. Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable.

Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and other qualitative considerations.

~~Chargebacks:~~

Chargebacks for fees and discounts represent the estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us. Our customers charge us for the discount provided to the healthcare entities. Chargebacks are generally determined at the time of resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.

~~Table of Contents~~

~~Government rebates~~

: We are subject to discount obligations under state Medicaid programs, Medicare, the Department of Veterans Affairs (“VA”), the Department of Defense (“DOD”), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in distribution channel inventories at the end of the reporting period.

~~Other incentives:~~

~~Other incentives offered by us include~~

~~co-payment~~

~~assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug~~

~~co-payments~~

~~by the patient. We calculate the accrual for co-payment assistance based on estimates of claims and the average~~

~~co-payment~~

assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.

~~Product revenue reserves and allowances:~~

As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable and distributor fees, government rebates, and other incentives are recoded as a component of accrued expenses. To date, we have determined a material reversal of revenue would not occur in a future period, for the estimates detailed above, as of September 30, 2019 and, therefore, the transaction price was not reduced further during the three months ended September 30, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known.

~~Accounts Receivable~~

In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Our contracts with customers have standard payment terms that generally require payment within 30 days for specialty pharmacy customers and 65 days for specialty distributor customers. We analyze accounts that are past due for collectability, and periodically evaluate the creditworthiness of our customers. As of September 30, 2019, we determined an allowance ~~for doubtful accounts was not required based upon our review~~using an expected loss model, representing the entity’s current estimate of ~~contractual payment terms and individual customer circumstances.~~

~~Inventory~~

Prior to regulatory approval, we expensed costs relating to the production of inventory as research and development expense in the period incurred. We capitalize the costs to manufacture our products incurred after regulatory approval when, based on our judgment, future commercialization is considered probable and the future economic benefit iscredit losses expected to be ~~realized. Such costs are generally recorded~~incurred. The previous accounting guidance, as costs of sales upon shipment. In connection therewith, we value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and manufacturing overhead, on a

~~first-in,~~

~~first-out~~

~~basis.~~

Raw materials and work in process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products.

Inventories that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made.

Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO that could potentially be available to support the commercial launch of our products were charged to research and development expense in the period incurred, as there was no alternative future use. We analyze our inventory levels for recoverability each reporting period. In the period in which there is an impairment identified, we write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value, and inventory in excess of expected sales requirements as cost of sales. The determination of whether inventory costs will be realizable is based on our estimates. If actual market conditions are less favorable than projectedapplied by us ~~additional write-downs of inventory may be required, which would be recorded as cost of sales.~~

~~Table of Contents~~

~~Cost of Sales~~

Cost of sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs, as well as third-party royalties payable on product revenue, net. In addition, shipping and handling costs for product shipments are recorded in cost of sales as incurred. Finally, cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances.

~~Deferred Royalty Obligation~~

We treat the liability related to net revenues, as discussed further in Note 12, as a deferred royalty obligation, amortized under the effective interest rate method over the estimated life of the revenue streams. We recognize interest expense

~~thereon~~

using the effective rate, which is based on our current estimates of future revenues over the life of the arrangement. In connection therewith, we periodically assess our expected revenues using internal projections, impute interest on the carrying value of the deferred royalty obligation, and record interest expense using

~~the~~

imputed effective interest rate. To the extent our estimates of future revenues are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, we will account for any such changes by adjusting the effective interest rate on a prospective basis, with a corresponding impact to the reclassification of our deferred royalty obligation. The assumptions used in determining the expected repayment term of the deferred royalty obligation and amortization period of the issuance costs requires that we make estimates that could impact the short-term and long-term classification of such costs, as well as the period over which such costs will be amortized.

~~Liquidity~~

At September 30, 2019, we had $269.6 million in cash, cash equivalents and investments. We have had recurring losses and incurred a loss of $150.9 million for the nine months ended September 30, 2019. Net cash used in operations for the nine months ended September 30, 2019 was $151.3 million. We expect that our cash, cash equivalents and investments at September 30, 2019, together with the cash we expect to generate from product sales and under our alliances, will be sufficient to fund current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements, during which time we plan to continue to commercialize XPOVIO in the United States, which commenced in July 2019.

~~2. Recent Accounting Pronouncements~~

~~Recently Adopted Accounting Standards~~

~~In February 2016, the FASB issued ASU No.~~

~~2016-02,~~

~~Leases (Topic 842)~~

~~(“ASU~~

~~2016-02”).~~

~~ASU~~

~~2016-02~~

~~supersedes the lease guidance under FASB ASC Topic 840,~~

~~Leases~~

~~, resulting in the creation of FASB ASC Topic 842,~~

~~Leases~~

~~(“ASC 842”). The new standard requires that all lessees (i) recognize, on the balance sheet, liabilities to remit lease payments and~~

~~right-of-use~~

assets, representing the right to use the underlying asset for the lease term for both finance and operating leases, and (ii) disclose qualitative and quantitative information about its leasing arrangements.

~~In July 2018, the FASB issued ASU No.~~

~~2018-10,~~

~~Codification Improvements to Topic 842, Leases~~

~~(“ASU~~

~~2018-10”)~~

~~and ASU No.~~

~~2018-11,~~

~~Leases (Topic 842) Targeted~~

~~Improvements~~

~~(“ASU~~

~~2018-11”).~~

~~The amendments in ASU~~

~~2018-10~~

~~and ASU~~

~~2018-11~~

~~provide additional clarification and implementation guidance on certain aspects of ASU~~

~~2016-02~~

~~and have the same effective and transition requirements as ASU~~

~~2016-02,~~

~~as detailed below. ASU~~

~~2018-11~~

~~provides entities the option to not provide comparative period financial statements and instead apply the transition requirements as of the effective date of ASU~~

~~2016-02.~~

~~ASU~~

~~2016-02,~~

~~ASU~~

~~2018-10,~~

~~and ASU~~

~~2018-11~~

are effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. We adopted the standard effective January 1, 2019 using the optional transition method under ASU

~~2018-11~~

~~and, therefore, prior period financial information has not been retrospectively adjusted.~~

~~Pursuant to the guidance under ASU~~

~~2016-02,~~

we elected the optional package of practical expedients to leases that commenced prior to the effective date, which allowed us to not reassess: (i) whether expired or existing contracts contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. The new standard also allows entities to make certain policy elections, some of which we elected, including: (i) a policy to not record

~~right-of-use~~

~~assets and leases on the balance sheet for short-term leases that qualify and (ii) a policy to not separate lease and~~

~~non-lease~~

components for certain classes of underlying assets on contracts entered into or modified after the effective date. We did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard.

~~Table of Contents~~

~~As summarized in the table below, the standard had a material impact on our condensed consolidated balance sheet as of September 30, 2019, specifically through recognition of~~

~~right-of-use~~

~~assets of $11.7 million and lease liabilities of $16.0 million for our existing operating lease for office space in Newton, MA on the effective date. The difference between the operating lease~~

~~right-of-use~~

~~assets and operating lease liabilities is due to the change in classification of deferred rent and lease incentives~~ through December 31, ~~2018 from liabilities to a reduction in our operating lease~~

~~right-of-use~~

~~assets. However,~~2019, was based on an incurred loss model. For available-for-sale debt securities with unrealized losses, ASU 2016-13 and the standard did not have a material impact on our condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2019, as expense for our existing operating leases continuesrelated amendments now require allowances to be ~~recognized consistent with~~recorded instead of reducing the ~~recognition pattern before adoption~~amortized cost of the ~~new standard. Please refer to Note 10, “Leases” for further information.~~

January 1, 2019
Prior to ASC
842 Adoption

ASC 842

Adjustment

January 1, 2019

as Adjusted

Consolidated balance sheet data (in thousands):







Operating lease and
right-of-use
assets
(1)

$
—
$
11,711

$
11,711

Deferred rent
(2)
$
390
$
(390
) $
—

Deferred rent
non-current

(2)
$
3,922
$
(3,922
) $
—

Operating lease liabilities
(3)
$
—
$
1,175
$
1,175

Non-current
operating lease liabilities
(3)
$
—
$
14,848
$

14,848

~~(1)~~

~~Represents capitalization of operating lease~~

~~right-of-use~~

~~assets, offset by reclassification of deferred rent~~investment. ASU 2016-13 and ~~tenant incentives to operating lease~~

~~right-of-use~~

~~assets.~~

~~(2)~~

~~Represents reclassification of deferred rent and tenant incentives to operating lease~~

~~right-of-use~~

~~assets.~~

~~(3)~~

~~Represents recognition of operating lease liabilities.~~

~~We implemented internal controls to enable~~ the ~~preparation of financial information upon adoption.~~

~~In June 2018, the FASB issued ASU No.~~

~~2018-07,~~

~~Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting~~

~~(“ASU~~

~~2018-07”).~~

~~ASU~~

~~2018-07~~

largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of Topic 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. The new guidance was adopted on January 1, 2019 and it did not have a material impact on our condensed consolidated financial statements.

~~In July 2018, the FASB issued ASU No.~~

~~2018-09,~~

~~Codification Improvements~~

~~(“ASU~~

~~2018-09”).~~

~~This amendment makes changes to a variety of topics to clarify, correct errors in, or make minor improvements to the Accounting Standards Codification. The~~related amendments are effective for annual periods beginning after December 15, 2018 and were adopted effective January 1, 2019. The adoption of these amendments did not have a material impact on our condensed consolidated financial statements.

~~In November 2018, the FASB issued ASU No.~~

~~2018-18,~~

~~Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606~~

~~(“ASU~~

~~2018-18”).~~

~~The amendments in ASU~~

~~2018-18~~

clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU

~~2018-18~~

are effective for interim and annual fiscal periods beginning after December 15, ~~2019, with early adoption permitted. The amendments in ASU~~

~~2018-18~~

~~should be applied retrospectively to the date of initial application of ASC 606.~~2019. We adopted this guidance effective January 1, ~~2019 using the modified retrospective approach.~~2020. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, as each of our arrangements detailed below within Note 5, “License and Asset Purchase Agreements,” were previously accounted for under ASC 606, not ASC 808, and we have no other arrangements within the scope of ASC 808.

~~On August 17, 2018, the SEC issued an amendment to Rule~~

~~3-04~~

~~of Regulation~~

~~S-X,~~

which extended the annual disclosure requirement of reporting changes in stockholders’ equity to interim periods. Such disclosures are to be provided in a note to the financial statements or in a separate financial statement and requires both the

~~year-to-date~~

information and subtotals for each interim period. On September 25, 2018, the SEC issued guidance under a Compliance and Disclosure Interpretation (“C&DI 105.09”) to clarify the effective date of the requirement. Under the guidance in C&DI 105.09, we implemented this updated disclosure requirement beginning with the Form

~~10-Q~~

~~for the quarterly period ended March 31, 2019, specifically through inclusion of the comparative condensed consolidated statements of stockholders’ equity.~~

statements.

~~Table of Contents~~

~~Recently Issued Accounting Standards~~

~~In June 2016, the FASB issued ASU No.~~

~~2016-13,~~

~~Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments~~

~~(“ASU~~

~~2016-13”).~~

~~ASU~~

~~2016-13~~

~~requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For~~

~~available-for-sale~~

~~debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU~~

~~2016-13~~

~~are effective for interim and annual fiscal periods beginning after December 15, 2019. We are currently evaluating the effects the adoption of ASU~~

~~2016-13~~

~~will have on our consolidated financial statements and related disclosures.~~

In August 2018, the FASB issued ASU No.

2018-13,

Fair Value ~~Measurement—~~Measurement - Disclosure Framework-Changes to the Disclosure Requirement for Fair Value Measurement

(“ASU

2018-13”).

The amendments in ASU

2018-13

modify the disclosure requirements on fair value measurements in ~~ASC~~Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments under ASU

2018-13

are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. We ~~are currently evaluating the effects the~~adopted this guidance effective January 1, 2020. The adoption of ~~ASU~~

~~2018-13~~

~~will~~this standard did not have a material impact on our condensed consolidated financial ~~statements and related disclosures.~~

statements.

In August 2018, the FASB issued ASU No.

2018-15,

Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40)

(“ASU

2018-15”).

ASU

2018-15

updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU

2018-15

are effective for interim and annual fiscal periods beginning after December 15, 2019, with early adoption permitted. We ~~do not expect the~~adopted this guidance effective January 1, 2020. The adoption of ~~ASU~~

~~2018-15~~

tothis standard did not have ~~a material~~an impact on our condensed consolidated financial statements.

CARES Act

In March 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was signed into law and provides an estimated $2.2 trillion to fight the COVID-19 pandemic and stimulate the U.S. economy. The business tax provisions of the CARES Act include temporary changes to income and non-income-based tax laws. Some of the key income tax provisions include (1) eliminating the 80% of taxable income limitations by allowing corporate entities to fully utilize net operating loss (“NOL”) carryforwards to offset taxable income in 2020, 2019 or 2018 and reinstating it for tax years after 2020; (2) allowing NOLs generated in 2020, 2019 or 2018 to be carried back five years; (3) increasing the net interest expense deduction limit to 50% of adjusted taxable income from 30% for the 2020 and 2019 tax years; (4) allowing taxpayers with alternative minimum tax credits to claim a refund for the entire amount of the credit instead of recovering the credit through refunds over a period of years, as required by the 2017 Tax Cut and Jobs Act; and (5) allowing entities to deduct more of their charitable cash contributions made during calendar year 2020 by increasing the taxable income limitation to 25% from 10%. Companies are required to account for these provisions in the period that includes the March 2020 enactment date (i.e., the first quarter for calendar year-end entities). We have assessed the impact of these provisions and they are not material to our condensed consolidated financial statements or related disclosures.

Measures not related to income-based taxes within the CARES Act include (1) allowing an employer to pay its share of Social Security payroll taxes that would otherwise be due from the date of enactment through December 31, 2020 over the following two years and (2) allowing eligible employers subject to closure due to the COVID-19 pandemic to receive a 50% credit on qualified wages against their employment taxes each quarter, with any excess credits eligible for refunds. These measures of the CARES Act also are not material to our condensed consolidated financial statements or related disclosures.

3. Product Revenue

To date, our only source of product revenue has been from the U.S. sales of XPOVIO, which we began shipping to our customers in July 2019.For the three and six months ended ~~September~~June 30, ~~2019,~~2020, we recorded ~~a total~~net product revenue of $

~~2.1~~

~~~~$18.6 million ~~as a reduction~~and $34.7 million , respectively, which was net of ~~revenue~~$3.6 million and $6.4 million, respectively, consisting primarily of distribution fees and cash discounts, as well as reserves for chargebacks, rebates and ~~returns.~~

returns. We did 0t have net product revenue for the three and six months ended June 30, 2019.

As of June 30, 2020 and December 31, 2019, net product revenue of $9.6 million and $7.9 million, respectively, were included in accounts receivable. To date, we have had 0 bad debt write-offs and we do not currently have credit issues with any customers. There were 0 credit losses associated with our accounts receivables as of June 30, 2020 and December 31, 2019.

4. Inventory

The following table presents our inventory of XPOVIO at ~~September~~June 30, ~~2019~~2020 and December 31, ~~2018~~2019 (in thousands):

	June 30, 2020		December 31, 2019
Raw materials and work in process	$	1,350	$	273
Finished goods		302		73
Total inventory	$	1,652	$	346

September 30,
2019

December 31,
2018
Raw materials and work in process


$
—







$
—


Finished goods

100

—

Total inventory
$
100
$
—

At ~~September~~June 30, ~~2019,~~2020, all of our inventory was related to XPOVIO, which was initially approved by the FDA in July 2019 and at which time we began to capitalize costs to manufacture XPOVIO. Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO and related material were charged to research and development expense in the period incurred. At ~~September~~June 30, ~~2019,~~2020, we ~~have~~ determined that a reserve related to XPOVIO inventory iswas not required.

~~Table of Contents~~

5. License and Asset Purchase Agreements

~~Antengene License Agreement~~

~~Effective May 23, 2018 (the “Antengene Effective Date”),~~

In prior periods, we entered into ~~a License Agreement~~out-licensing and asset purchase agreements with Anivive Lifesciences, Inc. (“~~Antengene License Agreement”~~Anivive”) ~~with~~, Ono Pharmaceutical Co., Ltd. (“Ono”), Biogen MA Inc. (“Biogen”), and Antengene Therapeutics Limited ~~a corporation organized~~(“Antengene”), all of which are accounted for within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”). For further details on the terms and ~~existing under~~accounting treatment considerations for these contracts, please refer to Note 11, “License and Asset Purchase Agreements,” to our Consolidated Financial Statements contained in Item 8 of our Annual Report.

In April 2020, we terminated our October 2017 license agreement with Ono for the ~~laws~~development and commercialization of selinexor and eltanexor for all human oncology indications in Japan, South Korea, Taiwan, Hong Kong, and the Association of Southeast Asian Nations (“~~Antengene”~~ASEAN”) countries. Subsequent to termination, all rights to selinexor and ~~a subsidiary of Antengene Corporation Co. Ltd., a corporation organized~~eltanexor were returned to us and ~~existing under~~no further consideration was exchanged between the ~~laws~~parties. Accordingly, we recognized $2.2 million in license and other revenue during the three months ended June 30, 2020, which represented the deferred revenue on the contract as of the ~~People’s Republic~~date of ~~China, pursuant~~termination.

In May 2020, we entered into an amendment to ~~which we granted~~our May 2018 license agreement with Antengene (the “Original Antengene Agreement” and, as amended, the “Amended Antengene Agreement”) to expand the territory for the exclusive development and commercialization rights ~~to develop~~of selinexor, eltanexor and ~~commercialize, at its own cost,~~

~~(i) selinexor, our lead, novel, oral Selective Inhibitor of Nuclear Export (“SINE”) compound, (ii) eltanexor, our second-generation oral SINE compound, and (iii)~~

KPT-9274,

~~our~~

~~first-in-class~~

~~orally bioavailable small molecule that is a~~

~~non-competitive~~

~~dual modulator of PAK4 and NAMPT,~~ each for the diagnosis, treatment and/or prevention of all human oncology indications, ~~(the “Oncology Field”),~~ as well as ~~(iv)~~ verdinexor ~~our lead compound in development for the treatment of viral indications~~ for the diagnosis, treatment and/or prevention of certain human

non-oncology

indications ~~(the~~

~~“Non-Oncology~~

~~Field”) (the “Antengene~~(“Antengene Licensed Compounds”). ~~We licensed~~Under the terms of the Original Antengene Agreement, we received an upfront cash payment of $11.7 million.

Under the terms of the Amended Antengene Agreement, Antengene now has the exclusive development and ~~commercial~~commercialization rights ~~to Antengene~~for selinexor, eltanexor, KPT-9274 and verdinexor in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, Australia and New Zealand (the “Antengene Territory”). Previously, Antengene’s territory covered mainland China and Macau for selinexor and eltanexor ~~in the Oncology Field in mainland China~~ and ~~Macau and licensed the development and commercial rights to Antengene for~~

~~KPT-9274~~

~~in the Oncology Field and verdinexor in the~~

~~Non-Oncology~~

~~Field in~~ mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam ~~(the “Antengene Territory”).~~

~~Pursuant to the terms of the Antengene License Agreement,~~for KPT-9274 and verdinexor. Furthermore, we received ana one-time upfront cash payment of $11.7 million in June 2020 and ~~could receive up~~are entitled to ~~$105.0 million in~~future milestone payments from Antengene if certain development, regulatory and commercialization goals are ~~achieved and up~~achieved. Finally, we are also eligible to ~~$45.0 million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low~~receive tiered double-digit ~~royalty~~royalties based on future net sales of ~~the Antengene Licensed Compounds~~selinexor and eltanexor, and tiered single- to double-digit royalties based on future net sales of verdinexor and KPT-9274 in the Antengene Territory. In addition, upon Antengene’s election and the parties’ full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the “Antengene Manufacturing Election”), we will grant to Antengene

~~non-exclusive~~

rights to manufacture the Antengene Licensed Compounds and products containing such compounds in or outside of the Antengene Territory solely for development and commercialization in the fields in the Antengene Territory.

As part of the Antengene License Agreement, Antengene will also have the right to participate in global clinical studies of the Antengene Licensed Compounds and will bear the cost and expense for patients enrolled in clinical studies in the Antengene Territory. Antengene is responsible for seeking regulatory and marketing approvals for the Antengene Licensed Compounds in the Antengene Territory, as well as any development of the products specifically necessary to obtain such approvals. Antengene is also responsible for the commercialization of the Antengene Licensed Compounds in the Oncology Field and

~~Non-Oncology~~

~~Field, as applicable, in the Antengene Territory at its own cost and expense.~~

Until such time as Antengene elects to manufacture its own drug substance, we will furnish clinical supplies of drug substance to Antengene for use in Antengene’s development efforts pursuant to a clinical supply agreement to be entered into by us and Antengene, and Antengene may elect to have us provide commercial supplies of drug product to Antengene pursuant to a commercial supply agreement to be entered into by us and Antengene, in each case the costs of which will be borne by Antengene.

~~The Antengene License Agreement will continue in effect on a~~

~~product-by-product,~~

~~country-by-country~~

basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, the Antengene License Agreement may be terminated earlier by (i) either party for breach of the Antengene License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Antengene on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days’ prior notice or (iii) us in the event Antengene challenges or assists with a challenge to certain of our patent rights.

We assessed the Amended Antengene ~~arrangement~~Agreement in accordance with ASC 606 and concluded that the amendment was a contract ~~counterparty, Antengene, is a customer.~~modification. We ~~identified~~further concluded that the following material promises under the contract: (i) exclusive licenses for each Antengene Licensed Compound, (ii) initial data transfers for each Antengene Licensed Compound, which consisted of regulatory data compiled by us for the Antengene Licensed Compounds as of the Antengene Effective Date, and (iii) obligations to stand-ready to provide an initial clinical supply for each Antengene Licensed Compound. We also identified immaterial promises under the contract relating to information exchanges and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Antengene, including (i) additional data transfers for each Antengene Licensed Compound, which would consist of the transfer of additional regulatory data compiled by us for each Antengene Licensed Compound after the Antengene Effective Date, (ii) obligations to provide additional clinical supply and related substance supply for each Antengene Licensed Compound upon request by Antengene, (iii) manufacturing technology transfers and licenses for each Antengene Licensed Compound under the Antengene Manufacturing Election, as detailed above, and (iv) options for a backup compound, which represents Antengene’s option to select a replacement compound in the event it elects to discontinue the development of the Antengene Licensed Compounds (the “Antengene Transfer Options”). The Antengene Transfer Options

~~Table of Contents~~

~~individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as~~ performance obligations under the Amended Antengene Agreement were the same performance obligations identified in the Original Antengene Agreement, as disclosed in Note 11, “License and Asset Purchase Agreements,” to our Consolidated Financial Statements contained in Item 8 of our Annual Report. Under the Original Antengene Agreement, we had already fulfilled all of our promises under the combined performance obligations for selinexor and KPT-9274. Accordingly, the licenses to the incremental territories for selinexor and KPT-9274 were considered distinct from the promised goods and services already provided. By contrast, we have not yet fulfilled all of our promises under the combined performance obligations for eltanexor and verdinexor under the Original Antengene Agreement. ~~Finally, we also identified certain other customer options that would create a manufacturing obligation~~Accordingly, the licenses to the incremental territories for ~~us if exercised by Antengene, including for commercial supply. These options do not represent a material right, as they~~eltanexor and verdinexor are ~~not offered at a significant and incremental discount.~~

In further evaluating the promises detailed above, we determined that the exclusive licenses, initial data transfers, and stand-ready obligation to provide initial clinical supply for each Antengene Licensed Compound were not distinct from ~~one another,~~promised goods and must be combined as four separate performance obligations (the “Antengene Combined License Obligation for selinexor”, “Antengene Combined License Obligation for eltanexor”, “Antengene Combined License Obligation for

~~KPT-9274”~~

and “Antengene Combined License Obligation for verdinexor”). This is because, for each Antengene Licensed Compound, Antengene requires the initial data transfer and initial clinical supply to derive benefit from the exclusive licenses, since we did not grant manufacturing licenses to any of the Antengene Licensed Compounds at contract inception. We also determined that each of the Antengene Transfer Options represents a distinct performance obligation. services already provided.

Based on ~~these determinations,~~the conclusions noted, we identified eight performance obligations at the inception of the Antengene License Agreement, including (i) the Antengene Combined License Obligation for selinexor, (ii) the Antengene Combined License Obligation for eltanexor, (iii) the Antengene Combined License Obligation for

~~KPT-9274,~~

(iv) the Antengene Combined License Obligation for verdinexor, and the four components of the Antengene Transfer Options, including (v) the material right for additional data transfer, (vi) the material right for additional clinical supply and related substance supply, (vii) the material right for manufacturing technology transfer and license, and (viii) the material right for the option for a backup compound.

~~We further determined that the~~

~~up-front~~

~~payment of $11.7 million constituted the entirety of the consideration included in~~updated the transaction price, ~~at contract inception,~~ which ~~was~~includes the $1.3 million unrecognized deferred revenue from the $11.7 million upfront payment we received from Antengene under the terms of the Original Antengene Agreement, and the $11.7 million upfront payment we received from Antengene under the terms of the Amended Antengene Agreement, and allocated the total, or $13.0 million, to the remaining performance obligations based on their ~~relative stand-alone~~estimated standalone selling ~~prices. We determined that substantially~~prices as of the effective date of the Amended Antengene Agreement. Since we had already fulfilled all of our promises under the ~~total standalone selling price in the arrangement is derived from the four Antengene Combined License Obligations~~combined performance obligations for selinexor ~~eltanexor,~~

~~KPT-9274~~

and ~~verdinexor. In connection therewith, we also estimated the standalone selling price for each~~KPT-9274 as of the ~~material rights within~~effective date of the Amended Antengene ~~Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes~~Agreement, we recognized a cumulative adjustment to license revenue of ~~allocation. Accordingly, we allocated~~$12.7 million during the ~~$11.7 million transaction price amongst~~three months ended June 30, 2020. For the ~~Antengene Combined License Obligations as follows: $9.4 million for selinexor, $1.0 million~~remaining promises to be fulfilled under the combined performance obligation for eltanexor, ~~$1.1~~we adjusted short-term deferred revenue to $0.3 million ~~for~~

~~KPT-9274,~~

~~and $0.2 million~~as of June 30, 2020. We will recognize such revenue when initial clinical supply of eltanexor is delivered to Antengene, which we expect to be within twelve months from June 30, 2020. For the remaining promises to be fulfilled under the combined performance obligation for verdinexor. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.

~~Upon execution of the Antengene License Agreement, the only fixed component~~verdinexor, none of the transaction price ~~included~~was allocated thereto, as it was assessed as immaterial in comparison to the ~~$11.7 million~~

~~up-front~~

~~payment owed~~other combined performance obligations under the Amended Antengene Agreement.

Finally, we also reassessed other promised goods and services within the modified contract, including customer options and material rights, ultimately concluding such promised goods and services continue to us. As referenced above, we are eligible to receive additional payments of up to $105.0 million in milestone payments if certain development goals are achieved and up to $45.0 million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, we would receive cost reimbursement in connection with Antengene’s election to receive additional clinical supply for the Antengene Licensed Compounds in the future.be immaterial. The future regulatory ~~milestones~~ and ~~cost reimbursement for providing additional clinical supply of the Antengene Licensed Compounds,~~commercial milestones, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price at contract inception and/or through ~~September~~June 30, ~~2019,~~2020, because the amounts were fully constrained as of ~~September~~June 30, ~~2019.~~2020. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside of our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization of XPOVIO by Antengene, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property licenses granted to Antengene and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will

re-evaluate

the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.

~~Through~~

In summary, we recognized $14.9 million in license and other revenue for the ~~nine~~three months ended ~~September~~June 30, ~~2019,~~2020, related to the license agreements with Ono and Antengene described above.

As summarized in the following table, which presents changes in balance sheet accounts for our out-licensing and asset purchase agreements, we recognized ~~$9.4~~$2.3 million ~~in revenue~~ under the Original Antengene ~~License~~ Agreement as the Antengene Combined License Obligation for selinexor was satisfied when the initial clinical supply of selinexor was delivered during the second quarter of 2019. Revenue will be recognized for the Antengene Combined License Obligation for eltanexor, the Antengene Combined License Obligation for

~~KPT-9274,~~

and the Antengene Combined License Obligation for verdinexor once our promise to provide initial clinical supply of each of the Antengene Licensed Compounds in the future is fulfilled. We currently expect the initial clinical supply of

~~KPT-9274~~

to be delivered within the next twelve months, and the initial clinical supplies of eltanexor and verdinexor are expected to be delivered in the fourth quarter of 2020. Accordingly, and as of September 30, 2019, the remaining $2.3 million of the upfront payment represents a contract liability, (i) $1.1 million of which was included in deferred revenue and is classified as a current liability and (ii) $1.2 million of which was included in deferred revenue and is classified as a

~~non-current~~

~~liability.~~

~~Table of Contents~~

~~Biogen Asset Purchase Agreement~~

~~On January 24, 2018, we entered into an Asset Purchase Agreement (the “APA”) and Letter Agreement with Biogen MA Inc., a Massachusetts corporation and subsidiary of Biogen, Inc. (“Biogen”).~~

~~Under the terms of the APA and Letter Agreement, we sold to Biogen exclusive worldwide rights to develop and commercialize our oral SINE compound~~

~~KPT-350~~

and certain related assets with an initial focus in amyotrophic lateral sclerosis (“ALS”) (the “Transfer of IP”), and also granted Biogen: (i) an exclusive worldwide license under certain of our intellectual property to

~~anufacture or have manufactured~~

~~KPT-350~~

~~(the “Manufacturing License”), (ii) a technology transfer package, consisting of information and our~~

~~know-how~~

~~regarding the manufacture of~~

~~KPT-350~~

(the “Manufacturing Technology Transfer”), (iii) a right, at Biogen’s request, to have us provide transition assistance regarding manufacturing and other matters (the “Transition Assistance”), (iv) existing inventory of

~~KPT-350~~

~~(the “Inventory”), (v) an initial supply of~~

~~KPT-350~~

~~(the “Initial Supply”), and (vi) a right, at Biogen’s request, to have us manufacture and supply the active pharmaceutical ingredient for an additional supply of~~

~~KPT-350~~

(the “Additional Supply”). In consideration for these rights, we received an upfront payment of $10.0 million, and we are eligible to receive additional payments of up to $142.0 million based on the achievement by Biogen of future specified development milestones, and up to $65.0 million based on the achievement by Biogen of future specified commercial milestones. We will also be eligible to receive tiered royalty payments that reach low double-digits based on future net sales until the later of the tenth anniversary of the first commercial sale of the applicable product and the expiration of specified patent protection for the applicable product, determined on a

~~country-by-country~~

~~basis.~~

~~We and Biogen have made customary representations and warranties and agreed to customary covenants in the APA, including covenants requiring Biogen to use commercially reasonable efforts to develop~~

~~KPT-350~~

in specified neurological indications, including ALS, in any of the United States, United Kingdom, France, Spain, Germany or Italy. The APA will continue in effect until the expiration of all royalty obligations, provided that the APA may be terminated earlier by Biogen, subject to the requirements that Biogen (i) negotiate in good faith with us regarding an assignment or license back to us the purchased assets and (ii) not transfer or license the purchased assets to a third party unless such third party assumes Biogen’s obligations to us under the APA.

We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Biogen, is a customer. We identified the following material promises in the arrangement: the Transfer of IP and the Manufacturing License. We also identified immaterial promises under the contract that were not deemed performance obligations. We further determined that other promises for Additional Supply and Transition Assistance represented customer options, which would create an obligation for us if exercised by Biogen. Since no additional or material consideration is owed to us by Biogen upon exercise of the customer options for Additional Supply and Transition Assistance, we determined that both are offered at significant and incremental discounts. Accordingly, they were assessed as material rights and, therefore, separate performance obligations in the arrangement. We then determined that the Transfer of IP and the Manufacturing License were not distinct from one another and must be combined as a performance obligation (the “Combined Performance Obligation”). This is because Biogen requires the Manufacturing License to derive benefit from the Transfer of IP. Based on these determinations, as well as the considerations noted above with respect to the material rights for Additional Supply and Transition Assistance, we identified three distinct performance obligations at the inception of the contract: (i) the Combined Performance Obligation, (ii) the material right for Additional Supply, and (iii) the material right for Transition Assistance. We further determined that the

~~up-front~~

payment of $10.0 million constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. In connection therewith, we estimated the stand-alone selling price of the (i) Combined Performance Obligation, (ii) material right for Additional Supply, and (iii) material right for Transition Assistance, and determined that the stand-alone selling price of the material rights for Additional Supply and Transition Assistance were insignificant based on various quantitative and qualitative considerations. Accordingly, we further determined that the allocation of the transaction price to the material rights for Additional Supply and Transition Assistance was insignificant. Based on the estimates of the stand-alone selling prices for each of the performance obligations, we determined that substantially all of the $10.0 million transaction price should be allocated to the Combined Performance Obligation. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.

~~Upon execution of the APA, the transaction price included only the $10.0 million~~

~~up-front~~

payment owed to us. We may receive further payments upon the achievement of certain regulatory and sales milestones, as detailed above, as well as tiered royalty payments that reach low double-digits based on future net sales. The future regulatory milestones, which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of September 30, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such milestones is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Biogen, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will

~~re-evaluate~~

~~the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.~~

~~Table of Contents~~

We recognized $10.0 million of revenue during the first quarter of 2018, which was when it had satisfied its promises under the Combined Performance Obligation by transferring the underlying promised goods.

~~Ono License Agreement~~

Effective October 11, 2017 (the “Ono Effective Date”), we entered into a license agreement (the “Ono License Agreement”) with Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan (“Ono”), pursuant to which we granted Ono exclusive rights to develop and commercialize, at its own cost, selinexor and eltanexor, for the diagnosis, treatment and/or prevention of all human oncology indications (the “Ono Field”) in Japan, Republic of Korea, Republic of China (Taiwan) and Hong Kong, as well as in the ten Southeast Asian countries currently comprising the Association of Southeast Asian Nations (the “Ono Territory”) (the “Ono Exclusive License”). Pursuant to the terms of the Ono License Agreement, we received an upfront payment of ¥2.5 billion (US$21.9 million on the date received), and could receive up to ¥10.15 billion (approximately US$90.5 million at the exchange rate as of the Ono Effective Date) in milestone payments if certain development goals are achieved and up to ¥9.0 billion (approximately US$80.2 million at the exchange rate as of the Ono Effective Date) in milestone payments if certain sales milestones are achieved, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, upon Ono’s election and the parties’ full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the “Ono Manufacturing Election”), we will grant to Ono

~~non-exclusive~~

~~rights to manufacture selinexor, eltanexor and products containing such compounds in or outside of the Ono Territory solely for development and commercialization in the Ono Field in the Ono Territory.~~

As part of the Ono License Agreement, Ono will also have the right to participate in global clinical studies of selinexor and eltanexor and will bear the cost and expense for patients enrolled in clinical studies in the Ono Territory. Ono is responsible for seeking regulatory and marketing approvals for selinexor and eltanexor in the Ono Territory, as well as any development of the products specifically necessary to obtain such approvals. Ono is also responsible for the commercialization of products containing selinexor or eltanexor in the Ono Field in the Ono Territory at its own cost and expense.

Subject to the Ono Manufacturing Election, we will furnish clinical supplies of drug substance to Ono for use in Ono’s development efforts pursuant to a clinical supply agreement to be entered into by us and Ono, and Ono may elect to have us provide commercial supplies of drug product to Ono pursuant to a commercial supply agreement to be entered into by us and Ono, in each case the costs of which will be borne by Ono.

~~The Ono License Agreement will continue in effect on a~~

~~product-by-product,~~

~~country-by-country~~

basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, the Ono License Agreement may be terminated earlier by (i) either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Ono on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days’ prior notice or (iii) us in the event Ono challenges or assists with a challenge to certain of our patent rights.

e assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Ono, is a customer. We identified the following material promises under the contract: (i) the Ono Exclusive License for selinexor and eltanexor, (ii) initial data transfer for selinexor and eltanexor, which consisted of regulatory data compiled by us for the licensed compounds and products as of the Ono Effective Date, (iii) initial clinical supply for selinexor, which consisted of units of clinical supply for Ono to conduct its Phase I Trial, and (iv) an obligation to stand-ready to provide initial clinical supply for eltanexor. We also identified immaterial promises under the contract relating to information exchanges, and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Ono, including the (i) additional data transfer for selinexor and eltanexor, which would consist of the transfer of additional regulatory data compiled by us for the licensed compounds and products after the Ono Effective Date, (ii) additional clinical supply and related substance supply for selinexor and eltanexor, which would consist of supplying Ono with units and substance of selinexor and eltanexor incremental to the initial clinical supply for selinexor and the obligation to stand-ready to provide initial clinical supply for eltanexor, as noted above, (iii) manufacturing technology transfer and license for selinexor and eltanexor under the Ono Manufacturing Election, as detailed above, and (iv) options for a backup compound, which represents Ono’s option to select a replacement compound in the event it elects to discontinue the development of either of the licensed compounds (the “Ono Transfer Options”). The Ono Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Ono License Agreement. We also identified certain other customer options that would create a manufacturing obligation for us if exercised by Ono, including commercial supply. This option is referred to herein as the “Ono Manufacturing Option.” The Ono Manufacturing Option does not represent a material right, as it is not offered at a significant and incremental discount.

~~Table of Contents~~

In further evaluating the promises detailed above, we determined that the (i) Ono Exclusive License, initial data transfer, and initial clinical supply for selinexor and (ii) Ono Exclusive License, initial data transfer, and obligation to stand-ready to provide initial clinical supply of eltanexor were not distinct from one another, and must be combined as two separate performance obligations (the

“Ono Combined License Obligation for selinexor” and the “Ono Combined License Obligation for eltanexor”). This is because, for both selinexor and eltanexor, Ono requires the initial data transfer and clinical supply to derive benefit from the Ono Exclusive License since we did not grant manufacturing licenses for selinexor and eltanexor at contract inception. We also determined that each of the Ono Transfer Options represents a distinct performance obligation. Based on these determinations, we identified six distinct performance obligations at the inception of the Ono License Agreement, including (i) the Ono Combined License Obligation for selinexor, (ii) the Ono Combined License Obligation for eltanexor, and the four components of the Ono Transfer Options, including (iii) the material right for additional data transfer, (iv) the material right for additional clinical supply and related substance supply, (iv) the material right for manufacturing technology transfer and license, and (vi) the material right for the option for a backup compound.

~~We further determined that the~~

~~up-front~~

payment of ¥2.5 billion (US$21.9 million on the date received) constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on our best estimate of their relative stand-alone selling prices. We determined that substantially all of the total standalone selling price in the arrangement is derived from the Ono Combined License Obligation for selinexor and the Ono Combined License Obligation for eltanexor. In connection therewith, we estimated the standalone selling price for each of the material rights within the Ono Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, we allocated the ¥2.5 billion (US$21.9 million on the date received) upfront transaction price between the Ono Combined License Obligations as follows: $19.7 million for selinexor and $2.2 million ~~for eltanexor. We believe that a change in the assumptions used to determine our best estimate~~upon termination of the ~~stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.~~

~~Upon execution of the~~license agreement with Ono ~~License Agreement, the transaction price included only the ¥2.5 billion (US$21.9 million on the date received)~~

~~up-front~~

payment owed to us. As referenced above, we are eligible to receive additional payments of up to ¥10.15 billion (approximately US$90.5 million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified development milestones and up to ¥9.0 billion (approximately US$80.2 million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified commercial milestones, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, we could receive cost reimbursement in connection with our promise to stand-ready to provide initial clinical supply for eltanexor in the future. The future regulatory milestones and cost reimbursement for providing initial clinical supply of eltanexor, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of September 30, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Ono, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to Ono and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will

~~re-evaluate~~

~~the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.~~

~~As the initial clinical supply of selinexor was delivered in April 2018, the Ono Combined License Obligation for selinexor was determined to be fulfilled and revenue of $19.7 million was recognized~~ during the ~~quarter~~six months ended

June

30, 2018. The transaction price allocated to the Ono Combined License Obligation for eltanexor will be recognized as revenue once our stand-ready promise to provide initial clinical supply of eltanexor in the future is fulfilled, which is the last remaining undelivered promise associated with the Ono Combined License Obligation for eltanexor. As of September 30, 2019, $2.2 million of the Ono License Agreement upfront payment is included in deferred revenue and is classified as a2020 (in thousands):

~~non-current~~

	December 31, 2019		Additions		Deductions		June 30, 2020
Short-term Deferred Revenue
Original Antengene Agreement	$	2,341	$	—	$	2,341	$	—
Amended Antengene Agreement		-		297				297
Total short-term deferred revenue	$	2,341	$	297	$	2,341	$	297
Long-term Deferred Revenue
Ono	$	2,192	$	—	$	2,192	$	—
Total long-term deferred revenue	$	2,192	$	—	$	2,192	$	—
Total deferred revenue	$	4,533	$	297	$	4,533	$	297

~~liability.~~

~~Anivive License Agreement~~

On April 28, 2017 (the “Anivive Effective Date”), we entered into a license agreement (the “Anivive Agreement”) with Anivive Lifesciences, Inc. (“Anivive”), a biopharmaceutical company engaged in the research, development and commercialization of animal health medicines, pursuant to which we have granted Anivive an exclusive, worldwide license to develop and commercialize verdinexor

~~(KPT-335)~~

for the treatment of cancer in companion animals (the “Anivive Exclusive License”). Pursuant to the terms of the Anivive Agreement, we received an upfront payment of $1.0 million and a payment of $0.3 million upon the completion of the technology transfer, which occurred during the year ended December 31, 2017. In addition, we are eligible to receive potential clinical, regulatory and commercial development milestone payments totaling up to $43.3 million, as well as a low double-digit royalty based on Anivive’s future net sales of verdinexor following commercialization. The potential future milestone payments are composed of $5.8 million based on achievement of clinical and regulatory milestone events and $37.5 million based on achievement of sales milestone events.

~~Table of Contents~~

We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Anivive, is a customer. We identified the following material promises under the contract, the Anivive Exclusive License and the technology transfer, which consisted of regulatory data compiled by us for the licensed compound and product as of the Anivive Effective Date. We also identified immaterial promises under the contract that were not deemed performance obligations, including participating on a product advisory committee and sharing regulatory matter information. We further determined that other promises for (i) transfer of additional technology in the future, if developed by us, and (ii) facilitating manufacturing and supply relationships with our third-party contract manufacturers represented customer options, would create an obligation for us if exercised by Anivive. Since no additional or immaterial consideration is owed to us by Anivive upon exercise of the customer options noted, we determined that both are offered at significant and incremental discounts. Accordingly, they were assessed as material rights and, therefore, separate performance obligations in the arrangement.

In further evaluating the promises detailed above, we determined that the Anivive Exclusive License and the technology transfer were not distinct from one another and must be combined as a performance obligation (the “Anivive Combined License Obligation”). This is because Anivive requires the technology transfer to derive benefit from the Anivive Exclusive License. Based on these determinations, we identified three distinct performance obligations at the inception of the contract: (i) the Anivive Combined License Obligation, (ii) the material right for transfer of additional technology in the future, if developed by us, and (iii) the material right for facilitating manufacturing and supply relationships with our third-party contract manufacturers.

~~We further determined that the~~

~~up-front~~

payment of $1.0 million upon contract execution, as well as the $0.3 million upon completion of the technology transfer, constituted the entirety of the consideration included in the transaction price as of the transition date, January 1, 2018, which was allocated to the performance obligations based on their relative stand-alone selling prices. In connection therewith, we estimated the stand-alone selling price of the (i) Anivive Combined License Obligation, (ii) material right for transfer of additional technology in the future, if developed by us, and (iii) the material right for facilitating manufacturing and supply relationships with our third-party contract manufacturers, and determined that the stand-alone selling price of the material rights noted were insignificant based on various qualitative considerations. Accordingly, we further determined that the allocation of the upfront payment to the material rights noted was insignificant. Based on the estimates of the stand-alone selling prices for each of the performance obligations, we determined that substantially all of the $1.3 million transaction price should be allocated to the Anivive Combined License Obligation. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.

~~As referenced above, the~~

~~up-front~~

payment of $1.0 million upon contract execution, as well as the $0.3 million upon completion of the technology transfer, constituted the entirety of the consideration included in the transaction price as of the transition date, January 1, 2018. We are also eligible to receive additional payments up to $5.8 million based on achievement of clinical and regulatory milestone events and up to $37.5 million based on achievement of sales milestone events, as well as a low double-digit royalty based on Anivive’s future net sales of verdinexor following commercialization. The future regulatory milestones, which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts are fully constrained as of September 30, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such milestones is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Anivive, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to Anivive and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our policy. We will

~~re-evaluate~~

~~the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.~~

To date, we have recognized $1.3 million of revenue associated with the Anivive Agreement. Revenue for the upfront payment and technology transfer milestone was recognized upon completion of the technology transfer in October 2017, as all promises under the Anivive Combined License Obligation had been fulfilled.

6. Fair Value of Financial Instruments

Financial instruments, including cash, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses, are presented at amounts that approximate fair value at ~~September~~June 30, ~~2019~~2020 and December 31, ~~2018.~~

~~Table of Contents~~

2019.

We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:


~~Level 1 inputs~~		~~Quoted prices in active markets for identical assets or liabilities~~


~~Level 2 inputs~~		~~Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly~~

~~Level 3 inputs~~		~~Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability~~

Level 1 inputs - Quoted prices in active markets for identical assets or liabilities

Level 2 inputs - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 inputs - Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability

Our cash equivalents are comprised of money market funds, commercial paper, and corporate debt securities. We measure these investments at fair value. The fair value of cash equivalents held in money market funds is determined based on “Level 1” inputs.

Items classified as Level 2 within the valuation hierarchy consist of commercial paper, corporate debt securities, and U.S. government and agency ~~securities and certificates of deposit.~~securities. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.

In certain cases where there is limited activity or less transparency around inputs to valuation, the related assets or liabilities are classified as Level 3. The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note ~~12,~~11, “Long-Term Obligations”, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of the deferred royalty obligation. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income (expense), net. The assumptions used in the option pricing Monte Carlo simulation model include: (1) our estimates of the probability and timing of related events; (2) the probability-weighted net sales of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones and royalties; (3) our risk-adjusted discount rate that includes a company specific risk premium; (4) our cost of debt; (5) volatility; and (6) the probability of a change in control occurring during the term of the instrument. Our embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note ~~12, “Long-Term Obligations.~~2, “Summary of Significant Accounting Policies,”

and Note 15, “Long-Term Obligations” to our Consolidated Financial Statements contained in Item 8 of our Annual Report.

The following table presents information about our financial assets and liability that have been measured at fair value at ~~September~~June 30, 2020 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):

Description	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash equivalents:
Money market funds	$	47,883	$	47,883	$	—	$	—
Commercial paper		3,000		—		3,000		—
Corporate debt securities		4,922		—		4,922		—
Investments:
Short-term:
Corporate debt securities		130,641		—		130,641		—
Commercial paper		59,940		—		59,940		—
U.S. government and agency securities		3,034		—		3,034		—
Long-term:
Corporate debt securities (one to two-year maturity)		47,957		—		47,957		—
U.S. government and agency securities (one to two-year maturity)		899		—		899		—
	$	298,276	$	47,883	$	250,393	$	—
Financial liability
Embedded derivative liability	$	2,300	$	—	$	—	$	2,300

The following table presents information about our financial assets and liability that have been measured at fair value at December 31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):

Description	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash equivalents:
Money market funds	$	71,380	$	71,380	$	—	$	—
Investments:
Short-term:
Corporate debt securities		89,079		—		89,079		—
Commercial paper		39,022		—		39,022		—
U.S. government and agency securities		4,997		—		4,997		—
Long-term
Corporate debt securities (one to two-year maturity)		2,016		—		2,016		—
	$	206,494	$	71,380	$	135,114	$	—
Financial liability
Embedded derivative liability	$	2,300	$	—	$	—	$	2,300

Description

Total

Quoted Prices
in Active
Markets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Financial assets

















Cash equivalents:

Money market funds
$
78,063
$
78,063
$
—
$
—

Investments:

Short-term:
Corporate debt securities

49,708

—

49,708

—

Commercial paper

36,440

—

36,440

—

U.S. government and agency securities

13,377

13,377

Long-term:

Corporate debt securities

2,022

2,022

Total financial assets
$
179,610
$
78,063
$
101,547
$
—

~~Table of Contents~~

The following table presents information about our financial assets that have been measured at fair value at December 31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):

Description

Total

Quoted Prices
in Active
Markets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Financial assets

















Cash equivalents:

Money market funds
$
  62,320
$
62,320
$
—
$
—

Corporate debt securities

6,823

—

6,823

—

Commercial paper

7,738

—

7,738

—

Investments:

Short-term:

Corporate debt securities

143,079

—

143,079

—

Commercial paper

43,978

—

43,978

—

U.S. government and agency securities

19,124

—

19,124

—

Certificate of deposit

3,997

—

3,997

—

Long-term:

Corporate debt securities (one to two year maturity)

2,001

—

2,001

—

$
  289,060
$
62,320
$
226,740
$
—

7. Investments

The following table summarizes our investments in corporate debt securities, commercial paper, and U.S. government and agency securities, classified as

available-for-sale,

as of ~~September~~June 30, ~~2019~~2020 (in thousands):

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Loss			Fair Value
Short-term:
Corporate debt securities	$	130,082	$	577	$	(18	)	$	130,641
Commercial paper		59,918		39		(17	)		59,940
U.S. government and agency securities		3,026		8		—			3,034
Long-term:
Corporate debt securities (one to two-year maturity)		47,593		372		(8	)		47,957
U.S. government and agency securities (one to two-year maturity)		899		—		—			899
	$	241,518	$	996	$	(43	)	$	242,471

Amortized Cost

Gross Unrealized
Gains

Gross Unrealized
Loss

Fair Value

Short-term:

















Corporate debt securities
$
49,692
$
  19
$
(3)
$
49,708

Commercial paper

36,431

12

(3)

36,440

U.S. government and agency securities

13,367

10

13,377

Long-term:

Corporate debt securities

2,021

1

2,022

$
101,511
$
42
$
(6
) $
101,547

The following table summarizes our investments in corporate debt securities, commercial paper, and U.S. government and agency securities, classified as

available-for-sale

as of December 31, ~~2018~~2019 (in thousands):

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Loss			Fair Value
Short-term:
Corporate debt securities	$	89,110	$	12	$	(43	)	$	89,079
Commercial paper		39,004		18		—			39,022
U.S. government and agency securities		4,990		7		—			4,997
Long-term:
Corporate debt securities (one to two-year maturity)		2,017		—		(1	)		2,016
	$	135,121	$	37	$	(44	)	$	135,114

Amortized Cost

Gross Unrealized
Gains

Gross Unrealized
Loss

Fair Value

Short-term:

















Corporate debt securities
$
143,254
$
3
$
(178)
$

143,079

Commercial paper

44,001

—

(23)

43,978

U.S. government and agency securities

19,131

10

(17)

19,124

Certificate of deposit

4,000

—

(3)

3,997

Long-term:

Corporate debt securities (one to two year maturity)

2,007

—

(6)

2,001

$
212,393
$
13
$
(227
) $
212,179

At September 30, 2019 and December 31, 2018, we held 11 and 79 debt securities, respectively, that were in an unrealized loss position. The aggregate fair value of debt securities in an unrealized loss position at September 30, 2019 and December 31, 2018 was $23.1 million and $180.6 million, respectively. As of September 30, 2019, 1 corporate debt security with a fair value of $1.0 million has been in a continuous unrealized loss position for more than 12 months. The unrealized loss related to this corporate debt security is included in accumulated other comprehensive loss as of September 30, 2019. At September 30, 2019, we did not intend to sell the security with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell this security before recovery of

~~its~~

~~amortized cost basis.~~

~~Table of Contents~~

We review investments ~~for other-than-temporary impairment~~ whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. ~~Other-than-temporary impairments~~We evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes to the rating of ~~investments are recognized in~~ the ~~condensed consolidated statements of operations if we have experienced~~security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and ~~have~~an allowance for credit losses is recorded for the ~~intent to sell~~credit loss on our condensed consolidated balance sheet, limited by the ~~investment or if it~~amount that the fair value is ~~more likely~~less than ~~not that we will be required to sell the investment before recovery of~~ the amortized cost basis. ~~Evidence considered~~Any impairment that is 0t related to a credit loss is recognized in ~~this assessment includes reasons~~other comprehensive income (loss).

Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense. Losses are charged against the ~~impairment, compliance with our investment policy,~~allowance when we believe the ~~severity and the duration~~uncollectability of an available-for-sale security is confirmed or when either of the ~~impairment and changes in value subsequent~~criteria regarding intent or requirement to ~~the end of the period.~~sell is met. The unrealized losses at ~~September~~June 30, ~~2019~~2020 and December 31, ~~2018 are~~2019 were attributable to changes ~~~~in interest rates and we do 0tnot believe any unrealized losses represent ~~other-than-temporary impairments.~~credit losses.

At June 30, 2020 and December 31, 2019, we held 34 and 27 commercial paper and corporate debt securities, respectively, that were in an unrealized loss position. The following table summarizes these available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded at June 30, 2020, aggregated by major security type and length of time in a continuous unrealized loss position (in thousands):

	Less than 12 Months					12 Months or Longer				Total
	Fair Value		Unrealized Losses			Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Available-for-sale securities
Commercial paper	$	37,446	$	(17	)	$	—	$	—	$	37,446	$	(17	)
Corporate debt securities		46,324		(26	)		—		—		46,324		(26	)
Total available-for-sale securities	$	83,770	$	(43	)	$	—	$	—	$	83,770	$	(43	)

8. Net Loss Per Share

Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Our potentially dilutive shares, which include outstanding stock options and unvested restricted stock ~~and restricted stock~~ units, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive ~~effect:~~effect (in thousands):

	As of June 30,
	2020		2019
Outstanding stock options		11,215		10,411
Unvested restricted stock units		1,693		904

Three and Nine
Months Ended
September 30,

2019

2018

Outstanding stock options



10,210,890





8,962,643



Unvested restricted stock units

834,600

25,000

We have the option to settle the conversion obligation for our 3.00% convertible senior notes issued October 2018, and due 2025,, in cash, shares or any combination of the two. As such notes were not convertible as of ~~September~~June 30, ~~2019,~~2020, they are not participating securities and do not have an impact on the calculation of basic ~~earnings or~~ loss per share. Based on our net loss position, there was no impact onto the calculation of dilutive loss per share during the three and ~~nine~~six months ended ~~September~~June 30, 2020 and 2019.

9. Stock-based Compensation

~~Stock Options~~

~~A summary of our stock option activity and related information follows:~~

Shares

Weighted-
Average
Exercise
Price
Per
Share

Weighted-
Average
Remaining
Contractual
Term
(years)

Aggregate
Intrinsic
Value
(in thousands)

Outstanding at December 31, 2018



8,917,084




$
13.78





7.4




$
  8,197



Granted

2,996,650

8.08

Exercised

(131,143
)
5.55

Canceled

(1,571,701
)
13.77

Outstanding at September 30, 2019

10,210,890

12.22

7.0
$
12,443

Exercisable at September 30, 2019

5,426,297
$
14.64

5.5
$
7,869

~~Total~~

The following table summarizes stock-based compensation ~~expense related to stock options~~expenses included in operating expenses for the ~~nine months ended September 30, 2019 and 2018 was $9.8 million and $12.8 million, respectively.~~

As of September 30, 2019, there was $28.7 million of total unrecognized stock-based compensation expense related to stock options. The expense is expected to be recognized over a weighted-average period of 2.77 years.

~~Table of Contents~~

~~Restricted Stock Units~~

A restricted stock unit (“RSU”) represents the right to receive one share of our common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of our common stock on the date of grant. We grant RSUs with service conditions that vest in 2 or 4 equal annual installments provided that the employee remains employed with us (“Time-Based RSUs”).

During the nine months ended September 30, 2019, we granted Time-Based RSUs under the 2013 Stock Incentive Plan (the “2013 Plan”) that vest in 4 equal annual installments. The following is a summary of RSU activity for the 2013 Plan for the nine months ended September 30, 2019:

Number of
Shares
Underlying RSUs

Weighted-
Average
Grant
Date
Fair
Value

Unvested at December 31, 2018



25,000




$
9.87



Granted

1,049,900

9.16

Forfeited

(230,300
)
9.24

Vested

(10,000
)
8.13

Unvested at September 30, 2019

834,600
$
9.18

~~The total stock-based compensation expense related to RSUs for the nine months ended September 30, 2019 and 2018 was $1.2 million and $0.3 million, respectively.~~

As of September 30, 2019, there was $6.4 million of unrecognized compensation costs related to unvested Time-Based RSUs, which are expected to be recognized over a weighted-average period of 3.34 years.

~~Employee Stock Purchase Plan~~

~~We have an Employee Stock Purchase Plan (“ESPP”) that permits eligible employees to enroll in~~

~~six~~

~~-month~~

offering periods. Participants may purchase shares of our common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first or last day of the applicable

~~six-month~~

offering period, whichever is lower. Purchase dates under the ESPP occur on or about May 1 and November 1 of each year. In 2013, our stockholders approved the reservation of 242,424 shares of our common stock for issuance under the ESPP, plus an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2015 and ending on December 31, 2023, equal to the lesser of 484,848 shares of our common stock, 1% of the number of outstanding shares on such date, or an amount determined by the board of directors.

For the nine months ended September 30, 2019 and 2018, we recorded stock-based compensation expense related to the ESPP of $0.7 million and $0.3 million, respectively. As of September 30, 2019, 720,676 shares of our common stock remained available for issuance under the ESPP. As of September 30, 2019, there was $0.1 million of total unrecognized stock-based compensation expense related to the ESPP.

~~10. Leases~~

~~Operating Leases~~

We are party to an operating lease of 98,502 square feet of office and research space in Newton, Massachusetts with a term through September 30, 2025 (the “Newton, MA Lease”). Pursuant to the Newton, MA Lease, we have provided a security deposit in the form of a cash-collateralized letter of credit in the amount of $0.6 million. The amount is classified within restricted cash.

~~Upon the adoption of ASU~~

~~2016-02,~~

~~we recorded an operating lease~~

~~right-of-use~~

asset of $11.7 million and corresponding lease liability of $16.0 million related only to the Newton, MA Lease. As of December 31, 2018, there was a balance of $1.7 million and $2.6 million related to unamortized deferred rent and tenant incentive allowances, respectively, for the Newton, MA Lease, both accounted for as liabilities. These balances were deducted from the lease liability on the Newton, MA Lease in arriving at the

~~right-of-use~~

~~asset upon adoption of ASU~~

~~2016-02~~

~~on January 1, 2019.~~

The Newton, MA Lease provides for increases in future minimum annual rental payments, as defined in the lease agreement. The Newton, MA Lease also includes real estate taxes and common area maintenance (“CAM”) charges in the annual rental payments. As these charges were included in minimum annual rental payments as part of our accounting for the Newton, MA Lease

under ASC 840 through December 31, 2018, we have included such amounts in the calculation of the operating lease liability, consistent with ASC 842 and our accounting policy elections thereunder, as specified in Note 2, “Recent Accounting Pronouncements.” The operating lease cost for the Newton, MA Lease for the nine months ended September 30, 2019 was $2.1 million, of which approximately $0.7 million was charges for CAM.

~~Table of Contents~~

In addition, we are party to short-term leases having a term of twelve months or less at the commencement date. We recognize short-term lease expense on a straight-line basis and do not record a related

~~right-of~~

~~use asset or lease liability for such leases. These costs were insignificant for the nine months ended September 30, 2019.~~

~~Lease Commitments~~

~~As of September 30, 2019, future minimum lease payments under~~

~~non-cancellable~~

~~operating lease agreements for which we have recognized operating lease~~

~~right-of-use~~

~~assets and liabilities are as follows~~periods indicated (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Cost of sales	$	28	$	-	$	62	$	-
Research and development		2,692		1,644		4,981		3,192
Selling, general and administrative		3,708		2,472		6,537		4,831
Total stock-based compensation	$	6,428	$	4,116	$	11,580	$	8,023

Years end
ing
December 31,

Future
Minimum
Payments

2019

$
793

2020

3,200

2021

3,277

2022

3,447

2023 and thereafter

10,453

Total minimum lease payments
$
21,170

Less: present value adjustment

(5,944
)

Present value of minimum lease payments
$
15,226

As of September 30, 2019, the remaining lease term on the Newton, MA Lease was 5.9 years. The lease has a renewal option for an additional five years, although there is no economic penalty for failure to exercise the option. However, because we did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard, and the renewal option was not previously considered in our assessment of the lease term for the Newton, MA Lease before adoption of ASC 842, the renewal option was not considered as part of the lease term in calculating the operating lease

~~right-of-use~~

~~assets and liabilities as of January 1, 2019.~~

As a discount rate was not directly observable for our Newton, MA Lease, the discount rate used to calculate the net present value of future payments was our incremental borrowing rate calculated at transition based on the remaining lease term. Upon adoption and through September 30, 2019, the discount rate used to calculate the operating lease liability was 11.0%. The incremental borrowing rate is the rate of interest that the we would expect to pay to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. In determining the incremental borrowing rate, we considered (i) our estimated public credit rating, (ii) our observable debt yields, as well as other bonds in the market issued by other companies with similar credit ratings as us, and (iii) adjustments necessary for collateral, lease term, and inflation or foreign currency.

~~11.~~

10. Equity

Underwritten Offerings

On ~~May 7, 2018,~~March 6, 2020, we completed a

follow-on

offering under our shelf registration statement on Form

S-3

~~(File No.~~

~~333-222726)~~

pursuant to which we issued an aggregate of ~~10,525,424~~7,187,500 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of ~~$14.75~~$24.00 per share. We received aggregate net proceeds of approximately ~~$145.7~~$161.8 million from the offering after deducting the underwriting discounts and commissions and other offering expenses.

Open Market Sale Agreement

On August 17, 2018, we entered into an Open Market Sale Agreement (the “Open Market Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $75.0 million ~~(the “Open Market Shares”)~~ from time to time through Jefferies (the “Open Market Offering”).

On May 5, 2020, we entered into Amendment No. 1 to the Open Market Sale Agreement, pursuant to which we increased the maximum aggregate offering price of shares of our common stock, that we may issue and sell from time to time through Jefferies, by $100.0 million, from $75.0 million to up to $175.0 million (the “Open Market Shares”).

Under the Open Market Sale Agreement, Jefferies may sell the Open Market Shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities ~~Act.~~Act of 1933, as amended (the “Securities Act”). We may sell the Open Market Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Open Market Sale Agreement, but we have 0no obligation to sell any of the Open Market Shares in ~~the~~an Open Market Offering.

~~Table of Contents~~

We or Jefferies may suspend or terminate the offering of Open Market Shares upon notice to the other party and subject to other conditions. We have agreed to pay Jefferies commissions for its services in acting as agent in the sale of the Open Market Shares in the amount of up to 3.0% of gross proceeds from the sale of the Open Market Shares pursuant to the Open Market Sale Agreement. We have also agreed to provide Jefferies with customary indemnification and contribution rights.

~~For the three and nine months ended September~~

As of June 30, ~~2019,~~2020, we have sold an aggregate of ~~1,634,451~~3,712,359 Open Market Shares under the Open Market Sale Agreement, for net proceeds of approximately ~~$14.6 million.~~

~~12.~~$46.2 million, all of which were sold during the year ended December 31, 2019. We did 0t sell Open Market Shares under the Open Market Sale Agreement during the three and six months ended June 30, 2020 and 2019.

11. Long-Term Obligations

3.00% Convertible Senior Notes due 2025

In October ~~16,~~ 2018, we ~~completed an offering of $150.0~~issued $172.5 million aggregate principal amount of ~~our 3.00%~~ convertible senior notes due 2025 (the “Notes”). In addition, on October 26, 2018, we issued an additional $22.5 million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act. In accordance with accounting guidance for debt with conversion and other options, we separately ~~accounted~~account for the liability component (“Liability Component”) and the embedded conversion option (“Equity Component”) of the Notes by allocating the proceeds between the Liability Component and the Equity Component, due to our ability to settle the Notes in cash, shares of our common stock or a combination of cash and shares of our common stock, at our option. In connection with the issuance of the Notes, we incurred approximately $5.6 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs between the Liability Component and the Equity Component based on the allocation of the proceeds. Of the total debt issuance costs, $2.2 million was allocated to the Equity Component and recorded as a reduction to additional

paid-in

capital and $3.4 million was allocated to the Liability Component and recorded as a reduction of the Notes. The portion allocated to the Liability Component is amortized to interest expense using the effective interest method over seven years.

The Notes are ~~our~~ senior unsecured obligations and bear interest at a rate of 3.00% per year, payable ~~semiannually~~semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019. Upon conversion, the Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.

The Notes will be subject to redemption at our option, on or after October 15, 2022, in whole or in part, if the conditions described below are satisfied. The Notes will mature on

October 15, 2025,

, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to satisfaction of certain conditions and during the periods described below, the Notes may be converted at an initial conversion rate of 63.0731 shares of common stock per $1 principal amount of the Notes (equivalent to an initial conversion price of approximately $15.85 per share of common stock).

Holders of the Notes may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time prior to the close of business on the business day immediately preceding

June 15, 2025

only under the following circumstances:

(1)

during any calendar quarter commencing after the calendar quarter ending on December 31, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least

trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day;

(2)

during the five business day period immediately after any five consecutive trading day period (the “Measurement Period”) in which the trading price per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;

(3)

if we call the Notes for redemption, until the close of business on the business day immediately preceding the redemption date; or

(4)

upon the occurrence of specified corporate events as described within the indenture governing the Notes.

As of ~~September~~June 30, ~~2019,~~2020, none of the above circumstances had occurred and as such, the Notes could not have been converted.

We may not redeem the Notes prior to October 15, 2022. On or after October 15, 2022, we may redeem for cash all or part of the Notes at our option if the last reported sale price of our common stock equals or exceeds 130% of the conversion price then in effect for at least

trading days (whether or not consecutive) during any 30 consecutive trading day period ending within 5 trading

days prior to the date on which we send any notice of redemption. The redemption price will be 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any convertible note for redemption will constitute a make-whole fundamental change with respect to that convertible note, in which case the conversion rate applicable to the conversion of that convertible note, if it is converted in connection with the redemption, will be increased in certain circumstances.

~~Table of Contents~~

The initial carrying amount of the Liability Component of $101.2 million was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our

non-convertible

borrowing rate for similar debt. The $67.9 million Equity Component of the Notes ~~of $67.9 million~~ was recognized as a debt discount and represents the difference between ~~the~~$172.5 million proceeds from the issuance of the Notes ~~of $172.5~~and approximately $104.7 million ~~and the~~ fair value of the liability of the Notes ~~of approximately $104.7 million~~ on their respective dates of issuance. The excess of the principal amount of the Liability Component over its carrying amount is amortized to interest expense using the effective interest method over seven years. The Equity Component is 0t remeasured as long as it continues to meet the conditions for equity classification.

The outstanding balances of the Notes as of ~~September~~June 30, ~~2019~~2020 consisted of the following (in thousands):

Liability component:
Principal	$	172,500
Less: debt discount and issuance costs, net		(58,724	)
Net carrying amount	$	113,776
Equity component:	$	65,641

Liability component:

Principal
$
172,500

Less: debt discount and issuance costs, net

(64,538
)

Net carrying amount
$
107,962

Equity component:
$
65,641

We determined the expected life of the Notes was equal to its seven-year term. The effective interest rate on the Liability Component of the Notes was 11.85%. As of ~~September~~June 30, ~~2019,~~2020, the

~~“if-converted~~

“if-converted value” did not exceed the remaining principal amount of the Notes. The fair value of the Notes was determined based on data points other than quoted prices that are observable, either directly or indirectly, and has been classified as Level 2 within the fair value hierarchy. The fair value of the Notes, which differs from their carrying value, is influenced by market interest rates, our stock price and stock price volatility. The estimated fair value of the Notes as of ~~September~~June 30, ~~2019~~2020 was approximately ~~$156.3~~$243.7 million.

The following table sets forth total interest expense recognized related to the Notes during the ~~nine~~three and six months ended ~~September~~June 30, 2020 and 2019 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Contractual interest expense	$	1,294	$	1,300	$	2,588	$	2,594
Amortization of debt discount		1,911		1,703		3,732		3,326
Amortization of debt issuance costs		96		86		187		167
Total interest expense	$	3,301	$	3,089	$	6,507	$	6,087

Nine
Months
Ended
September 30,
2019

Contractual interest expense

$
3,882

Amortization of debt discount

5,045

Amortization of debt issuance costs

253

Total interest expense
$
9,180

~~Table of Contents~~

Future minimum payments on the Notes as of ~~September~~June 30, ~~2019~~2020 were as follows (in thousands):

Years ended December 31,	Future Minimum Payments
2020	$	2,588
2021		5,175
2022		5,175
2023		5,175
2024 and thereafter		182,850
Total minimum payments	$	200,963
Less: interest		(28,463	)
Less: unamortized discount		(58,724	)
Convertible senior notes	$	113,776

Years ended December 31,

Future Minimum
Payments

2019

$
2,588

2020

5,175

2021

5,175

2022

5,175

2023 and thereafter

188,025

Total minimum payments
$
206,138

Less: interest

(33,638
)
Less: unamortized discount

(64,538
)
Less: current portion

—

Convertible senior notes
$
107,962

Deferred Royalty Obligation

In September 2019, we entered into a Revenue Interest Financing Agreement ~~(the “Revenue Interest Agreement”~~(“deferred royalty obligation”) with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P. (“HCR”) whereby HCR ~~will receive~~receives payments from us

~~ered~~

tiered percentage (the “Applicable Tiered Percentage”) of ~~future~~ net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and ~~royalties (the “Revenue Interests”).~~royalties. We received $75.0 million upon closing (the “First Investment Amount”) and have the right to receive an additional $75.0 million (the “Second Investment Amount” and together with the First Investment Amount, the “Investment Amount”) upon the achievement of future regulatory and commercial milestones and subject to the approval of both ~~parties and customary closing conditions.~~

parties.

In exchange for the First Investment Amount, HCR ~~will receive a~~receives tiered ~~royalty~~royalties in the

mid-single

digits based on worldwide net revenues of XPOVIO

and

any

of our

other future products,

, including ~~worldwi~~

worldwide net ~~pro~~

tproduct sales

and upfront payments, milestones, and royalties. The Applicable Tiered ~~Percentage~~

Percentages are

subject to reduction in the future if a target based on cumulative U.S. net sales is met. Total royalty payments are capped at 185% of the Investment Amount.

If HCR has not received 65% of the Investment Amount by December 31, 2022 or 100% of the Investment Amount by December 31, 2024, we must make a cash payment sufficient to gross ~~HCR~~ up the payments to such minimum amounts.

As the repayment of the funded amount is contingent upon worldwide net product sales and upfront payments, milestones, and royalties, the repayment term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period commenced on October 1, 2019 and expires on the earlier of (i) the date in which HCR has received cash payments totaling an aggregate of 185% of the Investment Amount or (ii) the legal maturity date of October 1, 2031. If HCR has not received payments equal to 185% of the Investment Amount by the twelve-year anniversary of the initial closing date, we shall pay an amount equal to the Investment Amount plus a specific annual rate of return less payments previously received.

We have evaluated the terms of the ~~Revenue Interest Agreement~~deferred royalty obligation and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, we have accounted for the transaction as long-term debt.

We have evaluated the terms of the debt and determined that the repayment of 185% of the Investment Amount, less any payments made to date, upon a change of control is an embedded derivative that requires bifurcation from the debt instrument and fair value recognition. We ~~determined~~determine the fair value of the derivative using an option pricing Monte Carlo simulation model taking into account the probability of change of control occurring and potential repayment amounts and timing of such payments that would result under various scenarios, as further described in Note 6.2, “Summary of Significant Accounting Policies” and Note 15, “Long-Term Obligations” to our Consolidated Financial Statements contained in Item 8 of our Annual Report. The aggregate fair value of the embedded derivative ~~at issuance date~~is $2.3 million and is included in deferred royalty obligation. We ~~will~~ remeasure the embedded derivative to fair value each reporting period until the time the features lapse and/or the termination of the ~~Revenue Interest Agreement.~~

deferred royalty obligation.

The effective interest rate as of ~~September~~June 30, ~~2019~~2020 was ~~17.3%~~approximately 18.3%. In connection with the ~~Revenue Interest Agreement,~~deferred royalty obligation, we incurred debt issuance costs totaling $1.4 ~~million.~~million in the quarter ended September 30, 2019. Debt issuance costs have been netted against the debt ~~as of September 30, 2019~~ and are being amortized over the estimated term of the debt using the effective interest method,

, adjusted on a prospective basis for changes in the underlying assumptions and inputs.

The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs ~~requires~~require that we make estimates that could impact the short and long-term classification of these costs, as well as the period over which these costs will be amortized.

~~Table of Contents~~

The carrying value of the deferred royalty obligation, ~~at September 30, 2019 was~~

~~$72.3~~

~~million based~~as presented on ~~$75.0 million of proceeds, net of fair value of the bifurcated embedded derivative liability and debt issuance costs incurred. The carrying value of the deferred royalty obligation~~our condensed consolidated balance sheet, approximates fair value at ~~September~~June 30, ~~2019~~2020 and was measured using Level 3 inputs.

~~Table~~ The estimated fair market value was calculated using an option pricing Monte Carlo simulation model with inputs consistent with those used in determining the embedded derivative values as described in Note 2, “Summary of ~~Contents~~

Significant Accounting Policies” and Note 15, “Long-Term Obligations” to our Consolidated Financial Statements contained in Item 8 of our Annual Report.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this quarterly ~~report.~~

report and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019, or Annual Report.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form

10-Q,

including the following discussion, contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form

10-Q,

including statements regarding possible achievement of discovery and development milestones, including regulatory submissions and approvals, our future discovery and development efforts, our commercialization efforts, our collaborations and partnering agreements with third parties, our strategy, our future operations, financial position and revenues, projected costs, prospects, plans and objectives of management, are forward looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are not guarantees of future performance and our actual results could differ materially from the plans, intentions, expectations or results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, our ability to successfully commercialize XPOVIO

^®

(selinexor), tablets; the impact of the ongoing COVID-19 pandemic on our business, including decreased sales of XPOVIO, interrupting or delaying research and development efforts, impacting the ability to procure sufficient supply for the development and commercialization of selinexor or other product candidates, delaying ongoing or planned clinical trials, impeding the execution of business plans, planned regulatory milestones and timelines, or inconveniencing patients; the adoption of XPOVIO in the commercial marketplace; adverse results in our drug discovery and clinical development ~~activities,~~activities; decisions made by the U.S. Food and Drug Administration, ~~(FDA)~~or FDA, and other regulatory authorities with respect to the development and commercialization of our drug ~~candidates,~~candidates; our ability to raise additional capital to support our clinical development program and other ~~operations,~~operations; our ability to develop products of commercial value and to identify, discover and obtain rights to additional potential product ~~candidates,~~candidates; our ability to obtain, maintain and enforce our intellectual property ~~rights,~~rights; the outcome of research and development activities and the fact that the preclinical and clinical testing of our compounds may not be predictive of the success of later clinical ~~trials,~~trials; our reliance on ~~third-parties,~~third-parties; competitive ~~developments,~~developments; the effect of current and future legislation and regulation and regulatory ~~actions,~~actions; as well as other risks described in this Quarterly Report on Form

10-Q,

our Annual Report, ~~on Form~~

~~10-K~~

~~for the year ended December 31, 2018 (2018 Form~~

~~10-K),~~

as filed with the Securities and Exchange Commission, ~~(SEC)~~or SEC, on February ~~28, 2019,~~26, 2020, and other filings with the SEC.

As a result of these and other factors, we may not actually achieve the plans, intentions, expectations or results disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

OVERVIEW

We are ~~an oncology-focused~~a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of novel,

first-in-class

drugs directed against nuclear ~~export~~transport and related targets for the treatment of cancer and other major diseases. Our

scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing and commercializing novel, small molecule S

elective

nhibitor of

uclear

xport

(

SINE

) compounds ~~function by binding with and inhibiting~~that inhibit the nuclear export protein exportin 1, ~~(XPO1).~~or XPO1. These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of high unmet medical need diseases. Our ~~initial focus has been on seeking~~SINE compounds were the ~~regulatory~~first oral XPO1 inhibitors in clinical development and to receive marketing approval ~~and commercialization of our lead SINE compound, selinexor, as an oral agent~~ in ~~cancer indications with significant unmet clinical need.~~

the U.S. In July 2019, our lead asset, XPOVIO, received marketing approval by the FDA ~~approved XPOVIO~~

~~(selinexor)~~ in combination with dexamethasone ~~for the treatment of~~to treat adult patients with relapsed or refractory multiple myeloma ~~(RRMM)~~ who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, or PIs, at least two immunomodulatory agents, or IMiDs, and an anti-CD38 monoclonal antibody. We refer to myeloma that is refractory to these five agents as penta-refractory myeloma. This indication iswas approved under ~~accelerated approval~~the FDA’s Accelerated Approval Program based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ~~ongoing,~~FDA has agreed that the randomized Phase 3 BOSTON (

rtezomib,

elinexor and Dexame

has

e) study evaluating selinexor in combination with Velcade

^®

(bortezomib) and

low-dose

dexamethasone ~~is intended to~~in patients with multiple myeloma after at least one prior line of therapy could serve as the confirmatory ~~trial.~~

~~The accelerated approval of XPOVIO was based on results from the Phase 2b STORM (~~

~~elinexor~~

~~reatment~~

~~efractory~~

~~yeloma)~~ trial ~~which was a multicenter,~~

~~single-arm,~~

open-label study of patients with RRMM. STORM Part 2 included 122 patients with RRMM who had previously received three or more anti-myeloma treatment regimens including an alkylating agent, glucocorticoids, bortezomib, carfilzomib, lenalidomide, pomalidomide, and an anti-CD38 monoclonal antibody; and whose myeloma was documented to be refractory to glucocorticoids, a proteasome inhibitor, an immunomodulatory agent, an anti-CD38 monoclonal antibody, and to the last line of therapy.

~~Table of Contents~~

In STORM Part 2, a total of 122 patients were treated with XPOVIO (80 mg) in combination with dexamethasone (20 mg) on Days 1 and 3 of every week. Eighty-three patients had RRMM that was documented to be refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. Treatment continued until disease progression, death, or unacceptable toxicity.

~~The major efficacy outcome measure was overall response rate (ORR), as assessed by an Independent Review Committee~~ based on the ~~International Myeloma Working Group (IMWG) Uniform Response Criteria~~positive topline data announced in March 2020. In July 2020, the FDA accepted our supplemental new drug application, or sNDA, for ~~Multiple Myeloma.~~XPOVIO, based on the BOSTON study, to treat patients with multiple myeloma after at least one prior line of therapy. The ~~approval~~FDA has assigned an action date of March 19, 2021 under the Prescription Drug User-Fee Act.

In June 2020, XPOVIO was based upon the efficacy and safety in a prespecified subgroup analysis of the 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab, as the benefit-risk ratio appeared to be greater in this more heavily pretreated population than in the overall trial population.

For the STORM Part 2 study’s major efficacy outcome measure, the ORR was 25.3% in the subgroup of 83 patients, which included one stringent complete response, no complete responses, four very good partial responses and 16 partial responses. The median time to first response for these patients was 4 weeks and the median duration of response was 3.8 months.

Amongst the 202 patients enrolled in STORM Parts 1 and 2 who were treated with XPOVIO (80 mg) in combination with dexamethasone (20 mg) on days 1 and 3 weekly, the most common adverse reactions (incidence

20%) were thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infections. The treatment discontinuation rate due to adverse reactions was 27%; 53% of patients had a reduction in the XPOVIO dose, and 65.3% had the dose of XPOVIO interrupted. The most frequent adverse reactions requiring permanent discontinuation in 4% or greater of patients who received XPOVIO included fatigue, nausea, and thrombocytopenia. The rate of fatal adverse reactions was 8.9%. Following accelerated approvalapproved by the FDA ~~XPOVIO became commercially available~~for a second indication to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. We began commercialization of this indication in June 2020. This indication was approved under the ~~United States~~FDA’s Accelerated Approval Program based on response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in ~~July 2019.~~

~~In addition, we submitted~~a confirmatory trial. The FDA has agreed that the XPORT-DLBCL-030 study could serve as the confirmatory trial for evaluating selinexor in DLBCL. This trial will assess the effect of selinexor or placebo added to a standard backbone immunochemotherapy of rituximab-gemcitabine-dexamethasone-platinum, or R-GDP, in patients with one to three prior treatments for DLBCL. Selinexor has received orphan drug designation from the FDA for the DLBCL indication. We expect that the XPORT-DLBCL-030 study will begin by the end of 2020. We are continuing to evaluate the optimal regulatory and access strategy for lymphoma and plan to submit a Marketing Authorization Application, ~~(MAA)~~or MAA, to the European Medicines Agency, ~~(EMA)~~or EMA, for the DLBCL indication as a Type II variation following the potential approval of XPOVIO in ~~January 2019 with a request for conditional~~multiple myeloma at the appropriate time in the future.

Our focus is on marketing XPOVIO in its currently approved indications as well as seeking the regulatory approval and potential commercialization of selinexor as ~~a treatment for patients~~an oral agent in additional cancer indications with heavily pretreated multiple myeloma based on the results of the STORM study. During March 2019, the EMA had inspectors conduct a Good Clinical Practices (GCP) inspection at our headquarters, which was also attended by the FDA, as well as inspections of two clinical sites that participated in Part 2 of the STORM study. While we did not receive any findings from the FDA, in May 2019, the EMA inspectors provided us a written inspection report seeking our responses to various questions and findings. We promptly addressed the questions and findings in the inspection report and submitted proposals to the EMA’s Committee for Medicinal Products for Human Use (CHMP). In September 2019, we received the Day 180 List of Outstanding Issues from CHMP, which identified two issues requiring resolution. First, CHMP requested that we reconfirm the IRC adjudicated response rate to justify a positive benefit-risk assessment and, second, CHMP requested that we address the findings from the GCP inspection and our corrective measures taken to justify that the clinical trial data are of sufficient quality to support a benefit-risk assessment. We are currently working with CHMP to address both topics and expect to receive a decision on the application in early 2020.

significant unmet medical needs. We plan to conduct additional clinical trials and seek additional approvals for the use of selinexor in combination with other oncology therapies to expand the patient populations that are eligible ~~for selinexor, as well as~~ to ~~move selinexor towards front-line cancer therapy. We~~be treated with selinexor. Thus, we are ~~also~~currently advancing the clinical development of selinexor in multiple hematological malignancies and solid tumor indications. ~~Oral selinexor is being evaluated~~Studies that support our approved indications include STORM (Selinexor Treatment of Refractory Myeloma) and SADAL (Selinexor Against Diffuse Aggressive Lymphoma). On March 2, 2020, we announced positive topline data from the pivotal, randomized Phase 3 BOSTON study in ~~company- and investigator-sponsored~~multiple myeloma. Ongoing clinical ~~trials in advanced hematologic malignancies and solid tumors. Clinical~~ trials evaluating selinexor include the Phase 1b/2 STOMP (

elinexor and Backbone

reatments

ultiple Myeloma

atients) study in combination with standard therapies in multiple myeloma, the Phase ~~2b SADAL (~~

~~elinexor~~

~~gainst~~

~~iffuse~~

~~ggressive~~

~~ymphoma) study in diffuse large~~

~~B-cell~~

~~lymphoma (DLBCL), the pivotal, randomized Phase 3 BOSTON study in multiple myeloma, the Phase~~ 2/3 SEAL (

linexor in

dvanced

iposarcoma) study evaluating single agent selinexor versus placebo in patients with previously treated, advanced unresectable dedifferentiated liposarcoma, and the Phase 3 SIENDO (

elinexor/Placebo After Combination Chemotherapy

n Patients with ~~advanced~~Advanced or ~~recurrent~~

Recurrent ENDO

metrial ~~cancer) study. During 2018~~Cancer) study evaluating selinexor as maintenance therapy in endometrial cancer. We have recently completed enrollment in the Phase 3 portion of the SEAL study and ~~2019,~~currently anticipate topline data in the second half of 2020. As a result of the positive results from STORM, in addition to the FDA approval of our first New Drug Application, or NDA, we also filed an MAA with the EMA in January 2019, as discussed in more detail below.

In April 2020, we initiated a global randomized Phase 2 clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19. This study, known as XPORT-CoV-1001, was expected to enroll approximately 230 patients at clinical sites in the U.S., Europe and Israel to assess the activity and safety of 20mg of selinexor given orally three times a week for two weeks. Patients tolerating therapy well and experiencing clinical benefit could continue treatment for an additional two weeks at the discretion of the treating physician. The primary endpoint of the study was time to clinical improvement based on improvement in the Ordinal Scale, consistent with the COVID-19 trial recommendations by the World Health Organization and the FDA. In addition to its role in cancer, XPO1 has also been shown to facilitate the transport of several viral proteins from the nucleus of the host cell to the cytoplasm, and it amplifies the activities of pro-inflammatory transcription factors. SINE compounds have shown potential to interfere with key host protein interactions with influenza, respiratory syncytial virus and other viruses, including SARS-CoV-2, the virus that causes COVID-19. In May 2020, the protocol was amended to allow enrollment of patients with more severe disease. Following a planned interim analysis (115 patients included in the efficacy analysis and 113 patients included in the safety analysis), the Data Safety Monitoring Board, or DSMB, for the study recommended that we discontinue the trial as it is unlikely to demonstrate a statistically significant efficacy benefit across the entire heterogenous patient population studied. However, the DSMB concluded that the trial was likely to show a benefit in a subpopulation of patients <75 years old who have a COVID-GRAM non-high-risk score (a clinical risk score for disease severity), which represented approximately 75% of these 115 patients. Preliminary results from unaudited site data indicate that in the ~~STORM~~specific subpopulation, a two-point improvement in Ordinal Score at Day 14 (the primary endpoint for the entire study) reached statistical significance, as did the two-point improvement in Ordinal Score by Day 28 and the rate of hospital discharge by Day 14 (all p≤0.05). Fatalities were similar across the two arms in this subpopulation (4/49 on selinexor and 2/37 on placebo). There was also a significant improvement in conversion to SARS-CoV2 PCR negative status on the selinexor arm as compared with the placebo arm across the entire population (p≤0.05). In patients ≥75 years old or with a COVID-GRAM high risk score, there was no improvement in clinical outcomes; fatalities were higher in the selinexor arm (6/15) than the placebo arm (1/12). While the rate of fatalities in the study was imbalanced in the patients ≥75 years old or with a COVID-GRAM high risk score, after a detailed review, the DSMB considered that the fatalities on study were due to severe COVID-19 disease and/or underlying comorbidities without a clear contribution of selinexor. After reviewing the safety and efficacy data that was shared with the DSMB, the FDA’s opinion was that the benefit-risk ratio was not favorable in the heterogenous patient population evaluated under the latest protocol for XPORT-CoV-1001, which included the patients with more severe disease, as described above. We will continue to analyze the data to further characterize the specific subpopulation that will likely benefit from selinexor and will work with the FDA to identify a path forward for future clinical development. We plan to seek potential partners and external funding to advance future clinical studies.

In June 2020, the first patient was dosed in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patients with newly diagnosed or recurrent glioblastoma, or GBM. This global study is expected to enroll approximately 400 patients at clinical sites in the U.S., Europe, and Israel. The randomized, multi-center, Phase 1/2 study is expected to be conducted in two phases: a Phase 1 dose finding study followed by a Phase 2 randomized efficacy exploration study, designed to independently evaluate three different combination regimens in three treatment arms in patients with newly diagnosed GBM (Arms A and B) or with recurrent GBM (Arm C). Arms A and B will investigate selinexor in combination with radiation therapy with or without the addition of temozolomide, while Arm C will evaluate the combination of selinexor and lomustine. The primary endpoints in the study are progression-free survival in patients with newly diagnosed GBM and overall survival in patients with recurrent GBM.

In addition to selinexor, we ~~reported positive~~

~~top-line~~

~~data from the SADAL study,~~are also advancing a pipeline of novel drug candidates including our other oral SINE compounds eltanexor and verdinexor, as well as ~~new~~our oral dual PAK4/NAMPT inhibitor, KPT-9274. We began clinical testing of eltanexor, a second-generation SINE compound, in late 2015. Our clinical development program for eltanexor includes myelodysplastic syndrome, or ~~updated interim data for the STOMP~~MDS, colorectal cancer and ~~SEAL studies.~~

metastatic castration-resistant prostate cancer. Based on clinical results to date and resource prioritization, we are continuing to focus on the ~~positive~~development of eltanexor in MDS. In August 2020, safety and efficacy results from a Phase 2 study of selinexor in patients with MDS or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents were published in The Lancet Haematology. Currently, no standard therapy for such patients exists. In the 23 evaluable patients, the overall response rate was 26% (95% CI 10 - 48) in six patients with marrow complete remission, with an additional 12 patients (52%, 95% CI 31 - 73) achieving stable disease. The most common grade 3 or 4 adverse events were thrombocytopenia (eight, or 32%, of 25 patients) and hyponatraemia (five, or 20%, of 25 patients). There were no drug-related serious adverse events and no treatment-related deaths. In addition, we began clinical testing of KPT-9274 in patients with hematologic or solid tumors during 2016 and in July 2020, dosed the first patient in a Phase 1/2 clinical study of KPT-9274 in combination with an anti-PD1 monoclonal antibody. Finally, verdinexor is our lead compound that is being evaluated as a potential therapy for viral, rare disease and autoimmune indications in humans and by a collaborator as a potential therapy for cancers in companion animals.

In May 2020, we agreed with Antengene Therapeutics Limited, or Antengene, to an expansion of their development and commercial rights to our compounds in parts of Asia, Australia and New Zealand by entering into an amendment to the May 2018 license agreement between us and Antengene, or the Original Antengene Agreement, and as amended, the Amended Antengene Agreement. We granted Antengene, our existing partner in China and other regions in Asia, the exclusive right to develop and commercialize selinexor and eltanexor in all human oncology indications in the following geographies comprising the Antengene Territory: Australia, New Zealand, South Korea, Taiwan, Hong Kong and the Association of Southeast Asian Nations, or ASEAN countries, which are currently comprised of Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam. The Amended Antengene Agreement also includes the development and commercialization of KPT-9274 in all human oncology indications and verdinexor in human non-oncology indications in Australia and New Zealand. Under the terms of the ~~SADAL study,~~Amended Antengene Agreement, we ~~plan~~received a one-time upfront payment of $11.7 million from Antengene in June 2020. We are also eligible to ~~submit a New Drug Application (NDA)~~receive additional payments if certain future prespecified development, regulatory and commercialization milestones are achieved by Antengene. In addition, we are also eligible to receive tiered double-digit royalties based on future net sales of selinexor and eltanexor, and tiered single- to double-digit royalties based on future net sales of verdinexor and KPT-9274 in the Antengene Territory. Certain countries in the Antengene Territory became available due to the ~~FDA with a request for accelerated approval for selinexor as a new treatment for patients with relapsed and/or refractory DLBCL after at least two prior multi-agent therapies~~reacquisition of exclusive development and ~~who are ineligible for stem cell transplantation (high dose chemotherapy with stem cell rescue)~~commercial rights from Ono Pharmaceutical Co., ~~including chimeric antigen receptor modified T (CAR-T) cell therapy. In November 2018,~~Ltd. in April 2020. We have chosen to retain the ~~FDA granted fast track designation~~rights to selinexor ~~for the treatment of patients that have relapsed and/or refractory DLBCL after at least two prior multi-agent therapies~~ and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. While the FDA previously agreed that the trial design and indication appear appropriate for accelerated approval, they reiterated to useltanexor in their feedback that the availability of accelerated approval will depend on the trial results and available therapies at the time of regulatory action. The FDA also has reiterated to us that it recommends, in general, a randomized trial with a progression-free survival endpoint as an initial registration approach and, for DLBCL, recommended two randomized trials that isolate the treatment effect of selinexor for a DLBCL indication. In addition, as we experienced with our NDA based on the results of Part 2 of the STORM study, the FDA has noted tolerability and dose optimization as review matters. We also plan to submit a MAA to the EMA with a request for conditional approval. We anticipate submitting the NDA by the end of 2019 and the MAA during 2020.

~~Table of Contents~~

Japan.

As of ~~September~~June 30, ~~2019,~~2020, we had an accumulated deficit of ~~$824.7~~$972.7 million. We had net losses of ~~$41.4~~$99.4 million and ~~$48.1~~$109.6 million for the ~~three~~six months ended ~~September~~June 30, ~~2019~~2020 and ~~2018, respectively, and net losses of $150.9 million and $120.2 million for the nine months ended September 30,~~ 2019, ~~and 2018,~~ respectively. As of ~~September~~June 30, ~~2019,~~2020, we have generated ~~$12.8~~$65.2 million to date in net product sales from XPOVIO, which first became commercially available in the ~~United States~~U.S. in July 2019.

Commercialization of XPOVIO in the United States

XPOVIO became commercially available to patients in the U.S. beginning in July 2019 and was approved for a second indication in June 2020. The commercialization of XPOVIO is being supported by approximately 70 Karyopharm sales representatives and nurse liaisons as well as KaryForward^TM, an extensive patient and healthcare provider support program. Our commercial efforts are also being supplemented by patient support initiatives coordinated by our dedicated network of participating specialty pharmacy providers.

As of June 30, 2020, nearly 3,200 XPOVIO prescriptions have been filled since launch, driven by strong demand from both academic and community-based physicians. Net product sales for XPOVIO were $34.7 million for the six months ended June 30, 2020. XPOVIO sales have been driven by a combination of new patient starts and prescription refills.

We plan to continue to build upon XPOVIO’s early commercial success in the late-line relapsed or refractory multiple myeloma market by educating physicians, healthcare providers and patients about XPOVIO’s clinical profile and unique mechanism of action. Based on the positive results from the BOSTON trial, which we announced in early March 2020, our commercial team is preparing for XPOVIO’s potential expansion into the second line relapsed or refractory multiple myeloma market, subject to the FDA’s review and approval of our sNDA based on the data from the BOSTON trial, which was accepted by the FDA in July 2020. Finally, following the FDA approval of XPOVIO to treat patients with DLBCL, in June 2020 we began to sell XPOVIO in this indication to hematologists and oncologists in the U.S. with our existing field sales force.

Commercialization Outside of the United States

In January 2019, we submitted an MAA to the EMA requesting conditional approval for selinexor in combination with dexamethasone as a treatment for patients with triple class refractory multiple myeloma, meaning patients who have received at least three prior therapies and whose disease is refractory to at least one PI, one IMiD, and one anti-CD38 monoclonal antibody. This submission was based on the results of the Phase 2b STORM study. We received feedback from EMA’s Committee for Medicinal Products for Human Use, or CHMP, including the integrated inspection report, based on site audits and a sponsor inspection. In January 2020, we were granted a three-month extension from CHMP to provide additional time to respond to the CHMP’s outstanding questions related to the application. We are currently working with CHMP to address the outstanding questions; however, due to reduced access to clinical trial sites as a result of the COVID-19 pandemic, we had not yet been able to completecertain re-monitoring activities and, therefore, requested, and the EMA has granted us, additional time to submit our response. We expect to submit the requested re-monitoring data in the third quarter of 2020, and we expect to receive an opinion from CHMP with respect to our MAA before the end of 2020. In addition, we expect to submit an MAA based on data from our BOSTON study before the end of 2020.

To commercialize selinexor following any regulatory approval outside of the U.S., we will work with existing and potential future partners to establish the appropriate commercial infrastructure outside of the U.S., or we may, in certain geographies, elect to establish the commercial infrastructure ourselves. We maintain complete commercial rights to selinexor in all territories outside of the Antengene Territory and Israel, including the U.S., Canada, Europe, Japan, and Latin America.

Uncertainty Relating to the COVID-19 Pandemic

The COVID-19 pandemic has and will continue to affect economies and businesses around the world. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our employees, patients and business operations. We have and may continue to experience disruptions in the future that could impact our results of operations and financial condition. We are unable to predict the impact that the COVID-19 pandemic will have on our operating results and financial condition due to numerous uncertainties. These uncertainties include the geographic spread of the pandemic, the severity of the virus, the duration of the outbreak, governmental, business or other actions, travel restrictions and social distancing, business closures or business disruptions, or changes to our operations, among others. We will continue to monitor the COVID-19 situation closely and intend to follow health and safety guidelines as they evolve. Further, the impacts of a potential worsening of global economic conditions and the continued disruptions to, and volatility in, the credit and financial markets, as well as other unanticipated consequences remain unknown. The situation surrounding the COVID-19 pandemic remains fluid and continues to rapidly evolve, and we are actively managing our response and assessing potential impacts to our operating results and financial condition, as well as adverse developments in our business. For further information regarding the impact of the COVID-19 pandemic on us, see Item 1A - Risk Factors included in this Quarterly Report on Form 10-Q.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES

We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as “critical” because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different ~~estimates—~~estimates - which also would have been ~~reasonable—~~reasonable - could have been used, which would have resulted in different financial results.

There were no changes to the critical accounting policies we identified in ~~the 2018 Form~~

~~10-K,~~

~~other than with respect to product revenue recognition, as described in Note 1 to the Condensed Consolidated Financial Statements included under Part I, Item 1 of this Quarterly Report on Form~~

~~10-Q.~~

our Annual Report. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies disclosed in ~~the 2018 Form~~

~~10-K,~~

~~as well as in Note 1 to the Condensed Consolidated Financial Statements included under Part I, Item 1 of this Quarterly Report on Form~~

~~10-Q.~~

our Annual Report.

RESULTS OF OPERATIONS

Comparison of the Three Months Ended ~~September~~June 30, ~~2019~~2020 and ~~September~~June 30, ~~2018~~2019

	For the Three Months Ended June 30,
	2020			2019			$ Change			% Change
	(in thousands)
Product revenue, net	$	18,601		$	—		$	18,601			100	%
License and other revenue		14,913			9,493			5,420			57	%
Operating expenses:
Cost of sales		396			—			396			100	%
Research and development		42,594			26,517			16,077			61	%
Selling, general and administrative		30,843			24,662			6,181			25	%
Loss from operations		(40,319	)		(41,686	)		1,367			(3	)%
Other expense, net		(5,970	)		(1,721	)		(4,249	)		247	%
Loss before income taxes		(46,289	)		(43,407	)		(2,882	)		7	%
Income tax provision		(137	)		(8	)		(129	)		1613	%
Net loss	$	(46,426	)	$	(43,415	)	$	(3,011	)		7	%

Three Months Ended
September 30,

2019

2018

$ Change

% Change

(in
thousands)

Revenues:





















Product revenue, net
$
12,821
$
—
$
12,821

100
%
License and other revenue

328

239

89

37
%
Operating expenses:

Cost of sales

1,013

—

1,013

100
%
Research and development

26,270

36,427

(10,157
)
(28
)%
Selling, general and administrative

25,267

12,966

12,301

95
%

Loss from operations

(39,401
)
(49,154
)
9,753

(20
)%
Other (expense) income, net

(1,946
)
1,085

(3,031
)
(279
)%

Loss before income taxes

(41,347
)
(48,069
)
6,722

(14
)%
Income tax provision

(20
)
(14
)
(6
)
43
%

Net loss
$
(41,367
) $
(48,083
) $
6,716

(14
)%

Product revenue, net.

We ~~began to record~~recognized $18.6 million of net product revenue ~~net~~ in the ~~third quarter~~three months ended June 30, 2020 from U.S. commercial sales of ~~2019 following the approval of~~XPOVIO. XPOVIO was initially approved by the FDA in July 2019, and ~~its subsequent commercial launch in the United States. We~~therefore we did not ~~generate~~have any net product revenue ~~from product sales prior to~~in the three months ended ~~September~~June 30, 2019.

License and other revenue. License and other revenue for the three months ended June 30, 2020 was $14.9 million compared to $9.5 million for the three months ended June 30, 2019. During the three months ended June 30, 2020, we recognized $12.7 million pursuant to the Amended Antengene Agreement, and $2.2 million upon reacquisition of the exclusive development and commercial rights from Ono Pharmaceutical Co., Ltd., or Ono. We recognized $9.4 million in revenue during the three months ended June 30, 2019 pursuant to the Original Antengene Agreement and $0.1 million related to clinical supply provided to various partners, as well as grant revenue pursuant to a government grant arrangement.

We expect license and other revenue to decrease in the third quarter of 2020 due to the non-recurring revenue recognized in the second quarter of 2020 pursuant to the terms of the Amended Antengene Agreement and the termination of the license agreement with Ono.

Cost of ~~Sales.~~

sales. Cost of sales includes the cost of producing and distributing inventories that are related to U.S. XPOVIO product revenue ~~in the United States~~ during the respective period (including salary-related and stock-based compensation expenses for employees involved with XPOVIO production and distribution) and third-party royalties payable on our net product revenue for XPOVIO. We began capitalizing XPOVIO inventory costs during the third quarter of 2019 subsequent to FDA approval, as our expectation iswas that such costs will be recoverable through commercialization of XPOVIO. Prior to the capitalization of XPOVIO inventory costs, such costs were recorded as research and development expenses in the period incurred. During the three months ended ~~September~~June 30, ~~2019,~~2020, we recorded ~~$1.0~~$0.4 million of cost of sales, including ~~$0.7~~$0.1 million related to royalties. The cost of sales during the three months ended ~~September~~June 30, ~~2019~~2020 only reflects a portion of the costs related to the manufacturing of XPOVIO and related materials, since, prior to FDA approval, these costs were expensed. The manufacturing costs of XPOVIO

on-hand

upon FDA approval were approximately $2.8 million. At ~~September~~June 30, ~~2019,~~2020, we ~~have~~had $2.7 million of this previously expensed XPOVIO and related material

on-hand.

We expect cost of sales to remain relatively consistent quarter over quarter for the remainder of the year.

Research and ~~Development Expense.~~

development expense.Research and development expense ~~decreased~~increased approximately ~~$10.2~~$16.1 million to ~~$26.3~~$42.6 million for the three months ended ~~September~~June 30, ~~2019~~2020 from approximately ~~$36.4~~$26.5 million for the three months ended ~~September~~June 30, ~~2018.~~2019. The ~~decrease is~~increase was primarily related to:

•

an increase of $9.6 million in clinical trial costs, primarily related to COVID-19 trial activity as well as continued activity in our ongoing clinical trials;

•

an increase of $4.1 million in personnel costs, primarily related to an increase in headcount;

~~a decrease of $4.8 million in personnel~~

•

an increase of $1.4 million in facility and IT infrastructure costs; and

•

an increase of $1.0 million in travel, consulting and professional costs.

~~Table of Contents~~

~~a decrease of $2.7 million in clinical trial costs, primarily related to the selinexor program;~~

~~a decrease of $1.8 million in consulting and professional costs;~~

~~a decrease of $0.6 million in miscellaneous costs; and~~

~~a decrease of $0.3 million in travel costs.~~

We expect our research and development expense to beremain relatively consistent quarter over quarter for the ~~final quarter~~remainder of ~~2019 as compared~~the year, with possible fluctuation over the quarters due to ~~the third quarter~~timing of ~~2019 as we moderate our spending on our development programs~~clinical trial study starts and related clinical ~~trials, while continuing clinical development of selinexor in our lead indications with a focus on regulatory submissions for selinexor.~~

trial enrollment.

Selling, ~~General~~general and ~~Administrative Expense.~~

administrative expense. Selling,

eneral and administrative expense increased approximately ~~$12.3~~$6.2 million to ~~$25.3~~$30.8 million for the three months ended ~~September~~June 30, ~~2019~~2020 from approximately ~~$13.0~~$24.6 million for ~~the~~ three months ended ~~September~~June 30, ~~2018.~~2019. The increase iswas primarily related to:

•

an increase of $4.1 million in commercial-related activities;

•

an increase of $3.0 million in personnel costs, primarily related to an increase in headcount; and

an increase of $7.5 million in personnel costs, primarily due to increased headcount and related onboarding costs associated with building our commercial team in connection with the U.S. commercial launch of XPOVIO;

•

an increase of $0.2 million in facility and IT infrastructure costs; partially offset by

•

a decrease of $1.1 million in travel, consulting and professional costs.

~~an increase of $3.1 million in commercial related activities;~~

~~an increase of $1.9 million in costs related to corporate training, travel and corporate events; and~~

~~an increase of $0.3 million in facility costs and information technology infrastructure costs; offset by~~

~~a decrease of $0.5 million in consulting and professional costs.~~

We expect our selling, general and administrative expenses to remain relatively consistent quarter over quarter for the remainder of ~~2019~~the year as a result of decreased travel and corporate events due to ~~support our expanding operating and commercial activities, particularly following~~COVID-19 impacts, offset by costs expected to be incurred for the ~~accelerated approval~~preparations in anticipation of ~~XPOVIO by~~ the ~~FDA in July 2019 and commercial~~BOSTON launch, ~~shortly thereafter.~~

if approved.

Other ~~Income (Expense),~~expense, net.

Other ~~(expense) income,~~expense, net ~~decreased~~increased from ~~$1.1~~$1.7 million ~~of other income, net~~ for the three months ended ~~September~~June 30, ~~2018~~2019 to ~~$1.9~~$6.0 million ~~of other expense, net~~ for the three months ended ~~September~~June 30, ~~2019.~~2020. The ~~decrease is~~net increase of approximately $4.3 million was primarily due to ~~$3.1 million of~~an increase in interest expense of $3.7 million, coupled with a decrease in interest income of $0.6 million. Of the $3.7 million increase in interest expense, $3.5 million was related to ~~the issuance of~~our Revenue Interest Financing Agreement, or deferred royalty obligation, and $0.2 million was related to our 3.00% senior convertible ~~senior~~ notes due 2025, ~~(Notes) in October 2018.~~

or Notes.

We expect interest expense to increase in the ~~fourth~~third quarter of ~~2019~~2020 and beyond, related to the ~~issuance of~~imputed interest on our deferred royalty obligation.

~~Table of Contents~~

Comparison of the ~~Nine~~six months ~~Ended September~~ended June 30, ~~2019~~2020 and ~~September~~June 30, ~~2018~~2019

	Six Months Ended June 30,
	2020			2019			$ Change			% Change
	(in thousands)
Product revenue, net	$	34,662		$	—		$	34,662			100	%
License and other revenue		16,990			9,648			7,342			76	%
Operating expenses:
Cost of sales		1,215			—			1,215			100	%
Research and development		76,591			64,491			12,100			19	%
Selling, general and administrative		61,521			51,765			9,756			19	%
Loss from operations		(87,675	)		(106,608	)		18,933			(18	)%
Other expense, net		(11,479	)		(2,950	)		(8,529	)		289	%
Loss before income taxes		(99,154	)		(109,558	)		10,404			(9	)%
Income tax provision		(203	)		(18	)		(185	)		1028	%
Net loss	$	(99,357	)	$	(109,576	)	$	10,219			(9	)%

Nine months Ended
September 30,

        2019

        2018

        $ Change

        % Change

(in thousands)

Revenues:

















Product revenue, net
$
12,821
$
—
$
12,821

100
%
License and other revenue

9,976

30,130

(20,154
)
(67
)%
Operating expenses:

Cost of sales

1,013

—

1,013

100
%

Research and development

90,761

122,482

(31,721
)
(26
)%
Selling, general and administrative

77,032

30,076

46,956

156
%

Loss from operations

(146,009
)
(122,428
)
(23,581
)
19
%
Other (expense) income, net

(4,896
)
2,240

(7,136
)
(319
)%

Loss before income taxes

(150,905
)
(120,188
)
(30,717
)
26
%
Income tax provision

(38
)
(9
)
(29
)
322
%

Net loss
$
(150,943
) $
(120,197
) $
(30,746
)
26
%

Product revenue, net.

We ~~began to record~~recognized $34.7 million of net product revenue ~~net~~ in the ~~third quarter~~six months ended June 30, 2020 from U.S. commercial sales of ~~2019 following the approval of~~XPOVIO. XPOVIO was initially approved by the FDA in July 2019, and ~~its subsequent commercial launch~~therefore we did not have any net product revenue in the ~~United States. We did not generate any~~six months ended June 30, 2019.

License and other revenue. License and other revenue ~~from product sales prior~~for the six months ended June 30, 2020 was $17.0 million compared to $9.6 million for the six months ended June 30, 2019. During the six months ended June 30, 2020, we recognized $13.8 million pursuant to the ~~three~~Antengene Agreement, $2.2 million upon reacquisition of the exclusive development and commercial rights from Ono, and $1.0 million related to clinical supply provided to various partners, as well as grant revenue pursuant to a government grant arrangement. During the six months ended ~~September 30, 2019.~~

~~License and Other Revenue.~~

~~During the nine months ended September~~June 30, 2019, we recognized $9.4 million in revenue pursuant to ~~a license arrangement with~~the Original Antengene ~~Therapeutics Limited,~~Agreement and $0.2 million in revenue for clinical supply provided to various partners, as well as ~~$0.3 million in~~grant revenue pursuant to a government grant arrangement.

Cost of sales. During the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2020, we ~~recognized $10.0~~recorded $1.2 million ~~in revenue pursuant to an asset purchase agreement with Biogen MA Inc. for the sale of~~

~~KPT-350~~

~~and $19.9 million in revenue primarily as a result~~ of ~~a license arrangement with Ono Pharmaceutical Co., Ltd.~~

~~Cost of Sales.~~

~~Cost~~cost of sales, ~~includes the cost of producing and distributing inventories that are~~including $0.9 million related to XPOVIO product revenue in the United States during the respective period (including salary-related and stock-based compensation expenses for employees involved with XPOVIO production and distribution) and third-party royalties payable on our net product revenue for XPOVIO.royalties. We began capitalizing XPOVIO inventory costs during the third quarter of 2019 subsequent to FDA approval ~~and our expectation that such costs will be recoverable through commercialization of XPOVIO. Prior to the capitalization~~ of XPOVIO, ~~inventory costs, such costs were recorded as research~~ and ~~development expenses in the period incurred. During the nine months ended September 30, 2019,~~therefore we ~~recorded $1.0 million of~~did not have cost of sales ~~including $0.7 million related to royalties. The cost of sales during~~for the ~~nine~~six months ended ~~September~~June 30, ~~2019 only reflects a portion of the costs related to the manufacturing of XPOVIO and related materials, since, prior to FDA approval, these costs were expensed. The manufacturing costs of XPOVIO~~

~~on-hand~~

~~upon approval were approximately $2.8 million. At September 30, 2019, we have $2.7 million of this previously expensed XPOVIO and related material~~

~~on-hand.~~

2019.

Research and ~~Development Expense.~~

development expense.Research and development expense ~~decreased~~increased approximately ~~$31.7~~$12.1 million to ~~$90.8~~$76.6 million for the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 from approximately ~~$122.5~~$64.5 million for the ~~nine~~six months ended ~~September~~June 30, ~~2018.~~2019. The ~~decrease is~~increase was primarily related to:

•

an increase of $6.1 million in personnel costs and consulting and professional expense;

•

an increase of $5.7 million in clinical trial costs; and

~~a decrease of $15.3 million in clinical trial costs, primarily related to the selinexor program;~~

•

an increase of $1.7 million in facility and IT infrastructure costs; partially offset by

•

a decrease of $1.4 million in travel, consulting and professional costs.

~~a decrease of $9.2 million in consulting~~

Selling, general and ~~professional costs;~~

~~a decrease of $7.5 million in personnel costs; and~~

~~a decrease of $0.6 million in travel costs; offset by~~

~~an increase of $0.9 million in facility costs and information technology infrastructure costs.~~

~~Selling, General and Administrative Expense.~~

administrative expense. Selling, general and administrative expense increased approximately ~~$47.0~~$9.8 million to ~~$77.0~~$61.5 million for the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 from approximately ~~$30.1~~$51.7 million for the ~~nine~~six months ended ~~September~~June 30, ~~2018.~~2019. The increase iswas primarily related to:

•

an increase of $6.7 million in commercial-related activities;

•

an increase of $4.3 million in personnel costs; and

•

an increase of $0.4 million in facility and IT infrastructure costs; partially offset by

•

a decrease of $1.6 million in travel, consulting and professional costs.

Other expense, net. Other expense, net increased from $3.0 million for the six months ended June 30, 2019 to $11.5 million for the six months ended June 30, 2020. The increase of ~~$28.8~~approximately $8.5 million ~~in personnel costs,~~was primarily due to ~~increased headcount and related onboarding costs associated with building our commercial team in preparation for and in connection with the U.S. commercial launch of XPOVIO;~~

~~Table of Contents~~

an ~~increase of $9.5 million in commercial related activities;~~

~~an increase of $5.7 million in costs related to corporate training, travel and corporate events;~~

~~an increase of $3.6 million in facility costs and information technology infrastructure costs; and~~

~~an increase of $0.2 million in consulting and professional costs; offset by~~

~~a decrease of $0.8 million in miscellaneous costs.~~

~~Other Income (Expense), net.~~

Other (expense) income, net decreased from $2.2 million of other income, net for the nine months ended September 30, 2018 to $4.9 million of other expense, net for the nine months ended September 30, 2019. The decrease is primarily due to $9.2 million of interest expense related to the issuance of the Notes in October 2018, offset by a $2.1 million increase in interest expense of $7.2 million, coupled with a decrease in interest income ~~due to increased returns resulting from a general~~of $1.3 million. $6.8 million of the increase in interest ~~rates~~expense was related to our deferred royalty obligation and ~~higher investment balances.~~

$0.4 million of the increase was attributable to our Notes.

LIQUIDITY AND CAPITAL RESOURCES

Sources of Liquidity

During the third quarter of 2019, we began generating revenues from ~~drug~~product sales, as XPOVIO first became commercially available in the ~~United States~~U.S. in July 2019. We have had limited revenues to date from product sales and have financed our operations principally through private placements of our preferred stock, proceeds from our initial public offering and follow-on offerings of common stock, proceeds from the issuance of convertible debt, proceeds pursuant to the ~~Revenue Interest Agreement (as defined below),~~deferred royalty obligation, and cash generated from our business development activities.

Although we do not currently expect that the ongoing COVID-19 pandemic will have a material impact on our business plans or results of operations, we are continually monitoring our liquidity and capital requirements in light of the evolving situation.

At ~~September~~June 30, ~~2019,~~2020, our principal source of liquidity was ~~$269.6~~$345.6 million of cash, cash equivalents and investments. We have had recurring losses and incurred a loss of ~~$150.9~~$99.4 million for the ~~nine~~six months ended ~~September~~June 30, ~~2019.~~2020. Net cash used in operations for the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 was ~~$151.3~~$85.3 million. We expect that cash, cash equivalents and investments at ~~September~~June 30, ~~2019~~2020 will be sufficient to fund our current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of the financial statements contained in this Quarterly Report on Form

~~10-Q,~~

10-Q.

On May 5, 2020, we entered into Amendment No. 1 to the Open Market Sale Agreement,dated August 17, 2018, or the Open Market Sale Agreement, with Jefferies LLC, as agent, or Jefferies, pursuant to which we increased the maximum aggregate offering price of shares of our common stock that we may issue and sell from time to time through Jefferies, by $100.0 million from $75.0 million to up to $175.0 million. We did not sell any shares under the Open Market Sale Agreement during the second quarter of 2020. As of July 31, 2020, we have sold an aggregate of 3,712,359 shares under the Open Market Sale Agreement, for net proceeds of approximately $46.2 million, all of which ~~time~~were sold in 2019.

On March 6, 2020, we ~~plan~~completed a follow-on offering under our shelf registration statement on Form S-3 pursuant to ~~enhance~~which we issued an aggregate of 7,187,500 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $24.00 per share. We received aggregate net proceeds of approximately $161.8 million from the offering after deducting the underwriting discounts and ~~support the commercial infrastructure for the sale of XPOVIO in the United States that began in July 2019.~~

commissions and other offering expenses.

On September 14, 2019, we entered into a ~~Revenue Interest Financing Agreement (the “Revenue Interest Agreement”)~~deferred royalty obligation, with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P, ~~(“HCR”).~~or HCR. Pursuant to the ~~Revenue Interest Agreement,~~deferred royalty obligation, HCR paid us $75.0 million, ~~(the “First Investment Amount”),~~ less certain transaction expenses, at the initial closing, which occurred on September 27, 2019, as disclosed in Note 1211 to the Condensed Consolidated Financial Statements included under Part I, Item 1 of this Quarterly Report on Form 10-Q.

On October 16, 2018, we completed an offering of $150.0 million aggregate principal amount of the Notes. In addition, on October 26, 2018, we issued an additional $22.5 million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended. The net proceeds from the sale of the Notes was $166.9 million, after deducting the initial purchasers’ discounts and commissions and actual offering expenses payable by us.

In August 2018, we entered into an open market sale agreement (Open Market Sale Agreement) with Jefferies LLC, as agent, relating to an “at the market offering”, pursuant to which we may issue and sell shares of our common stock, having an aggregate offering price of up to $75.0 million. As of October 31, 2019, we had sold an aggregate of 1,634,451 shares under the Open Market Sale Agreement, for net proceeds of approximately $14.6 million, all of which were sold during the third quarter of 2019.

On May 7, 2018, we completed a

follow-on

offering under our shelf registration statement on Form

S-3

~~(File No.~~

~~333-222726)~~

pursuant to which we issued an aggregate of 10,525,424 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $14.75 per share. We received aggregate net proceeds of approximately $145.7 million from the offering after deducting the underwriting discounts and commissions and other offering expenses.

During the years ended December 31, 2018 and 2017, we received $44.6 million in upfront payments under our arrangements with Anivive Lifesciences, Inc., Ono Pharmaceutical Co., Ltd., Biogen MA Inc., and Antengene Therapeutics Limited, pursuant to which we are also entitled to receive milestone payments, if certain development goals and sales milestones are achieved, as well as royalties on future net sales of the licensed and sold products in the territories under such arrangements.

~~Table of Contents~~

Cash Flows

The following table provides information regarding our cash ~~flows:~~flows (in thousands):

	Six Months Ended June 30,
	2020			2019
Net cash used in operating activities	$	(85,288	)	$	(114,827	)
Net cash (used in) provided by investing activities		(106,513	)		71,794
Net cash provided by financing activities		166,875			547
Effect of exchange rate changes		(32	)		9
Net decrease in cash, cash equivalents and restricted cash	$	(24,958	)	$	(42,477	)

Nine months Ended
September 30,

2019

2018

(in thousands)
Net cash used in operating activities


$
(151,333
)





$
(110,945
)

Net cash provided by (used in) investing activities

111,969

(4,554
)
Net cash provided by financing activities

89,369

148,333

Effect of exchange rate changes

(26
)
(9
)

Net increase in cash, cash equivalents and restricted cash
$
49,979
$
32,825

Operating activities.

The net cash used in operating activities in both periods resulted primarily from our net losses adjusted for

non-cash

charges and changes in the components of working capital. The ~~increase~~decrease in cash used in operating activities during the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, compared to the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, was primarily driven by our ~~increased~~decreased loss from operations during that period.

Investing activities.

The net cash (used in) provided by ~~(used in)~~ investing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, compared to the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, primarily reflects ana $159.1 million increase in ~~maturity~~the purchases of investments, ~~of $108.1~~coupled with a $19.2 million ~~offset by a~~ decrease in ~~purchases~~proceeds from the maturities of ~~$7.3 million.~~

investments.

Financing activities.

The net cash provided by financing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, compared to the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, reflects ~~a decrease~~an increase of ~~$59.0 million~~$166.3 million. The increase was primarily related to the net cash proceeds of ~~$73.7 million from the execution of the Revenue Interest Agreement with HCR in September 2019 and the net proceeds of $14.6~~$161.8 million from the sale of ~~Open Market Shares~~shares of our common stock from the follow-on offering under ~~the Open Market Sale Agreement~~our shelf registration statement on Form S-3 during the ~~third~~first quarter of ~~2019,~~2020, coupled with a $4.5 million increase in proceeds from the exercise of stock options and shares issued under our Employee Stock Purchase Program in the first half of 2020 compared to the ~~net proceeds~~first half of ~~$145.7 million from our follow-on offering in May 2018.~~

2019.

Funding Requirements

We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to commercialize XPOVIO and continue the clinical trials of, and as we seek marketing approval for, our drug candidates. In addition, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution of any of our drug candidates for which we obtain marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time for any such ~~drug.~~drug candidate. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts.

Our future capital requirements will depend on many factors, including:

•

revenue generated from commercial sales of XPOVIO;

•

costs related to the sales and marketing of XPOVIO;

~~revenue generated from commercial sales of XPOVIO;~~

•

the costs, timing and outcome of regulatory review of our drug candidates;

•

the costs of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our drug candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;

•

the amount of revenue received from commercial sales of our drug candidates for which we receive marketing approval;

•

the progress and results of our current and planned clinical trials of selinexor;

•

the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;

•

our ability to establish and maintain collaborations on favorable terms, if at all;

•

the success of any collaborations that we may enter into with third parties;

•

the extent to which we acquire or in-license other drugs and technologies;

•

the costs associated with legal activities, including litigation, arising in the course of business activities and our ability to prevail in any such legal disputes; and

•

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.

~~costs related to the sales and marketing of XPOVIO;~~

~~the costs, timing and outcome of regulatory review of our drug candidates;~~

~~the amount of revenue received from commercial sales of our drug candidates for which we receive marketing approval;~~

~~the progress and results of our current and planned clinical trials of selinexor;~~

~~the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;~~

~~our ability to establish and maintain collaborations on favorable terms, if at all;~~

~~the success of any collaborations that we may enter into with third parties;~~

~~the extent to which we acquire or~~

~~in-license~~

~~other drugs and technologies;~~

~~Table of Contents~~

~~the costs associated with legal activities, including litigation, arising in the course of business activities and our ability to prevail in any such legal disputes; and~~

~~the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.~~

Identifying potential drug candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete. In addition, our drug candidates for which we receive marketing approval may not achieve commercial success. Our ability to become and remain profitable depends on our ability to generate revenue. While we began to generate revenue from the sales of XPOVIO in July 2019, there can be no assurance as to the amount or timing of any such revenue, and we may not achieve profitability for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

~~Contractual Obligations~~

~~As of September 30, 2019,~~ We may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have contractual obligations under the Revenue Interest Agreement with HCR, as disclosed in Note 12 to the Condensed Consolidated Financial Statements included under Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no other material changes tosufficient funds for our ~~contractual obligations described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the 2018 Form 10-K.~~

current or future operating plans.

OFF-BALANCE

SHEET ARRANGEMENTS

We did not have during the periods presented, and we do not currently have, any

off-balance

sheet arrangements, as defined under SEC rules.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents, ~~restricted cash~~ and investments of ~~$270.3~~$345.6 million as of ~~September~~June 30, ~~2019.~~2020. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio.

We do not believe our cash, cash equivalents, restricted cash and investments have significant risk of default or illiquidity. While we believe our cash, cash equivalents and investments do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in securities at one or more financial institutions that are in excess of federally insured limits. Given the potential instability of financial institutions, we cannot provide assurance that we will not experience losses on these deposits and investments.

We are also exposed to market risk related to changes in foreign currency exchange rates. We contract with contract research organizations and contract manufacturing organizations that are located in Canada and Europe, which are denominated in foreign currencies. We also contract with a number of clinical trial sites outside of the ~~United States,~~U.S., and our budgets for those studies are frequently denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these agreements. We do not currently hedge our foreign currency exchange rate risk.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (principal executive officer) and Senior Vice President, Chief Financial Officer and Treasurer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of ~~September~~June 30, ~~2019.~~2020. The term “disclosure controls and procedures,” as defined in Rules

13a-15(e)

and

15d-15(e)

under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies our judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of

~~Table of Contents~~

~~September~~ June 30, ~~2019,~~2020, our Chief Executive Officer and our Senior Vice President, Chief Financial Officer and Treasurer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

During the fiscal quarter ended September 30, 2019, we began generating product revenue from the sale of XPOVIO in the United States. We consider the accounting for our net product revenue to be material to the results of operations for the three and nine months ended September 30, 2019, and believe that the additional internal controls and procedures related to the accounting for net product revenue under ASC 606,

~~Revenue from Contracts with Customers,~~

~~have a material effect on our internal control over financial reporting. No other~~

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended ~~September~~June 30, ~~2019~~2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART ~~II—~~II - OTHER INFORMATION

Item 1. Legal Proceedings.

We ~~were recently~~have been named as a defendant in a securities class action litigation filed on July 23, 2019, in the U.S. District Court for the District of Massachusetts. AThe complaint was filed ~~on July 23, 2019,~~ by the Allegheny County Employees’ Retirement System, against us and certain of our current and former executive officers and directors as well as the underwriters of our public offerings of common stock conducted in April 2017 and May 2018. This complaint was voluntarily dismissed on March 12, 2020. A second complaint was filed by Heather Mehdi on September 17, 2019, in the same court and against the same defendants with the exception of the underwriters. In April 2020, the court appointed a lead plaintiff, Myo Thant, who filed an amended complaint on June 29, 2020. The ~~two complaints are related and we expect them to be consolidated by the court. Both complaints allege~~amended complaint alleges violations of federal securities laws based on our disclosures related to the results from the Phase 2 SOPRA study and Part 2 of the Phase 2b STORM study, and ~~seek~~seeks unspecified compensatory damages, including interest; reasonable costs and expenses, including attorneys’ and expert fees; ~~unspecified recessionary damages;~~ and such equitable/injunctive relief or other relief as the court may deem just and proper. We have reviewed the allegations and believe they are without merit. We moved to dismiss the complaint on July 31, 2020 and additional briefing deadlines are scheduled through September 2020. We intend to defend vigorously against this litigation.

Item 1A. Risk Factors.

Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report on Form

10-Q

and in other documents that we file with the Securities and Exchange Commission, or SEC, in evaluating us and our business. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks we face. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations.

The COVID-19 pandemic has adversely disrupted, and is expected to continue to adversely disrupt, our operations, including our clinical trial activities and commercial operations, which could have an adverse effect on our business and financial results.

The outbreak of the novel coronavirus disease, or COVID-19, is a global pandemic that has affected many segments of the global economy. As a result, we have experienced, and we expect to continue to experience, disruptions that could adversely impact our business, clinical trial activities and commercial operations, including:

•

negative impact to revenue for XPOVIO^® (selinexor) tablets, which may continue as the COVID-19 pandemic persists, including as a result of decreased new patient starts due to the inability of our sales force and our patients to meet with healthcare professionals;

•

delays or difficulties in enrolling patients in our clinical trials, including our SEAL, SIENDO and STOMP trials;

•

delays or difficulties in initiating new clinical studies, including clinical site initiation and difficulties in recruiting clinical site investigators and clinical site staff;

~~Risks Related~~

•

reduction or diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;

•

interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by government officials or entities, employers and others or interruption of clinical trial patient visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of clinical trial data and clinical study endpoints;

•

interruption or delays in the operations of the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies, including the European Medicines Agency, or EMA, which may impact regulatory review and approval timelines, such as the EMA review of our Marketing Authorization Application, or MAA, for selinexor in multiple myeloma based on the results on the STORM study and any resulting impact to the timing of our expected submission of an MAA for selinexor in multiple myeloma supported by the results of the BOSTON study or any future MAA submission;

•

negative impacts on any or all aspects of our operations due business disruptions related to COVID-19 at our third-party vendors who we rely upon in the conduct of our business; and

•

limitations on employee resources that would otherwise be focused on the conduct of our business, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, and an increased reliance on working from home.

The COVID-19 pandemic continues to evolve, and its ultimate scope, duration and effects are unknown. The extent of the ~~Discovery, Development~~impact of the disruptions to our business, including commercial sales and ~~Commercialization~~clinical trials, as a result of the pandemic will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and actions to contain the pandemic or treat its impact, including social distancing and quarantines or lock-downs in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.

Our ~~Drugs~~pursuit of a treatment for severe COVID-19 in hospitalized patients is at an early stage. We have not previously tested selinexor in this capacity and ~~Drug Candidates~~

cannot assure you that selinexor will prove to be an effective treatment of severe COVID-19 or approved for marketing by the FDA, EMA or other regulatory authorities.

In April 2020, we announced the initiation of a global, randomized clinical trial to evaluate the use of selinexor to treat hospitalized patients with severe COVID-19. In May 2020, the protocol was amended to allow enrollment of patients with more severe disease. Following a planned interim analysis (115 patients included in the efficacy analysis and 113 patients included in the safety analysis), the Data Safety Monitoring Board, or DSMB, for the study recommended that we discontinue the trial as it is unlikely to demonstrate a statistically significant efficacy benefit across the entire heterogenous patient population studied. However, the DSMB concluded that the trial was likely to show a benefit in a subpopulation of patients <75 years old who have a COVID-GRAM non-high-risk score (a clinical risk score for disease severity), which represented approximately 75% of these 115 patients. Preliminary results indicate that in the specific subpopulation, a two-point improvement in Ordinal Score at Day 14 (the primary endpoint for the entire study) reached statistical significance, as did the two-point improvement in Ordinal Score by Day 28 and the rate of hospital discharge by Day 14 (all p≤0.05). Fatalities were similar across the two arms in this subpopulation (4/49 on selinexor and 2/37 on placebo). There was also a significant improvement in conversion to SARS-CoV2 PCR negative status on the selinexor arm as compared with the placebo arm across the entire population (p≤0.05). In patients ≥75 years old or with a COVID-GRAM high risk score, there was no improvement in clinical outcomes; fatalities were higher in the selinexor arm (6/15) than the placebo arm (1/12). While the rate of fatalities in the study was imbalanced in the patients ≥75 years old or with a COVID-GRAM high risk score, after a detailed review, the DSMB considered that the fatalities on study were due to severe COVID-19 disease and/or underlying comorbidities without a clear contribution of selinexor. After reviewing the safety and efficacy data that was shared with the DSMB, the FDA’s opinion was that the benefit-risk ratio was not favorable in the heterogenous patient population evaluated under the latest protocol for XPORT-CoV-1001, which included the patients with more severe disease as described above. We will continue to analyze the data to further characterize the specific subpopulation that will likely benefit from selinexor and will work with the FDA to identify a path forward for future clinical development. We will also seek potential partners and external funding to advance future clinical studies.

Although we believe that selinexor has the potential to provide anti-viral and/or anti-inflammatory benefits to patients with severe COVID-19, selinexor has not previously been tested as a treatment for patients with severe viral infections and, therefore, we cannot predict its efficacy or whether we will be able to obtain marketing approval from the FDA, EMA or other regulatory authorities. Our development of this potential treatment is in early stages, and we may be unable to provide a treatment that successfully treats the virus and/or its symptoms in a timely manner, if at all, particularly in light of our recent decision to discontinue the current trial. In addition, we may not be able to enter into an arrangement with a third party or obtain external funding to advance future clinical studies in COIVD-19 in a timely manner, or at all. If the pandemic is effectively contained or the risk of COVID-19 infection is diminished or eliminated before we can successfully complete clinical development and obtain regulatory approval of selinexor as a treatment for COVID-19, we may be unable to recoup any costs we incur in the development of this additional indication for selinexor and we may never recognize any revenue from the sale of selinexor to treat COVID-19, even if we do receive one or more regulatory approvals.

Furthermore, the biotechnology market is highly competitive and there are numerous companies that are currently pursuing a treatment or vaccine for COVID-19. Our competitors may develop these products more rapidly or more effectively than us. If our competitors are more successful in developing, obtaining regulatory approval or commercializing their products than us, their success could adversely affect our competitive position in this area and harm our business prospects.

We depend heavily on the success of ~~XPOVIO~~

~~(selinexor).~~XPOVIO. If we are unable to successfully commercialize our current and future indications of XPOVIO or successfully develop ~~selinexor for additional indications,~~our other drug candidates within or outside of the U.S., or if we experience significant delays in doing so, our business will be materially harmed.

We have invested a significant portion of our efforts and financial resources in the research and development of our lead drug, ~~candidate,~~ selinexor. Our ability to generate revenues from the sale of drugs that treat cancer and other diseases in humans will depend heavily on the successful development, regulatory approval and commercialization of selinexor. OnIn July 3, 2019, the ~~U.S. Food and Drug Administration, or~~ FDA granted accelerated approval for XPOVIO in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma ~~(RRMM)~~ who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal ~~antibody.~~antibody, or the multiple myeloma indication. In June 2020, the FDA granted accelerated approval for XPOVIO for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy, or the DLBCL indication. Our ability to generate ~~product~~ revenues from the sale of drugs that treat cancer and other diseases in humans will depend heavily on ~~our~~the successful development, additional regulatory approvals and commercialization of ~~XPOVIO and our obtaining additional marketing approvals for, and successfully commercializing, selinexor for additional indications.~~

selinexor.

The commercial success of our current and future indications of XPOVIO and the successful clinical development of ~~selinexor and~~ our other drug candidates will depend on several factors, including the following:

•

our ability to successfully launch our approved products, including the recently approved DLBCL indication for XPOVIO, or any drug candidates for which we obtain marketing approval, whether alone or in collaboration with others;

•

the consistency of any new data we collect and analyses we conduct with prior results, whether they support a favorable safety, efficacy and effectiveness profile of XPOVIO and any potential impact on our FDA accelerated approvals and/or FDA package insert for XPOVIO;

~~successful commercialization of XPOVIO in the United States, including establishing and maintaining sales, marketing and distribution capabilities for XPOVIO;~~

•

our ability to comply with FDA post-marketing requirements and commitments, including through successfully conducting additional studies that confirm clinical efficacy, effectiveness and safety of XPOVIO and acceptance of the same by the FDA and the medical community since continued approval for our current indications may be contingent upon verification of a clinical benefit in confirmatory trials;

•

acceptance of our current and future indications of XPOVIO and, if and when approved, our other drug candidates, by patients, the medical community and third-party payors;

•

obtaining and maintaining coverage, adequate pricing and reimbursement by third-party payors, including government payors, for XPOVIO and our drug candidates, if approved;

•

successful and timely completion of preclinical studies;

•

acceptance by the FDA of investigational new drug applications, or INDs, for our drug candidates prior to commencing clinical studies;

•

successful and timely enrollment in, and completion of, clinical trials, including demonstration of a favorable risk-benefit ratio;

•

receipt of marketing approvals from applicable regulatory authorities in a timely fashion;

•

establishing and maintaining commercial manufacturing capabilities or making arrangements with third-party manufacturers;

•

obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drugs and drug candidates;

•

establishing and maintaining sales, marketing, manufacturing and distribution capabilities to commercialize our currently approved drugs and any drug candidates for which we obtain marketing approval, whether alone or in collaboration with others;

•

effectively competing with other therapies;

•

maintaining an acceptable safety profile of our approved drugs;

•

compliance with existing and new health care laws and regulations currently being considered or implemented in the U.S., including government pricing, price reporting and other disclosure requirements related to such laws and regulations and the potential impact of such requirements on physician prescribing practices and payor coverage;

•

enforcing and defending intellectual property rights and claims;

•

maintaining and growing an organization of scientists and business people, including collaborators, who can develop and commercialize our drug candidates; and

•

the impact of the COVID-19 pandemic on the above factors, including the limitation of our sales professionals to meet with healthcare professionals as the result of travel restrictions or hospital limitations on access for non-patients.

~~Table of Contents~~

our ability to comply with FDA post-marketing requirements and commitments, including through successfully conducting additional studies that confirm clinical efficacy, effectiveness and safety of XPOVIO and acceptance of the same by the FDA and medical community since continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials;

~~acceptance of XPOVIO and, if and when approved, our drug candidates by patients, the medical community and third-party payors;~~

~~obtaining and maintaining coverage, adequate pricing and adequate reimbursement by third-party payors, including government payors, for XPOVIO and our drug candidates;~~

~~successful completion of preclinical studies;~~

~~acceptance by the FDA of investigational new drug applications, or INDs, for our drug candidates prior to commencing clinical studies;~~

~~successful enrollment in, and completion of, clinical trials, including demonstration of a favorable risk-benefit ratio;~~

~~receipt of marketing approvals from applicable regulatory authorities;~~

~~establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;~~

~~obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;~~

establishing sales, marketing, manufacturing and distribution capabilities to commercialize any drug candidates for which we may obtain marketing approval, whether alone or in collaboration with others;

~~launching commercial sales of any drug candidates for which we obtain marketing approval, whether alone or in collaboration with others;~~

~~effectively competing with other therapies;~~

~~maintaining an acceptable safety profile of the drugs following approval;~~

~~enforcing and defending intellectual property rights and claims; and~~

~~maintaining and growing an organization of scientists and business people, including collaborators, who can develop and commercialize our drug candidates.~~

If we do not achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to successfully commercialize XPOVIO or our drug candidates, if approved, which would materially harm our business.

The results of previous clinical trials may not be predictive of future results and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or

non-U.S.

regulatory authorities.

Clinical failure can occur at any stage of the clinical ~~development.~~development process. Clinical trials may produce negative or inconclusive results, and we or any collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our drug candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale. Success in early-stage clinical trials does not mean that future larger registration clinical trials will be successful because drug candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and

non-U.S.

regulatory authorities despite having progressed through early-stage clinical trials. Drug candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent registration clinical trials. Additionally, ~~the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials, and~~ interim results of a clinical trial are not necessarily indicative of final results.

In addition, the design of a clinical trial can determine whether its results will support approval of a drug, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and conduct a clinical trial to support regulatory approval. Further, if our drug candidates are found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for them and our business would be harmed. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.

In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same drug candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the dropout rate ~~of dropout~~ among clinical trial participants. We do not know whether any Phase 2, Phase 3 or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain regulatory approval to market our drug candidates.

~~Table of Contents~~

Further, our drug candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or other registration trials. The FDA or

non-U.S.

regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change the requirements for the approval of a drug candidate even after providing a positive opinion on, or otherwise reviewing and providing comments or advice on, a protocol for a clinical trial that has the potential to result in approval by the FDA or another regulatory authority. In addition, any of these regulatory authorities may also approve a drug candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. Furthermore, the FDA or

non-U.S.

regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our drug candidates.

To date, we have had several discussions with the FDA and

non-U.S.

regulatory authorities regarding the design of our later phase clinical trials for selinexor, including the BOSTON, STORM, SADAL and SEAL studies. In July 2019 and June 2020, the FDA approved the multiple myeloma indication and the DLBCL indication, respectively, under ~~accelerated approval~~its Accelerated Approval program based on response rate from the STORM ~~study, XPOVIO in combination with dexamethasone for the treatment of adult patients with RRMM who have received at least four prior therapies~~ and ~~whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.~~SADAL studies, respectively. We plan to seek additional regulatory approvals of selinexor in North America and Europe in each indication with respect to which such later phase clinical trial is being conducted and with respect to which we receive positive results that may support full or accelerated approval, as the case may be. We or our current or future partners may also seek such approvals in other geographies. We cannot be certain that we will commence additional later phase trials or complete ongoing later phase trials as anticipated. Before obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and well-controlled clinical studies, and, with respect to approval in the ~~United States,~~U.S., to the satisfaction of the FDA, that the drug candidate is safe and effective for use for that target indication. There is no assurance that the FDA or

non-U.S.

regulatory authorities would consider our current and planned later phase clinical trials to be sufficient to serve as the basis for filing for approval or to gain approval of selinexor for any indication. The FDA and

non-U.S.

regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that selinexor or any of our other drug candidates is safe and effective. If we are required to conduct additional clinical trials of selinexor or our other drug candidates prior to approval of additional indications in earlier lines of therapy or in combination with other drugs, including additional earlier phase clinical trials that may be required prior to commencing any later phase clinical trials, or additional clinical trials following completion of our current and planned later phase clinical trials, we ~~will~~may need substantial additional funds, and there is no assurance that the results of any such additional clinical trials will be sufficient for approval.

The results to date in preclinical and early clinical studies conducted by us or our academic collaborators and in Phase 1 and Phase 2 clinical trials that we are currently conducting include the response of tumors to selinexor. We expect that in any later phase clinical trial where patients are randomized to receive either selinexor on the one hand, or standard of care, supportive care or placebo on the other hand, the primary endpoint will be either ~~progression free~~progression-free survival, meaning the length of time on treatment until objective tumor progression, or overall survival, while the primary endpoint in any later phase clinical trial that is not similarly randomized may be different. For example, the primary endpoint of our Phase 2/3 SEAL study, the clinical trial of selinexor in patients with dedifferentiated liposarcoma, and ~~a primary endpoint~~ of our Phase 3 BOSTON study, the clinical trial of selinexor in combination with Velcade (bortezomib) and dexamethasone in patients with multiple myeloma, is ~~progression free~~progression-free survival. In some instances, the FDA and other regulatory bodies have accepted overall response rate as a surrogate for a clinical benefit and have granted regulatory approvals based on this or other surrogate endpoints. Overall response rate is defined as the portion of patients with tumor size reduction of a predefined amount for a minimum time period. For some types of cancer, we may use overall response rate as a primary endpoint, as we did in our SADAL study and our STORM study. These clinical trials ~~will~~were not be randomized against control arms and the primary endpoints of these trials ~~are~~were overall response rate. If selinexor does not demonstrate sufficient overall response rates ~~in these indications, or~~for any other indication for which a clinical trial has overall response rate as a primary endpoint, or if the FDA or

non-U.S.

regulatory authorities do not deem overall response rate a sufficient endpoint, or deem a positive overall response rate to be insufficient, itselinexor will likely not be approved for that indication based on the applicable study. ~~With respect~~

Finally, independent review committees are typically implemented to adjudicate efficacy outcomes in clinical studies that are intended to support requests for regulatory approval. For example, in our STORM study, the primary endpoint of overall response rate was determined based on efficacy adjudications by an independent review committee, or IRC, comprised of physicians who are expert in treating and evaluating patients with multiple myeloma. While the FDA agreed with the assessments of the IRC for the STORM ~~and SADAL studies,~~study in conducting its review of those data, we cannot be certain that other regulatory authorities will agree with the ~~FDA has reiterated~~assessments of the IRC for STORM or any other study for which we may submit data to ~~us that it recommends, in general,~~support a ~~randomized trial with a progression-free survival endpoint as an initial registration approach.~~

request for regulatory approval.

We may not be successful in our efforts to identify or discover additional potential drug candidates.

Part of our strategy involves identifying and developing drug candidates to build a pipeline of novel drug candidates. Our drug discovery efforts may not be successful in identifying compounds that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying potential drug candidates, yet fail to yield drug candidates for clinical development for a number of reasons, including:

•

the research methodology used may not be successful in identifying potential drug candidates;

•

potential drug candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and/or achieve market acceptance; or

~~the research methodology used may not be successful in identifying potential drug candidates;~~

•

potential drug candidates may not be effective in treating their targeted diseases.

~~Table of Contents~~

~~potential drug candidates may not be effective in treating their targeted diseases.~~

Research programs to identify new drug candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential drug candidate that ultimately proves to be unsuccessful.

If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to ~~obtain~~generate revenues from the sale of drugs in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.

Clinical drug development is a lengthy and expensive process, with an uncertain outcome. If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such drug candidates.

Before obtaining marketing approval from regulatory authorities for the sale of our drug candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later stage clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, certain data from our Phase 1 and Phase 2 clinical trials of selinexor ~~to date~~ are based on unaudited data provided by our clinical trial investigators. An audit of this data may change the conclusions drawn from this unaudited data provided by our clinical trial investigators indicating less promising results than we currently anticipate. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their drug candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drug candidates. Furthermore, the failure of any drug candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of XPOVIO or our other drug candidates and/or cause the FDA or other regulatory authorities to require additional testing before any of our drug candidates are approved.

We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our drug candidates, including:

•

delays associated with the COVID-19 pandemic, including impacts to healthcare systems, our trial sites’ ability to conduct trials, and interruption or unavailability of clinical supplies, regulatory reviews, site monitors and patient enrollment;

•

regulatory authorities or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;

~~regulatory authorities or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;~~

•

feedback from regulatory authorities that requires us to modify the design of our clinical trials;

•

delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or contract research organizations;

•

clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials, suspend ongoing clinical trials or abandon drug development programs;

•

the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;

•

our third-party contractors, including those manufacturing our drug candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;

•

we or our investigators might have to suspend or terminate clinical trials of our drug candidates for various reasons, including non-compliance with regulatory requirements, a finding that our drug candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;

•

regulators may recommend or require us to perform additional or unanticipated clinical trials to obtain approval;

•

regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate;

•

the cost of clinical trials of our drug candidates may be greater than we anticipate;

•

the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and

•

any partners and collaborators that help conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.

As we seek to advance our clinical programs, we remain in close contact with our contract research organizations, clinical sites and suppliers to attempt to assess the impacts that the COVID-19 pandemic has had and may continue to have on our clinical trials, current timelines and costs and to consider whether we can implement appropriate mitigating measures to help to lessen such impacts. At this time, however, we cannot fully forecast the scope of impacts that the COVID-19 pandemic may have on our ability to initiate trial sites, enroll and assess patients, supply study drug and report trial results. To date, we have incurred delays in enrollment for our SEAL, SIENDO and STOMP clinical trials. In addition, we may experience delays in certain regulatory filings, which may impact our approval timelines, such as the EMA review of our ~~clinical trials;~~

~~we may have delays~~MAA for selinexor in ~~reaching or fail~~multiple myeloma based on the results on the STORM study and any resulting impact to ~~reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or contract research organizations;~~

~~clinical trials~~the timing of our ~~drug candidates may produce negative~~expected submission of an MAA for selinexor in multiple myeloma supported by the results of the BOSTON study or ~~inconclusive results,~~any future MAA submission. Further, in response to the COVID-19 pandemic, the FDA issued guidance on March 18, 2020, and ~~we may decide, or regulatory authorities may require us,~~updated it on July 2, 2020, to ~~conduct additional clinical trials, suspend ongoing clinical trials or abandon drug development programs;~~

address the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;

~~we or our investigators might have to suspend or terminate clinical trials of our drug candidates for various reasons, including~~

~~non-compliance~~

with regulatory requirements, a finding that our drug candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;

~~regulators may recommend or require us to perform additional or unanticipated clinical trials to obtain approval;~~

~~regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate;~~

~~the cost~~conduct of clinical trials during the pandemic. The guidance sets out a number of ~~our drug candidates may be greater than we anticipate;~~

~~the supply or quality~~considerations for sponsors of ~~our drug candidates or other materials necessary to conduct~~ clinical trials ~~of our drug candidates may be insufficient or inadequate;~~

~~Table of Contents~~

~~regulators may revise~~impacted by the ~~requirements for approving our drug candidates, or such requirements may not be~~pandemic, including the requirement to include in the clinical study report (or as ~~we anticipate;~~a separate document) contingency measures implemented to manage the study, and

any ~~partners and collaborators that help conduct clinical trials may face any~~disruption of the ~~above issues,~~study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruption by unique subject identifier and ~~may conduct clinical trials in ways they view as advantageous~~by investigational site, and a description of how the individual’s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to ~~them but that are suboptimal~~collect critical safety and/or efficacy data) on the safety and efficacy results reported for ~~us.~~

the study.

If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our drug candidates or other testing, on a timely basis or at all, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:

•

be delayed in obtaining marketing approval for our drug candidates;

•

not obtain marketing approval at all;

•

obtain marketing approval in some countries and not in others;

~~be delayed in obtaining marketing approval for our drug candidates;~~

•

obtain approval for indications or patient populations that are not as broad as intended or desired;

•

obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;

•

be subject to additional post-marketing testing requirements; or

•

have the drug removed from the market after obtaining marketing approval.

~~not obtain marketing approval at all;~~

~~obtain marketing approval in some countries and not in others;~~

~~obtain approval for indications or patient populations that are not as broad as intended or desired;~~

~~obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;~~

~~be subject to additional post-marketing testing requirements; or~~

~~have the drug removed from the market after obtaining marketing approval.~~

Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at ~~all.~~all, particularly as a result of the COVID-19 pandemic. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our drug candidates, allow our competitors to bring drugs to market before we do or impair our ability to successfully commercialize our drug candidates, which would harm our business and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of regulatory approval of our drug candidates.

If we experience delays or difficulties in the enrollment of patients in clinical trials, or we are otherwise delayed in our ability to conduct clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the ~~United States.~~U.S. In addition, some of our competitors may have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ drug candidates.

Patient enrollment is affected by other factors, including:

•

potential disruptions caused by the COVID-19 pandemic, including difficulties in initiating clinical sites or enrolling participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies, and other factors;

•

severity of the disease under investigation;

~~severity~~

•

availability and efficacy of approved drugs for the disease under investigation;

•

patient eligibility criteria for the study in question;

•

competing drugs in clinical development;

•

actual or perceived risks and benefits of the drug candidate under study;

~~availability and efficacy of approved drugs for the disease under investigation;~~

•

restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;

•

external negative impacts to our efforts to facilitate timely enrollment in clinical trials, such as the ongoing governmental “stay at home” orders related to the COVID-19 pandemic;

•

patient referral practices of physicians;

•

the ability to monitor patients adequately during and after treatment; and

~~patient eligibility criteria for the study in question;~~

•

proximity and availability of clinical trial sites for prospective patients.

~~competing drugs in clinical development;~~

~~perceived risks and benefits of the drug candidate under study;~~

~~restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;~~

~~efforts to facilitate timely enrollment in clinical trials;~~

~~patient referral practices of physicians;~~

~~the ability to monitor patients adequately during and after treatment; and~~

~~proximity and availability of clinical trial sites for prospective patients.~~

In addition, patient enrollment may be affected by future regulatory actions, such as Form 483 observations or ~~the partial~~ clinical ~~hold we were subject to previously. In~~holds. For example, in February 2017, following the conclusion of a joint inspection conducted by the FDA and Danish Medicines Agency at our corporate headquarters, the FDA issued a Form 483 noting certain deficiencies in procedures and documentation that were identified in our selinexor development program. We implemented corrective actions, preventative actions and other initiatives directed at resolving the deficiencies identified in the Form 483 observations and provided the FDA with our responses to the Form 483 observations in February 2017.

~~Table of Contents~~

In addition, in March 2017, the FDA notified us that it had placed the clinical trials under our IND for selinexor on partial clinical hold, which is an order by the FDA to delay or suspend part of a sponsor’s clinical work requested under its IND as well as investigator-sponsored trials. The partial clinical hold was due to incomplete information in the existing version of the investigator’s brochure, including an incomplete list of serious adverse events, or SAEs, associated with selinexor, and not as a result of any new information regarding the safety profile of selinexor. The partial clinical holds on the clinical trials of selinexor were lifted by the FDA Division of Hematology Products (effective March 30, 2017), Division of Oncology Products 1 (effective April 5, 2017) and Division of Oncology Products 2 (effective March 31, 2017). However, ifIf in the future we are delayed in addressing, or unable to address, any concerns of the FDA or other regulators, we could be subject to other Form 483 observations or clinical holds and consequently be delayed or prevented from enrolling patients in our current or future clinical trials.

Our inability to enroll a sufficient number of patients for our clinical trials ~~would~~could result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may also result in increased development costs for our drug candidates, which ~~would~~could cause the value of our company to decline and limit our ability to obtain additional financing.

If serious adverse or unacceptable side effects are identified ~~during the development of our drug candidates~~ or we observe limited efficacy of our drugs or drug candidates, we may need to abandon or limit the development or commercialization of one or more of our drugs or drug candidates, ~~or it could~~and such findings may delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.

Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. If our current or future indications of XPOVIO or any of our drug candidates are associated with undesirable side effects or have characteristics that are unexpected in clinical trials or following approval and/or commercialization, we may need to abandon their development or limit development or marketing to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. ~~For example, we have modified our informed consent form and advised patients already enrolled in our clinical trials of the potential for worsening of~~

~~pre-existing~~

~~cataracts as a result of treatment with selinexor.~~ Adverse events, or AEs, in our clinical trials to date have been generally predictable and typically manageable, including through prophylactic care or dose reductions, although some patients have experienced more serious AEs. The most common drug-related AEs ~~were~~in our clinical trials for XPOVIO included gastrointestinal, such as nausea, anorexia, diarrhea, vomiting, cytopenias, hyponatremia, constitutional symptoms of anorexia/weight loss, fatigue and ~~vomiting,~~neurological adverse reactions, including dizziness, syncope, depressed level of consciousness, and ~~fatigue.~~mental status changes. These side effects were generally mild or moderate in severity. The most common AEs that were Grade 3 or Grade 4, meaning they were more than mild or moderate in severity, ~~were~~included thrombocytopenia, or low count of platelets in the blood, and neutropenia, or low neutrophil counts. To date, the most common AEs in the multiple myeloma patient population have been managed with supportive care and dose modifications. However, a number of patients have withdrawn from our clinical trials as a result of AEs. For example, ~~amongst~~among the 202 patients enrolled in Parts 1 and 2 of the STORM study who were treated with selinexor in combination with dexamethasone, the most common AEs (incidence

≥

~~20%~~ ≥20%) were thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infections. The treatment discontinuation rate in the STORM study due to AEs was 27%; 53% of patients had a reduction in the selinexor dose, and 65.3% had the dose of selinexor interrupted. In this group of patients, the most frequent AEs requiring permanent discontinuation in 4% or greater of patients who received selinexor included fatigue, nausea, and thrombocytopenia. Similarly, in the SADAL study, ~~as of April 3, 2019,~~ among the ~~127~~134 patients included in the safety analysis, the most common AEs (incidence ≥20%) in patients with DLBCL were fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, and pyrexia. Grade 3-4 laboratory abnormalities (≥15%) were thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia. The treatment discontinuation rate in the SADAL study due to AEs was ~~13.5%~~17%; ~~49.6%~~49% of patients had a reduction in the selinexor dose, and ~~90.6%~~61% had the dose of selinexor ~~interrupted or withheld with the most common AEs (incidence~~

≥

~~20%) being thrombocytopenia, nausea, fatigue, anemia, anorexia, diarrhea, constipation, weight loss, neutropenia, vomiting, pyrexia and asthenia. A small percentage of~~interrupted. Some patients across our clinical trials have experienced serious adverse events, or SAEs, deemed by us and the clinical investigator to be related to selinexor. SAEs generally refer to AEs that result in death, are life threatening, require hospitalization or prolonging of hospitalization, or cause a significant and permanent disruption of normal life functions, congenital anomalies or birth defects, or require intervention to prevent such an outcome.

~~These~~

The occurrence of AEs ~~and the resulting dose modification and/or treatment discontinuation rates or safety or toxicity issues that we may experience~~ in either our clinical trials ~~in the future~~or following regulatory approval could result in a more restrictive label for any drug candidates approved for marketing or could result in the delay or denial of approval to market any drug candidates by the FDA or comparable foreign regulatory authorities, which could prevent us from ~~ever~~ generating sufficient revenue from the sale of drugs or achieving profitability. Results of our trials could reveal an unacceptably high severity and prevalence of side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our drug candidates for any or all targeted indications. Many compounds that initially showed promise in early-stage trials for treating cancer or other diseases have later been found to cause side effects that prevented further development of the compound. If such an event occurs after any of our drug candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:

•

regulatory authorities may withdraw the approval of such drug;

•

regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;

~~regulatory authorities may withdraw the approval of such drug;~~

•

regulatory authorities may require one or more post-marketing studies;

•

we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;

•

we could be sued and held liable for harm caused to patients; and

•

our reputation may suffer.

~~Table of Contents~~

~~regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;~~

~~regulatory authorities may require one or more post-marketing studies;~~

~~regulatory authorities may withdraw the approval of such drug;~~

~~we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;~~

~~we could be sued and held liable for harm caused to patients; and~~

~~our reputation may suffer.~~

Any of these events could prevent us from achieving or maintaining market acceptance of the affected drug candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating ~~revenues~~sufficient revenue from the sale of our drugs and harm our business and results of operations.

The FDA or

non-U.S.

regulatory authorities may disagree with our and/or our clinical trial investigators’ interpretation of data from clinical trials in determining if serious adverse or unacceptable side effects are drug-related.

We, and our clinical trial investigators, currently determine if serious adverse or unacceptable side effects are drug-related. The FDA or

non-U.S.

regulatory authorities may disagree with our or our clinical trial investigators’ interpretation of data from clinical trials and the conclusion by us or our clinical trial investigators that a serious adverse effect or unacceptable side effect was not drug-related. The FDA or

non-U.S.

regulatory authorities may require more information, including additional preclinical or clinical data to support approval, which may cause us to incur additional expenses, delay or prevent the approval of one of our drug candidates, and/or delay or cause us to change our commercialization plans, or we may decide to abandon the development or commercialization of the drug candidate altogether.

We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any additional commercially-viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.

XPOVIO or any of our drug candidates that receives marketing approval may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.

XPOVIO or any of our drug candidates ~~receives~~that receive marketing approval may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Efforts to educate the medical community and third-party payors on the benefits of our drug candidates ~~will~~ require significant resources and may not be successful. For example, current cancer treatments like chemotherapy and radiation therapy are well-established in the medical community, and doctors may continue to rely on these treatments. If XPOVIO or our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from sales of drugs and we may not become profitable. The degree of market acceptance of XPOVIO for each approved indication and for our drug candidates, if approved for commercial sale, will depend on a number of factors, including:

•

efficacy and potential advantages compared to alternative treatments;

•

the ability to offer our drugs for sale at competitive prices;

~~efficacy and potential advantages~~

•

convenience and ease of administration compared to alternative treatments;

•

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

•

the strength of marketing and distribution support;

•

the timing of market introduction of competitive products;

~~the ability to offer our drugs for sale at competitive prices;~~

•

sufficient third-party coverage or reimbursement;

•

effectiveness of our sales and marketing efforts;

•

adverse publicity about our drugs or favorable publicity about competitive products;

•

the prevalence and severity of any side effects;

~~convenience and ease of administration compared to alternative treatments;~~

•

any restrictions on the use of our drugs together with other medications; and

•

the inability of certain types of patients to take our drugs.

~~the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;~~

~~the strength of marketing and distribution support;~~

~~the timing of market introduction of competitive products;~~

~~sufficient third-party coverage or reimbursement;~~

~~effectiveness of our sales and marketing efforts;~~

~~Table of Contents~~

~~adverse publicity about our drugs or favorable publicity about competitive products;~~

~~the prevalence and severity of any side effects;~~

~~any restrictions on the use of our drugs together with other medications; and~~

~~inability of certain types of patients to take our drugs.~~

Our estimates of the potential market opportunities for XPOVIO and our drug candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for XPOVIO, selinexor or any other drug candidates may be smaller than we expect, and as a result our product revenue may be limited and it may be more difficult for us to achieve ~~or maintain~~ profitability.

If we are unable to ~~establish and~~ maintain or expand our sales, marketing and distribution capabilities or maintain current agreements or enter into additional sales, marketing and distribution agreements with third parties, we may not be successful in commercializing XPOVIO or any of our drug candidates that we may develop if and when they are approved.

We ~~are in the process of establishing and maintaining~~have built a sales and marketing infrastructure for XPOVIO, our first commercial product, in hematological malignancies and our company ~~does~~did not previously have any prior experience in the sales, marketing or distribution of pharmaceutical drugs. ~~To achieve commercial success~~If XPOVIO or any of our other drug candidates is approved for ~~any approved drug for which sales and marketing is not the responsibility of any strategic collaborator that~~additional indications beyond hematological malignancies, we ~~have or may have in the future, we must either develop a~~will need to substantially evolve our sales, marketing and distribution ~~organization or outsource these functions~~capabilities and we may not do be able to ~~other third parties.~~do so successfully. In the future, we may choose to ~~build a~~expand our sales, marketing and distribution infrastructure to market or

co-promote

one or more of our drug candidates, if and when they are approved, or enter into additional collaborations with respect to the sale, marketing and distribution of our drug candidates. We intend to work with existing and potential partners to establish the commercial infrastructure to support a potential launch of selinexor outside of the ~~United States.~~

U.S.

There are risks involved with both establishing and maintaining our own sales, marketing and distribution capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any commercial launch of a drug candidate. Further, we may underestimate the size of the sales force required for a successful product launch and we may need to expand our sales force earlier and at a higher cost than we anticipated. If the commercial launch of any of our drug candidates for which we establish a commercial infrastructure is delayed or does not occur for any reason, including if we do not receive marketing approval onin the timeframe we expect, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.

Factors that may inhibit our efforts to commercialize XPOVIO or any drug candidates for which we receive marketing approval on our own include:

•

our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;

•

the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe current or future drugs;

~~our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;~~

•

the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive drug lines;

•

unforeseen costs and expenses associated with creating an independent sales, marketing and distribution organization;

•

our inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies; and

•

existing or new competitors taking share from XPOVIO or preventing XPOVIO from gaining share in its approved indications.

~~the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;~~

~~the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive drug lines;~~

~~unforeseen costs and expenses associated with creating an independent sales, marketing and distribution organization; and~~

~~inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.~~

Entering into arrangements with third parties to perform sales and marketing services may result in lower revenues from the sale of drug or the profitability of these revenues to us than if we were to market and sell any drugs that we develop ourselves. In addition, we may not be successful in maintaining current arrangements or entering into additional arrangements with third parties to sell, market and distribute XPOVIO or any of our drug candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drugs effectively. Furthermore, we may be unable to enter into an arrangement with a third party if the current restrictions relating to COVID-19 continue to restrict travel, limit the ability of us or potential partners to negotiate and consummate a transaction in a timely manner, or if the COVID-19 pandemic causes a prolonged economic downturn. The extent to which the pandemic impacts our search for a partner will depend on future developments, which are highly uncertain and cannot be predicted, including additional information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. If the disruptions posed by the COVID-19 pandemic or other matters of global concern continue for an extensive period of time, our ability to consummate an arrangement may be materially adversely affected.

If we do not successfully establish and maintain sales, marketing and distribution capabilities, ~~successfully,~~ either on our own or in collaboration with third parties, we will not be successful in commercializing XPOVIO or any of our drug candidates for which we obtain marketing approval.

~~Table of Contents~~

We have a limited number of ~~engagements~~contractual arrangements with specialty pharmacies and specialty distributors. The specialty pharmacies sell XPOVIO directly to patients. The specialty distributors sell XPOVIO to healthcare entities who then resell XPOVIO to patients. While we have entered into agreements with each of these pharmacies and distributors to distribute XPOVIO in the ~~United States,~~U.S., they may not perform as agreed or they may terminate their agreements with us. Also, we may need to enter into agreements with additional pharmacies or distributors, and there is no guarantee that we will be able to do so on commercially reasonable terms or at all. If we are unable to maintain and, if needed, expand, our network of specialty pharmacies and specialty distributors, we would be exposed to substantial distribution risk.

We may not receive royalty or milestone revenue under our ~~license~~partnership agreements for several years, or at all.

~~Our license~~

Certain of our partnership agreements provide for payments on achievement of development, regulatory and/or commercialization milestones and for royalties on product sales. However, because drug development entails a high risk of failure, we may never realize any material portion of the milestone revenue provided in our ~~license~~partnership agreements and we do not expect to receive any royalty revenue for several years, if at all.

We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.

The discovery, development and commercialization of new drugs is highly ~~competitive.~~competitive, particularly in the cancer field. We face competition with respect to XPOVIO and our drug candidates and will face competition with respect to any drug candidates that we may seek to discover and develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of major pharmaceutical, specialty pharmaceutical and biotechnology companies that currently market and sell drugs and/or are pursuing the development of drugs for the treatment of cancer and the other disease indications for which we are developing our drug ~~candidates, although we believe that to date, none of these competitive drugs and therapies currently in development are based on scientific approaches that are the same as our approach.~~candidates. Potential competitors also include academic institutions and governmental agencies and public and private research institutions.

We are initially focused on developing our current drug candidates for the treatment of cancer. There are a variety of available therapies marketed for cancer. In many cases, cancer drugs are administered in combination to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic drugs. We expect that any of our drug candidates that are approved will be priced at a significant premium over competitive generic drugs. This may make it difficult for us to achieve our business strategy of using our drug candidates in combination with existing therapies or replacing existing therapies with our drug candidates.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are more effective, safer, more convenient or less costly than any that we are developing or that would render our drug candidates obsolete or

non-competitive.

Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or preventing us from entering into a particular indication at all.

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.

Even if we are able to effectively commercialize XPOVIO or any drug candidate that we may develop, the drugs may not receive coverage or may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, all of which would harm our business.

The legislation and regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or drug licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. In the United States, approval and reimbursement decisions are not linked directly, but there is increasing scrutiny from the Congress and regulatory authorities of the pricing of pharmaceutical products. As a result, we might obtain marketing approval for a drug in a particular

~~Table of Contents~~

country, but then be subject to price regulations that delay our commercial launch of the drug, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the drug in that country. In the U.S., approval and reimbursement decisions are not linked directly, but there is increasing scrutiny from the Congress and regulatory authorities of the pricing of pharmaceutical products. Adverse pricing limitations may also hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain marketing approval.

Our ability to effectively commercialize XPOVIO or any of our product candidates that we may develop successfully will depend, in part, on the extent to which reimbursement for these drugs and related treatments ~~will be~~is available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Obtaining and maintaining adequate reimbursement for XPOVIO and any of our product candidates, if approved, may be difficult. Moreover, the process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for our products by third-party payors.

A primary trend in the healthcare industry in the ~~United States~~U.S. and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek, with respect to an approved product, additional clinical evidence that goes beyond the data required to obtain marketing approval. They may require such evidence to demonstrate clinical benefits and value in specific patient populations or they may call for costly pharmaceutical studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies before covering our products. Accordingly, we cannot be sure that reimbursement will be or will continue to be available for XPOVIO and any drug candidate that we commercialize and, if reimbursement is available, we cannot be sure as to the level of reimbursement and whether it will be adequate. Coverage and reimbursement may impact the demand for, or the price of, XPOVIO or any drug candidate for which we obtain marketing approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize XPOVIO or any drug candidate for which we obtain marketing approval.

There may be significant delays in obtaining reimbursement for newly-approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable regulatory authorities outside of the ~~United States.~~U.S. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the ~~United States.~~U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.

Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and to limit commercialization of XPOVIO and any other drugs that we may develop.

We face an inherent risk of product liability exposure related to the testing of our drug candidates in human clinical trials. We face an even greater risk as we commercialize XPOVIO or any other drugs that we may develop. For example, we may be sued if any drug we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against claims that our drug candidates or drugs caused injuries, we will incur substantial liabilities or be required to limit commercialization of our drug candidates. Regardless of merit or eventual outcome, liability claims may result in:

•

decreased demand for XPOVIO and any other drugs that we may develop;

•

injury to our reputation and significant negative media attention;

~~decreased demand for XPOVIO and any other drugs that we may develop;~~

•

withdrawal of clinical trial participants;

•

initiation of investigations by regulators;

•

product recalls, withdrawals or labeling, marketing or promotional restrictions;

•

significant costs to defend the related litigation;

~~injury to our reputation and significant negative media attention;~~

•

substantial monetary awards to trial participants or patients;

•

loss of revenue;

•

reduced resources of our management to pursue our business strategy; and

•

the inability to successfully commercialize XPOVIO and any other drugs that we may develop.

~~withdrawal of clinical trial participants;~~

~~initiation of investigations by regulators;~~

~~product recalls, withdrawals or labeling, marketing or promotional restrictions;~~

~~Table of Contents~~

~~significant costs to defend the related litigation;~~

~~substantial monetary awards to trial participants or patients;~~

~~loss of revenue;~~

~~reduced resources of our management to pursue our business strategy; and~~

~~the inability to successfully commercialize XPOVIO and any other drugs that we may develop.~~

We currently hold clinical trial and general product liability insurance coverage, but that coverage may not be adequate to cover any and all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

The business that we conduct outside of the ~~United States~~U.S. may be adversely affected by international ~~risk~~risks and uncertainties.

Although our operations are based in the ~~United States,~~U.S., we conduct business outside of the ~~United States~~U.S. and expect to continue to do so in the future. For instance, many of the sites at which our clinical trials are being conducted are located outside of the ~~United States.~~U.S. In addition, we are seeking and continue to plan to seek approvals to sell our products in foreign countries. Any business that we conduct outside of the ~~United States~~U.S. will be subject to additional risks that may materially adversely affect our ability to conduct business in international markets, including:

•

potentially reduced protection of our intellectual property rights;

•

the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally;

~~potentially reduced protection for intellectual property rights;~~

•

unexpected changes in tariffs, trade barriers or regulatory requirements;

•

economic weakness, including inflation, volatility in currency exchange rates or political instability in particular foreign economies and markets, including as a result of the current economic situation stemming from the COVID-19 pandemic;

•

workforce uncertainty in countries where labor unrest is more common than in the U.S.;

•

production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad;

~~the potential for~~

~~so-called~~

parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally;

•

business interruptions resulting from pandemics (including the COVID-19 pandemic), geo-political actions, including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and fires; and

•

failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act, or FCPA.

~~unexpected changes in tariffs, trade barriers and regulatory requirements;~~

~~economic weakness, including inflation, volatility in currency exchange rates or political instability in particular foreign economies and markets;~~

~~workforce uncertainty in countries where labor unrest is more common than in the United States;~~

~~production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad;~~

~~business interruptions resulting from~~

~~geo-political~~

~~actions, including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and fires; and~~

~~failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act, or FCPA.~~

Risks Related to Our Financial Position, Convertible Senior Notes, Revenue Interest Financing Agreement and Need for Additional Capital

We have incurred significant losses since inception. We expect to continue to incur losses in the future and may never achieve or maintain profitability.

Since inception, we have incurred significant operating losses. Our net loss was ~~$150.9~~$99.4 million for the ~~nine~~six months ended ~~September~~June 30, ~~2019.~~2020. As of ~~September~~June 30, ~~2019,~~2020, we had an accumulated deficit of ~~$824.7~~$972.7 million. ~~As we only recently launched~~With the launch of our first

FDA-approved

product, XPOVIO, in July 2019, we have had limited revenues to date from product sales and have historically financed our operations ~~to date~~ principally through private placements of our preferred stock, proceeds from our initial public offering and

follow-on

offerings of common stock, issuance of convertible debt, proceeds from a revenue interest financing agreement and cash generated from our business development activities. We have devoted substantially all of our efforts to research and development, including preclinical studies and clinical trials, pursuing regulatory approvals and engaging in activities to commercially launch XPOVIO for ~~the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least~~its two ~~proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.~~FDA-approved indications. Other than the FDA’s two accelerated ~~approval~~approvals of XPOVIO, our lead drug, ~~candidate,~~ oral selinexor (for indications not yet approved), as well as eltanexor, verdinexor, ~~eltanexor~~ and

KPT-9274,

are in clinical development. Although we expect to continue to generate revenue from sales of XPOVIO, there can be no assurance as to the amount or timing of any such revenue, and we expect to continue to incur significant expenses and operating losses. The net losses we incur may fluctuate significantly from quarter to quarter.

~~Table of Contents~~

We anticipate that ~~our expenses~~we will continue to ~~increase substantially as compared to prior periods~~incur substantial expenses as we continue to commercialize XPOVIO in the ~~Unites States~~U.S. and potentially outside of the U.S. and engage in activities to prepare for the potential approval and commercialization of additional indications for selinexor ~~and the potential approval of~~as well as our other drug ~~candidates, including due to the impact of increased headcount, to support our clinical and commercialization activities, expanded infrastructure and increased insurance premiums.~~

candidates.

We anticipate that our expenses will increase substantially if and as we:

•

continue to commercialize XPOVIO in the U.S., including the commercial launch of the recently approved DLBCL indication, and seek regulatory approval for XPOVIO outside of the U.S.;

•

continue to grow our sales, marketing and distribution infrastructure to support the commercialization of XPOVIO and any drug candidates for which we may obtain marketing approval, prior to or upon receiving marketing approval in the U.S. or outside of the U.S.;

~~continue to commercialize XPOVIO in the United States and seek regulatory approval for XPOVIO outside of the United States;~~

•

continue our research and preclinical and clinical development of our drug candidates;

•

initiate additional clinical trials for our drug candidates;

•

seek marketing approvals for any of our drug candidates that successfully complete clinical trials;

•

maintain, expand and protect our intellectual property portfolio;

•

manufacture XPOVIO and our drug candidates;

continue to grow our sales, marketing and distribution infrastructure during the commercialization of XPOVIO and any drug candidates for which we may obtain marketing approval, prior to or upon receiving marketing approval;

•

hire additional clinical, quality control, scientific, commercial and management personnel;

•

identify additional drug candidates;

•

acquire or in-license other drugs and technologies;

•

add operational, financial and management information systems and personnel, including personnel to support our drug development, any commercialization efforts and our other operations as a public company; and

~~continue our research and preclinical and clinical development of our drug candidates;~~

•

increase our product liability insurance coverage as we grow our commercialization efforts.

~~initiate additional clinical trials for our drug candidates;~~

~~seek marketing approvals for any of our drug candidates that successfully complete clinical trials;~~

~~maintain, expand and protect our intellectual property portfolio;~~

~~manufacture our drug candidates;~~

~~hire additional clinical, quality control, scientific, commercial and management personnel;~~

~~identify additional drug candidates;~~

~~acquire or~~

~~in-license~~

~~other drugs and technologies;~~

~~increase our product liability insurance coverage as we initiate and expand our commercialization efforts.~~

Our ability to become and remain profitable depends on our ability to commercialize a drug or drugs with significant market potential, either on our own or with a collaborator. While we began to generate revenue from the sales of XPOVIO in July 2019, there can be no assurance as to the amount or timing of any such revenue, and we may not achieve profitability for several years, if at all. This will require us to be successful in a range of challenging activities, including:

•

continued successful commercialization of XPOVIO, including by maintaining our sales force, marketing and distribution capabilities;

•

achieving an adequate level of market acceptance and obtaining and maintaining coverage and adequate reimbursement from third-party payors for XPOVIO and any other drugs we commercialize;

~~successful launching of XPOVIO, including by further developing our sales force, marketing and distribution capabilities;~~

•

completing preclinical studies and clinical trials of our drug candidates;

•

obtaining marketing approval for these drug candidates;

•

manufacturing at commercial scale, marketing, selling and distributing XPOVIO or any drug candidates for which we may obtain marketing approval;

•

maintaining regulatory and marketing approvals for XPOVIO and for any drug candidates for which we obtain marketing approval;

~~achieving an adequate level of market acceptance and obtaining and maintaining coverage and adequate reimbursement from third-party payors for XPOVIO and any other drugs we commercialize;~~

•

establishing and managing any collaborations for the development, marketing and/or commercialization of our drug candidates;

•

hiring and building a full commercial organization required for the marketing, selling and distribution for those drugs for which we obtain marketing approval;

•

navigating the negative impacts resulting from the ongoing COVID-19 pandemic to the healthcare systems and the ability of our clinical trial sites to conduct current or future trials; and

•

obtaining, maintaining and protecting our intellectual property rights.

~~completing preclinical studies and clinical trials of our drug candidates;~~

~~obtaining marketing approval for these drug candidates;~~

~~manufacturing at commercial scale, marketing, selling and distributing XPOVIO or any drug candidates for which we may obtain marketing approval;~~

~~maintaining regulatory and marketing approvals for XPOVIO and for any drug candidates for which we obtain marketing approval;~~

~~establishing and managing any collaborations for the development, marketing and/or commercialization of our drug candidates;~~

~~hiring and building a full commercial organization required for the marketing, selling and distribution for those drugs for which we obtain marketing approval; and~~

~~obtaining, maintaining and protecting our intellectual property rights.~~

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses could increase if we are required by the FDA or other regulatory authorities to perform clinical trials and

non-clinical

studies in addition to those that have been conducted or are currently expected, or if there are any delays in the development of ~~any of~~ our drug candidates or the manufacture of any of our drug candidates.

~~Table of Contents~~

XPOVIO is our only product that has been approved for sale and it has only been approved in the United States for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.U.S. Our ability to become and remain profitable will depend, in part, on the timing and success of commercial sales of XPOVIO for its two currently approved indications, which wewere commercially launched in the ~~United States~~U.S. in July ~~2019.~~2019 and June 2020, respectively. However, the successful commercialization of XPOVIO in the ~~United States~~U.S. is subject to many risks. We are currently undertaking our first commercial launch with XPOVIO, and we may not be able to do so successfully. There are numerous examples of unsuccessful product launches and failures to meet expectations of market potential, including by pharmaceutical companies with more experience and resources than us. We do not anticipate that our revenue from sales of XPOVIO alone, in the currently approved indications, will be sufficient for us to become profitable for several years, if at all.

We may never succeed in these activities and may never generate revenues that are significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.

The nature and length of our operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.

We were incorporated in 2008 and commenced operations in 2009. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our platform, identifying potential drug candidates, conducting preclinical studies and early-phase and later-phase clinical trials of our drug candidates and ~~establishing a commercial infrastructure to launch~~commercializing XPOVIO. ~~We only recently launched XPOVIO and are still in the process of executing our commercial launch plan and, to~~To date, we have not generated significant revenue from the sale of XPOVIO. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

In addition, as a business with a short operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We ~~will~~ need to continue to successfully transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.

As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any particular quarterly or annual periods as indications of future operating performance.

We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and drug development programs or commercialization efforts.

We expect our expenses to increase in connection with our ongoing activities, particularly as we commercialize XPOVIO, ~~(selinexor)~~including in the recently approved DLBCL indication, and continue the clinical trials of, and seek marketing approval and prepare for commercialization of, selinexor in additional indications and our other drug candidates. Our expenses have increased as we ~~have begun commercializing~~continue to commercialize XPOVIO, including costs associated with our sales force and increased marketing and distribution capabilities. If we obtain marketing approval for any drug candidates that we develop, we expect to incur significant additional commercialization expenses for such drug candidate to the extent that such sales, marketing, manufacturing and distribution functions are not the responsibility of any collaborator that we may have at such time for any such drug candidate. Furthermore, we will continue to incur additional costs associated with operating as a public company, hiring additional personnel and expanding our facilities. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Further, any sustained disruption in the capital markets from the COVID-19 pandemic could negatively impact our ability to raise capital and we cannot predict the extent or duration of the macro-economic disruption stemming from the COVID-19 pandemic. If the macro-economic disruption continues for pro-longed periods, we may need to raise additional capital and capital may not be available on acceptable terms, or at all.

If we are unable to raise capital when needed or on attractive terms, we ~~would~~could be forced to delay, reduce or eliminate our research and drug development programs or any current or future commercialization efforts.

We expect that our existing cash, cash equivalents and investments will enable us to fund our current operating and capital expenditure plans for at least twelve months from the date of issuance of the financial statements contained in this Quarterly Report on Form

10-Q.

Our future capital requirements will depend on many factors, including:

•

our ability to successfully commercialize XPOVIO in the U.S.;

•

the cost of, and our ability to expand and maintain, the commercial infrastructure required to support the commercialization of XPOVIO and any other drug for which we receive marketing approval, including product sales, medical affairs, marketing and distribution;

~~our ability to successfully commercialize and sell XPOVIO in the United States;~~

•

the progress and results of our current and planned clinical trials of selinexor;

•

the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;

•

the costs, timing and outcome of regulatory review of our drug candidates, including whether any additional clinical trials or other activities are required for approval or label expansion;

•

our ability to establish and maintain collaborations on favorable terms;

•

the success of any collaborations that we have entered into and may enter into with third parties;

•

the extent to which we acquire or in-license other drugs and technologies;

•

the costs of commercialization activities, including costs related to product sales, marketing, manufacturing and distribution functions, for XPOVIO or any of our drug candidates for which we receive marketing approval, and pre-commercialization costs for our drug candidates incurred prior to receiving any such marketing approval, including the costs and timing of establishing product sales, marketing, manufacturing and distribution capabilities that are not the responsibility of any collaborator that we may have at such time;

•

the amount of revenue, if any, received from commercial sales of our drug candidates, if approved;

•

the terms and timing of any future collaborations, partnerships, licensing, marketing, distribution or other arrangements that we may establish; and

~~the progress and results of our current and planned clinical trials of selinexor;~~

•

the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.

~~the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;~~

~~Table of Contents~~

~~the costs, timing and outcome of regulatory review of our drug candidates, including whether any additional clinical trials or other activities are required for approval or label expansion;~~

~~our ability to establish and maintain collaborations on favorable terms;~~

~~the success of any collaborations that we have entered into and may enter into with third parties;~~

~~the extent to which we acquire or~~

~~in-license~~

~~other drugs and technologies;~~

~~the costs of commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our drug candidates for which we receive marketing approval, and~~

~~pre-commercialization~~

costs for our drug candidates incurred prior to receiving any such marketing approval, including the costs and timing of establishing product sales, marketing, manufacturing and distribution capabilities that are not the responsibility of any collaborator that we may have at such time;

~~the amount of revenue, if any, received from commercial sales of our drug candidates, assuming receipt of marketing approval;~~

~~the terms and timing of any future collaborations, partnerships, licensing, marketing, distribution or other arrangements that we may establish; and~~

~~the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.~~

Identifying potential drug candidates, conducting preclinical studies and clinical trials, seeking marketing approvals and commercializing products are time-consuming, expensive and uncertain processes that take years to complete. Although we commercially launched XPOVIO in its two approved indications in July 2019 and June 2020, respectively, we do not anticipate that our revenue from product sales of XPOVIO will be sufficient for us to become profitable for several years, if at all. In addition, we may never generate the necessary data or results required to obtain marketing approval of our drug candidates. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. ~~Adequate additional financing may not be available to us on acceptable terms, or at all.~~ In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. Adequate additional financing may not be available to us on acceptable terms, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate development activities for one or more of our drug candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize XPOVIO or our drug candidates for which we obtain marketing approval.

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

Global credit and financial markets have experienced extreme disruptions over ~~some of~~ the past several years. Such disruptions have resulted, and could in the future result, in diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. ~~There can be no assurance that any deterioration~~For example, in ~~credit~~the past few months, the spread of COVID-19 has resulted in businesses suspending or terminating global operations and ~~financial markets~~travel, self-imposed or government-mandated quarantines, and ~~confidence~~an overall slowdown of economic activity in ~~economic conditions will not occur.~~many areas. Our general business strategy may be compromised by economic downturns, a volatile business environment and unpredictable and unstable market ~~conditions.~~conditions, such as the current global situation resulting from the COVID-19 pandemic. If the equity and credit markets continue to deteriorate, it may make any necessary equity or debt financing more difficult to secure, more costly or more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could harm our growth strategy, financial performance and stock price and could require us to delay or abandon plans with respect to our business, including clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers or other third parties with which we conduct business may not survive difficult economic times, including the current global situation resulting from the COVID-19 pandemic, which could directly affect our ability to attain our operating goals on schedule and on budget.

Our indebtedness could limit cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the Convertible Senior Notes due 2025, or Notes.

We incurred $172.5 million of indebtedness as a result of the sale of the Notes and $75.0 million as a result of the initial closing pursuant to the Revenue Interest Financing Agreement, or Revenue Interest Agreement, that we entered into with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P., or HCR, on September 14, 2019. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:

•

increasing our vulnerability to adverse economic and industry conditions;

•

limiting our ability to obtain additional financing;

~~increasing our vulnerability to adverse economic and industry conditions;~~

•

requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;

•

limiting our flexibility to plan for, or react to, changes in our business;

•

diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the Notes; and

•

placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.

~~limiting our ability to obtain additional financing;~~

~~Table of Contents~~

~~requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;~~

~~limiting our flexibility to plan for, or react to, changes in our business;~~

~~diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the Notes; and~~

~~placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.~~

Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including the Notes, and our cash needs may increase in the future.

Servicing the Notes will require a significant amount of cash, and we may not have sufficient cash flow from our business to make payments on our indebtedness.

Our ability to pay the principal of or interest and additional interest, if any, on the Notes or to make cash payments in connection with any conversion of the Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service the Notes or other future indebtedness and make necessary capital expenditures. In addition, if the impact of the COVID-19 pandemic to our results of operations and business prospects is more severe and prolonged than we currently anticipate, our ability to repay the Notes could be impaired. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring indebtedness or obtaining additional debt financing or equity capital on terms that may be onerous or highly dilutive. Our ability to refinance the Notes or other future indebtedness will depend on the capital markets, ~~and~~ our financial condition at such time and our obligations under any other existing indebtedness in effect at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the Notes.

We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash, to repurchase the Notes for cash upon a fundamental change, to pay the redemption price for any Notes we redeem or to refinance the Notes, and any future debt we incur may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.

Holders may require us to repurchase their Notes following a fundamental change at a cash repurchase price generally equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest and additional interest, if any. In addition, upon conversion, unless we elect to deliver solely shares of our common stock to settle conversions (other than paying cash in lieu of delivering any fractional share), we must satisfy the conversion in cash. We may not have enough available cash or be able to obtain financing at the time we are required to repurchase the Notes, pay cash amounts due upon conversion or redemption of the Notes or refinance the Notes. In addition, our ability to repurchase the Notes, to pay cash upon conversion or redemption of the Notes or to refinance the Notes may be limited by law, regulatory authority or agreements governing any future indebtedness that we may incur. Our failure to repurchase notes at a time when the repurchase is required by the indenture governing the Notes or to pay cash upon conversion of the Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness, if any. Moreover, the occurrence of a fundamental change under the indenture could constitute an event of default under any such agreements. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or to pay cash upon conversion of the Notes.

The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.

In the event the conditional conversion feature of the Notes is triggered, holders of Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal amount of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.

In May 2008, the Financial Accounting Standards Board, or FASB, issued FASB Staff Position No. APB

14-1,

Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement), which has subsequently been codified as Accounting Standards Codification

470-20,

Debt with Conversion and Other Options, or ASC

470-20.

Under ASC

470-20,

an entity must separately account for the liability and equity components of the convertible debt instruments (such as the Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest

~~Table of Contents~~

cost. The effect of ASC

470-20

on the accounting for the Notes is that the equity component is required to be included in the additional

paid-in

capital section of stockholders’ equity ~~on our consolidated balance sheet~~ at the issuance date, and the value of the equity component would be treated as debt discount for purposes of accounting for the debt component of the Notes. As a result, we will be required to record a greater amount of

non-cash

interest expense as a result of the amortization of the discounted carrying value of the Notes to their face amount over the term of the Notes. We will report a larger net loss in our financial results because ASC

470-20

will require interest to include both the amortization of the value of the debt discount and the instrument’s coupon interest rate, which could adversely affect our future financial results, the market price of our common stock and the trading price of the Notes.

In addition, under certain circumstances, convertible debt instruments (such as the Notes) that may be settled entirely or partly in cash are currently eligible to be accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued. We cannot be sure that the accounting standards in the future will continue to permit the use of the treasury stock method. If we are unable to use the treasury stock method in accounting for the shares issuable upon conversion of the Notes, then our diluted earnings per share would be adversely affected.

Furthermore, if any of the conditions to the convertibility of the Notes is satisfied, then we may be required under applicable accounting standards to reclassify the liability carrying value of the Notes as a current, rather than a long-term, liability. This reclassification could be required even if no holders convert their Notes and could materially reduce our reported working capital.

Our Revenue Interest Agreement with HCR contains various covenants and other provisions, which, if violated, could result in the acceleration of payments due under such agreement.

On September 14, 2019, we entered into the Revenue Interest Agreement with HCR. Pursuant to the Revenue Interest Agreement, we are required to comply with various covenants relating to the conduct of our business and the commercialization of ~~XPOVIO.~~XPOVIO, including obligations to use commercially reasonable efforts to commercialize our products and limits on our ability to incur or prepay indebtedness, create or incur liens, pay dividends on or repurchase outstanding shares of our capital stock or dispose of assets. In addition, the Revenue Interest Agreement includes customary events of default upon the occurrence of enumerated events, including

non-payment

of revenue interests, failure to perform certain covenants and the occurrence of insolvency proceedings, specified judgments, specified cross-defaults or specified revocations, or withdrawals or cancellations of regulatory approval for XPOVIO. Upon the occurrence of an event of default and in the event of a change of control, HCR may accelerate payments due under the Revenue Interest Agreement up to $138.8 million, less the aggregate of all of the payments ~~made~~previously paid to ~~date.~~HCR. Upon the occurrence of specified material adverse events or the material breach of specified representations and warranties, which will not be considered events of default, HCR may elect to terminate the Revenue Interest Agreement and require us to make payments necessary for HCR to receive ~~$75~~$75.0 million, less the aggregate of all of the payments made to date, plus a specified annual rate of return. In the event that we are unable to make such payment, then HCR may be able to foreclose on the collateral that was pledged to HCR, which consists of all of our present and future assets relating to XPOVIO. Any such foreclosure remedy would significantly and adversely affect us and could result in us losing our interest in such assets.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates.

Until such time, if ever, as we can generate substantial revenues from the sale of drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. For example, during the term of the Revenue Interest Agreement, we cannot make any voluntary or optional cash payment or prepayment on our existing convertible debt and cannot enter into any new debt without the consent of HCR.

If we raise funds through further collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our research and drug development or current or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.

~~Table of Contents~~

Risks Related to Our Dependence on Third Parties

We depend on third parties for certain aspects of the development, marketing and/or commercialization of XPOVIO or our drug candidates and plan to enter into additional collaborations. If those collaborations are not successful, we may not be able to capitalize on the market potential of ~~these~~XPOVIO or our drug candidates.

We intend to maintain our existing collaborations and will continue to seek additional third-party collaborators for certain aspects of the development, marketing and/or commercialization of our drug ~~candidates.~~candidates within and outside of the U.S. For example, we ~~have entered into~~are parties to a license ~~arrangements~~arrangement with ~~Ono Pharmaceutical Co., Ltd. and~~ Antengene Therapeutics Limited and a distribution agreement with Promedico Ltd. and plan to continue to seek to enter into additional license and distribution relationships, for marketing and commercialization of selinexor for other geographies outside of the ~~United States.~~U.S. In addition, we intend to seek one or more collaborators to aid in the further development, marketing and/or commercialization of selinexor and our other SINE compounds for indications outside of oncology. ~~Our likely~~Potential collaborators for any collaboration arrangements include large and

mid-size

pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In connection with any such arrangements with third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development, marketing and/or commercialization of our drug candidates. Our ability to generate revenues from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements.

In addition, the third-parties upon whom we rely to develop, market and commercialize XPOVIO and our drug candidates could be negatively impacted by the COVID-19 pandemic, including as a result of businesses suspending or terminating global operations and travel, self-imposed or government-mandated quarantines, and an overall slowdown of economic activity. If our third-party collaborators are so affected, our business prospects and results of operations could be severely adversely impacted.

Collaborations involving our drug products and candidates pose the following risks to us:

•

collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;

•

collaborators may not perform their obligations as expected or in compliance with applicable regulatory requirements;

~~collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;~~

•

collaborators may not pursue development, marketing and/or commercialization of our drug candidates or may elect not to continue or renew development, marketing or commercialization programs based on clinical trial results, changes in the collaborator’s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;

•

collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;

•

collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drugs or drug candidates if the collaborators believe that competitive drugs are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

•

a collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to the marketing and distribution of such drug or drugs;

~~collaborators may not perform their obligations as expected or in compliance with applicable regulatory requirements;~~

•

disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;

•

collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

•

collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

•

disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our drugs or drug candidates or that result in costly litigation or arbitration that diverts management’s attention and resources of our company;

•

we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a change of control;

•

collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing and/or commercialization of the applicable drug candidates;

•

collaborators may learn about our discoveries and use this knowledge to compete with us in the future; and

•

the number and type of our collaborations could adversely affect our attractiveness to collaborators or acquirers.

~~a collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to the marketing and distribution of such drug or drugs;~~

~~collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;~~

~~we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a change of control;~~

~~collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing and/or commercialization of the applicable drug candidates;~~

~~collaborators may learn about our discoveries and use this knowledge to compete with us in the future; and~~

~~the number and type of our collaborations could adversely affect our attractiveness to collaborators or acquirers.~~

~~Table of Contents~~

Collaboration agreements may not lead to development or commercialization of drug candidates in the most efficient manner, or at all. If our collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report on Form

10-Q

also apply to the activities of our collaborators.

If we are unable to establish and maintain our agreements with third parties to distribute XPOVIO to patients, our results of operations and business could be adversely affected.

We rely on third parties to commercially distribute XPOVIO to patients. For example, we have contracted with a limited number of specialty pharmacies and specialty distributors to sell and distribute XPOVIO. The use of specialty pharmacies and specialty distributors involves certain risks, including, but not limited to, risks that these organizations will:

•

not provide us accurate or timely information regarding their inventories, the number of patients who are using XPOVIO or serious adverse reactions, events and/or product complaints regarding XPOVIO;

•

not effectively sell or support XPOVIO or communicate publicly concerning XPOVIO in a manner that is contrary to FDA rules and regulations;

~~not provide us accurate or timely information regarding their inventories, the number of patients who are using XPOVIO or serious adverse reactions, events and/or product complaints regarding~~

•

reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support XPOVIO;

•

not devote the resources necessary to sell XPOVIO in the volumes and within the time frames that we expect;

•

be unable to satisfy financial obligations to us or others; or

•

cease operations.

~~not effectively sell or support XPOVIO or communicate publicly concerning XPOVIO in a manner that is contrary to FDA rules and regulations;~~

~~reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support XPOVIO;~~

~~not devote the resources necessary to sell XPOVIO in the volumes and within the time frames that we expect;~~

~~be unable to satisfy financial obligations to us or others; or~~

~~cease operations.~~

Any such events may result in decreased product sales and lower product revenue, which would harm our results of operations and business.

If we are not able to maintain our existing collaborations or establish additional collaborations as we currently plan, we may have to alter our development and commercialization plans and our business could be adversely affected.

Our drug development programs and the commercialization of our drug candidates for which we receive marketing approval will require substantial additional cash to fund expenses. As noted above, we expect to maintain our existing collaborations and collaborate with additional pharmaceutical and biotechnology companies for the development of our drug candidates and the commercialization of our drugs or the potential commercialization of our drug candidates.

We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside of the ~~United States,~~U.S., the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our drug candidate.

We may also be restricted under then-existing collaboration agreements from entering into future agreements on certain terms with potential collaborators.

Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.

~~Table of Contents~~

We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such drug candidate, reduce or delay its development program or one or more of our other development programs, delay the commercialization of a drug or a drug candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate revenue from sales of drugs.

We rely on some third parties as we conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.

We rely on some third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, as we conduct our clinical trials. We currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our drug development activities.

Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The ~~European Medicines Agency, or~~ EMA also requires us to comply with comparable standards. Regulatory authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and trial sites. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or any of the third parties that we rely on in connection with our clinical trials fail to comply with applicable requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with such requirements.

We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our drug candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates. In such an event, our financial results and the commercial prospects for our drug candidates could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed.

We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of such third parties could delay clinical development or marketing approval of our drug candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue from sales of drugs.

In addition, as discussed above, the third-parties upon whom we rely to conduct our clinical trials could be negatively impacted as a result of disruptions caused by the COVID-19 pandemic, including difficulties in initiating clinical sites or enrolling participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies, and other factors. If these third parties are so affected, our business prospects and results of operations could be severely adversely impacted.

We rely on third parties to conduct investigator-sponsored clinical trials of selinexor and our other drug candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our drug candidates may delay or impair our ability to obtain regulatory approval for selinexor and our other drug candidates.

We rely on academic and private

non-academic

institutions to conduct and sponsor clinical trials relating to selinexor and our other drug candidates. We do not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or

non-U.S.

regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.

Such arrangements will provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we do not have control over the timing and reporting of the data from investigator-sponsored trials, nor do we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our drug candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our drug candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.

~~Table of Contents~~

Additionally, the FDA or

non-U.S.

regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, the FDA or

non-U.S.

regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.

We contract with third parties for the manufacture of our drug candidates for preclinical studies and clinical trials and expect to continue to do so in connection with the commercialization of XPOVIO and for clinical trials and commercialization of any drug candidates that we develop and commercialize. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not have any manufacturing facilities or personnel. We do not currently have nor do we plan to build internal infrastructure or capability to manufacture XPOVIO or our drug candidates for use in the conduct of our clinical trials or for commercial supply. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our drug candidates for preclinical studies and clinical ~~trials under the guidance of members of our organization.~~trials. We have engaged third-party manufacturers for drug substance and drug product services. ~~We do not have a long term supply agreement with any of these third-party manufacturers, and we purchase our required drug supplies on a purchase order basis.~~

We currently rely, and expect to continue to rely, on third-party manufacturers or third-party collaborators for the manufacture of commercial quantities of any drug candidate that we commercialize following marketing approval. Reliance on third-party manufacturers entails risks, including:

~~reliance on the third party for regulatory compliance and quality assurance;~~

~~the possible breach of the manufacturing agreement by the third party;~~

the possible failure of the third party to manufacture our drugs or drug candidates according to our schedule, or at all, including if the third-party manufacturer gives greater priority to the supply of other drugs over our drugs and drug candidates, or otherwise does not satisfactorily perform according to the terms of the manufacturing agreement;

equipment malfunctions, power outages or other general disruptions experienced by our third-party manufacturers to their respective operations and other general problems with a multi-step manufacturing process;

~~the possible misappropriation or disclosure by the third party or others of our proprietary information, including our trade secrets and~~

~~know-how;~~

~~and~~

~~the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.~~

We have engaged a third-party contract manufacturer for the commercial production of XPOVIO and intend to do the same for any drug candidate that is approved by any regulatory agency. Reliance on third-party manufacturers entails risks, including:

•

reliance on the third party for regulatory compliance and quality assurance;

•

the possible breach of the manufacturing agreement by the third party;

•

the possible misappropriation or disclosure by the third party or others of our proprietary information, including our trade secrets and know-how; and

•

the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

This process is difficult and time consuming and we may face competition for access to manufacturing facilities, as there are a limited number of contract manufacturers operating under current Good Manufacturing Practices, or cGMPs, that are capable of manufacturing our drug candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could negatively impact our XPOVIO revenues or delay ~~our commercialization.~~

commercialization of any drug candidates that are subsequently approved.

Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the ~~United States.~~U.S. Facilities used by our third-party manufacturers must be inspected by the FDA after we submit an NDA and before potential approval of the drug candidate. Similar regulations apply to manufacturers of our drug candidates for use or sale in foreign countries. We do not control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of our drug candidates. If our manufacturers cannot successfully manufacture material that conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable drug candidate as alternative qualified manufacturing facilities may not be available on a timely basis or at all. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies

for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMPs or other regulatory requirements could result in sanctions being imposed on us or the contract manufacturer, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions,

~~Table of Contents~~

interruptions in supply and criminal prosecutions, any of which could significantly and adversely affect supplies of our drug candidates and have a material adverse impact on our business, financial condition and results of operations. Any drugs that we may develop may compete with other drug candidates and drugs for access to manufacturing facilities. ~~There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.~~

Any performance failure on the part of our existing or future manufacturers could delay clinical development, marketing approval or commercialization. For example, as a result of the COVID-19 pandemic, our suppliers and contract manufacturers could be disrupted by worker absenteeism, quarantines, or other travel or health-related restrictions or could incur increased costs associated with ensuring the safety and health of their personnel. If our suppliers or contract manufacturers are so affected, our supply chain could be disrupted, our product shipments could be delayed, our costs could be increased and our business could be adversely affected. If our current contract manufacturers cannot perform as agreed, we may be required to replace those manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our drug candidates or drugs, we may incur added costs and delays in identifying and qualifying any such replacement.

Our current and anticipated future dependence upon others for the manufacture of XPOVIO or any drug candidates that we develop may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.

Risks Related to Regulatory Approval and Marketing of Our Products and Product Candidates and Other Legal Compliance Matters

Even if we complete the necessary preclinical studies and clinical trials for our product candidates, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug ~~candidates.~~candidates in a timely manner, or at all. As a result, we cannot predict when or if we or any of our collaborators will obtain marketing approval to commercialize a drug candidate.

The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drugs are subject to extensive regulation by the FDA and comparable foreign regulatory authorities, whose laws and regulations may differ from country to country. We are not permitted to market our drug candidates in the ~~United States~~U.S. or in other countries until we or any of our collaborators receive approval of an NDA from the FDA or marketing approval from applicable regulatory authorities outside of the ~~United States.~~U.S. In July 2019 and June 2020, the FDA approved XPOVIO

~~(selinexor)~~ in ~~combination with dexamethasone for~~ the ~~treatment of adult patients with RRMM who have received at least four prior therapies~~multiple myeloma indication and ~~whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This~~the DLBCL indication, ~~is approved under accelerated approval based on response rate.~~respectively. Continued approval for ~~this indication~~these indications may be contingent upon verification and description of clinical benefit in aone or more confirmatory ~~trial. The ongoing,~~trials. For example, the FDA has agreed that the randomized Phase 3 BOSTON study evaluating selinexor in combination with Velcade

^®

(bortezomib) and

low-dose

dexamethasone could serve as the confirmatory trial for the multiple myeloma indication and the XPORT-DLBCL-030 study will serve as the confirmatory ~~trial.~~trial for evaluating selinexor in DLBCL. The BOSTON and XPORT-DLBCL-030 studies are post-marketing requirements for continued marketing authorization under the FDA’s Accelerated Approval program issued by the FDA in July 2019 and June 2020, respectively, for XPOVIO based on the results of the STORM study and SADAL study, respectively. If the FDA does not approve our supplemental New Drug Application, or sNDA, submission based on the data from the BOSTON study, we will suffer substantial harm, including potential loss of the accelerated approval for XPOVIO based on the results of the STORM and SADAL studies. In addition, we submitted a ~~Marketing Authorization Application (MAA)~~MAA to the ~~European Medicines Agency (EMA)~~EMA in January 2019 with a request for conditional approval of selinexor as a treatment for patients with heavily pretreated multiple myeloma based on the results of the STORM study. During March 2019, the EMA had inspectors conduct a Good Clinical Practices, ~~(GCP)~~or GCP, inspection at our headquarters, which was also attended by the FDA, as well as inspections of two clinical sites that participated in Part 2 of the STORM study. While we did not receive any findings from the FDA, in May 2019, the EMA inspectors provided us a written inspection report seeking our responses to various questions and findings. We promptly addressed the questions and findings in the inspection report and submitted proposals to the EMA’s Committee for Medicinal Products for Human Use, ~~(CHMP).~~or CHMP. In September 2019, we received the Day 180 List of Outstanding Issues from CHMP, which identified two issues requiring resolution. First, CHMP requested that we reconfirm the IRC adjudicated response rate to justify a positive benefit-risk assessment and, second, CHMP requested that we address the findings from the GCP inspection and our corrective measures taken to justify that the clinical trial data are of sufficient quality to support a benefit-risk assessment. In January 2020, we were granted a three-month extension from CHMP to provide additional time to respond to the outstanding questions. We are currently working with CHMP to address ~~both topics~~the outstanding questions; however, due to reduced access to clinical trial sites as a result of the COVID-19 pandemic, and, ~~expect~~therefore, have requested, and the EMA has granted us, additional time to ~~receive a decision on~~submit our response. With the ~~application in early 2020. We~~exception of our sNDA submission to the FDA requesting approval of selinexor to treat multiple myeloma after at least one prior line of therapy, we have not submitted any other application for, or received any marketing approval of, any of our drug candidates in the ~~United States~~U.S. or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA. The process of obtaining marketing approvals, both in the ~~United States~~U.S. and abroad, is a lengthy, expensive and uncertain process. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the

type, complexity and novelty of the drug candidates involved.

In addition, we may experience delays in the regulatory review process for our drug candidates as a result of the ongoing COVID-19 pandemic, such as the EMA review of our MAA for selinexor in multiple myeloma based on the results on the STORM study and any resulting impact to the timing of our expected submission of an MAA for selinexor in multiple myeloma supported by the results of the BOSTON study or any future MAA submission.

Further, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other studies and testing. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of a drug candidate. Any marketing approval we or any of our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable.

Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any of our collaborators to generate revenue from the particular drug candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.

~~Table of Contents~~

~~Since XPOVIO received~~

Under the FDA’s accelerated approval ~~by the FDA,~~regulations, we must still comply with post-approval development and regulatory requirements to maintain ~~that~~our approval of XPOVIO and, if we fail to do so, the FDA could withdraw its approval of XPOVIO for either of the currently approved indications, which would lead to substantially lower revenues.

For drugs ~~granted accelerated approval,~~approved under the FDA’s Accelerated Approval Program, the FDA typically requires post-marketing confirmatory trials to evaluate the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence. As a condition of the accelerated approval of XPOVIO for the multiple myeloma indication, we are required to (i) complete and submit a final report with full datasets from the BOSTON study following completion of the study, (ii) conduct a randomized phase 2 clinical trial of selinexor plus dexamethasone with ~~two different~~three doses of selinexor ~~that are lower than~~including the approved dose of 80 mg on days 1 and 3 of each week and two doses that are lower than the approved dose, in a similar patient population for which XPOVIO is indicated (which we plan to conduct outside of the ~~United States)~~U.S.), (iii) conduct a ~~hepatic impairment~~ trial with selinexor in patients ~~with cancer~~who have mild, moderate or severe hepatic impairment, and (iv) conduct a drug interaction trial with selinexor in patients to evaluate the effect of

co-administration

of a strong CYP3A4 inhibitor on the pharmacokinetics of selinexor.

As a condition of the accelerated approval of XPOVIO for the DLBCL indication, we are required to (i) complete and submit a final report with full datasets from a randomized, double-blind, placebo-controlled phase 3 trial that verifies and describes the clinical benefit of selinexor in patients with relapsed or refractory DLBCL and (ii) provide the interim and final analyses of a randomized phase 2 clinical trial of selinexor to characterize the safety and efficacy of at least two different dosing regimens of selinexor monotherapy in patients with relapsed or refractory DLBCL after at least two prior lines of systemic therapy.

The FDA may withdraw approval of ~~a product candidate~~XPOVIO for either approved ~~under the accelerated approval pathway~~indication if, for example, ~~the~~a trial required to verify the predicted clinical benefit of ~~our product candidate~~XPOVIO fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates that ~~our product candidate~~XPOVIO is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials relating to our product candidate. Similar risks to those described above are also applicable to any application that we have submitted or may submit to the EMA to support conditional approval of selinexor to treat heavily pretreated multiple myeloma, relapsed/refractory DLBCL, or any other cancer indication.

There can be no assurance that the ~~BOSTON study conducted~~FDA or any similar regulatory authority will determine that any confirmatory trial we conduct as part of our post-marketing obligations, will confirm that the surrogate marker used for accelerated approval of XPOVIO ~~will eventually show~~showed an adequate correlation with clinical outcomes. If the ~~BOSTON study fails~~FDA or any similar regulatory authority determines that our confirmatory trials fail to show such adequate correlation, we may not be able to maintain our previously granted marketing ~~approval~~approvals of XPOVIO.

Our failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the ~~United States would~~U.S. does not assure approval of product candidates in foreign jurisdictions.

In order to market and sell our drugs in the European Union and many other jurisdictions, we and our current or future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside of the ~~United States~~U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the ~~United States,~~U.S., it is required that the drug be approved for reimbursement before the drug can be approved for sale in that country. We and our collaborators may not obtain approvals from regulatory authorities outside of the ~~United States~~U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the ~~United States~~U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory approval in

one country may have a negative effect on the regulatory process in other countries. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.

Additionally, onin June ~~23,~~ 2016, the electorate in the United Kingdom, or UK, voted in favor of leaving the European Union, commonly referred to as Brexit. ~~On March 29, 2017,~~Following protracted negotiations, the ~~United Kingdom formally notified~~UK left the European Union ~~of its intention to withdraw pursuant to Article 50 of~~on January 31, 2020. Under the Lisbon Treaty. The United Kingdom had a period of a maximum of two years from the date of its formal notification to negotiate the terms of its withdrawal from, and future relationship with, the European Union. If no formal withdrawal agreement, ~~can be reached~~there is a transitional period until December 31, 2020 (extendable up to two years). Discussions between the ~~United Kingdom~~UK and the European Union ~~then it is expected that the United Kingdom’s membership of the European Union would automatically terminate~~have so far mainly focused on ~~the deadline, which was initially March 29, 2019. That deadline has~~finalizing withdrawal issues and transition agreements but have been ~~extended to October 31, 2019 to allow the parties to negotiate a withdrawal agreement, which has proven to be~~ extremely difficult to date. ~~Discussions between~~To date, only an outline of a trade agreement has been reached. Much remains open but the ~~United Kingdom and~~Prime Minister has indicated that the ~~European Union~~UK will ~~continue~~not seek to ~~focus on withdrawal issues and transition agreements. However, limited progress to date in these negotiations and ongoing uncertainty within~~extend the ~~United Kingdom Government and Parliament sustains~~transitional period beyond the ~~possibility~~end of 2020. If no trade agreement has been reached before the end of the ~~United Kingdom leaving the European Union without a withdrawal agreement and associated transition~~transitional period, ~~in place, which is likely to cause~~there may be significant market and economic disruption.

The Prime Minister has also indicated that the UK will not accept high regulatory alignment with the EU.

Since ~~a significant proportion of~~ the regulatory framework for pharmaceutical products in the ~~United Kingdom~~UK covering quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, ~~the withdrawal~~Brexit could materially impact the future regulatory regime ~~with respect~~that applies to products and the approval of ~~our~~ product candidates in the ~~United Kingdom or the European Union.~~UK. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, ~~would prevent~~may force us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the ~~United Kingdom~~UK and/or European Union for our product candidates, which could significantly and materially harm our business.

~~Table of Contents~~

We may seek approval from the FDA or comparable

non-U.S.

regulatory authorities to use accelerated development pathways for our product ~~candidates, including for selinexor in diffuse large~~

~~B-cell~~

~~lymphoma.~~candidates. If we are not able to use such pathways, we may be required to conduct additional clinical trials beyond those that we contemplate and that would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we receive them at all. In addition, even if we are able to use an accelerated approval pathway, it may not lead to expedited approval of our product candidates, or approval at all.

Under the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Prior to seeking such accelerated approval, we will continue to seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval.

~~We intend to use the data from the SADAL study to support an NDA request that the FDA consider granting accelerated approval for selinexor in relapsed and/or refractory diffuse large~~

~~B-cell~~

lymphoma, or DLBCL, and work with the FDA to determine the appropriate timeline for the submission of the NDA. In November 2018, the FDA granted fast track designation to selinexor for the treatment of patients that have relapsed and/or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. While the FDA agreed that the trial design and indication appear appropriate for accelerated approval, they reiterated to us in their feedback that the availability of accelerated approval will depend on the trial results and available therapies at the time of regulatory action. The FDA also has reiterated to us that it recommends, in general, a randomized trial with a progression-free survival endpoint as an initial registration approach and, for DLBCL, recommended two randomized trials that isolate the treatment effect of selinexor for a DLBCL indication. In addition, as we experienced with our NDA based on the results of Part 2 of the STORM study, the FDA has noted tolerability and dose optimization as review matters. Although we believe that our SADAL study presents an opportunity for us to request that the FDA grant accelerated approval for selinexor in relapsed and/or refractory DLBCL, there can be no assurance that the FDA will grant such approval, whether on an accelerated basis, or at all.

There can ~~also~~ be no assurance that the FDA will agree with our surrogate endpoints or intermediate clinical endpoints in any of our clinical trials, or that we will decide to pursue or submit any additional NDAs for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from FDA, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all.

A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

A fast track designation or breakthrough therapy status by the FDA is not assured and, in any event, may not actually lead to a faster development or regulatory review or approval process and, moreover, would not assure FDA approval of our product candidates.

We may be eligible for fast track designation or breakthrough therapy status for product candidates that we develop. If a product is intended for the treatment of a serious or life-threatening disease or condition and the product demonstrates the potential to address unmet medical needs for this disease or condition, the product sponsor may apply for FDA fast track designation. Additionally, a product candidate may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may

~~Table of Contents~~

demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for such designation or status, the FDA could decide not to grant it. Moreover, even if we do receive such a designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures and there is no assurance that our product candidate will be approved by the FDA.

~~In April 2018,~~ For example, in connection with our NDA for XPOVIO, in March 2019, the FDA ~~granted~~extended the Prescription Drug User Fee Act, or PDUFA, action date by three months following our submission of additional, existing clinical information as an amendment to the NDA, which resulted in a nine-month review cycle despite the fast track designation to selinexor for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy that include regimens comprised of an alkylating agent, a glucocorticoid, Velcade

~~(bortezomib), Kyprolis~~

~~(carfilzomib), Revlimid~~

~~(lenalidomide), Pomalyst~~

~~(pomalidomide) and Darzalex~~

(daratumumab) and whose disease is refractory to at least one proteasome inhibitor (Velcade or Kyprolis), one immunomodulatory agent (Revlimid or Pomalyst), glucocorticoids and to Darzalex, as well as to the most recent therapy. In addition, in November 2018, the FDA granted fast track designation to selinexor for the treatment of patients that have relapsed and/or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. However, even with these fast track designations, we may not experience a faster development process, review or approval compared to conventional FDA procedures and there is no assurance that selinexor will be approved by the FDA for additional indications.designation. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.

Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidate.

If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the FDA’s goal to review an application is six months, rather than the standard review period of ten months. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may ~~decide~~ not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. For example, in connection with our NDA for XPOVIO, in March 2019, the FDA extended the ~~Prescription Drug User Fee Act (PDUFA)~~PDUFA action date by three months following our submission of additional, existing clinical information as an amendment to the NDA, which resulted in a nine-month review cycle. Receiving priority review from the FDA does not guarantee approval within the

six-month

review cycle or thereafter.

We may not be able to obtain orphan drug exclusivity for our product candidates.

Regulatory authorities in some jurisdictions, including the ~~United States~~U.S. and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the ~~United States.~~

U.S.

Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the ~~United States~~U.S. and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.

Even if we obtain orphan drug exclusivity from the FDA for a product, as we have for XPOVIO as a treatment for patients with heavily pretreated multiple myeloma and selinexor in acute myeloid leukemia and DLBCL, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.

On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA’s

pre-existing

regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.

~~Table of Contents~~

Even if we or any of our collaborators obtain marketing approvals for our drug candidates, the terms of approvals and ongoing regulation of our drugs may limit how we, or they, manufacture and market our drugs, which could materially impair our ability to generate revenue.

Once marketing approval has been granted, an approved drug and its manufacturer and marketer are subject to ongoing review and extensive regulation. We and our collaborators must therefore comply with requirements concerning advertising and promotion for XPOVIO or for any of our drug candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the drug’s approved labeling. Thus, we and our collaborators may not be able to promote any drugs we develop for indications or uses for which they are not approved.

In addition, manufacturers of approved drugs and those manufacturers’ facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.

Accordingly, in connection with our currently approved products and assuming we or our current or future collaborators receive marketing approval for one or more of our drug candidates, we, and our collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.

If we and our collaborators are not able to comply with post-approval regulatory requirements, ~~we and our collaborators~~regulatory authorities could ~~have~~withdraw the marketing approvals ~~for~~of our drugs, ~~withdrawn by regulatory authorities,~~ and our or our collaborators’ ability to market any future drugs could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.

XPOVIO and any of our drug candidates for which we or our collaborators obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market, and we and our collaborators may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our drugs following approval.

XPOVIO and any of our drug candidates for which we or our collaborators obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such drug, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. For example, as a condition of the XPOVIO approval for the multiple myeloma and DLBCL indications, we are required to complete certain post-marketing commitments, as described above. Even if marketing approval of a drug candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy, which could include requirements for a restricted distribution system.

The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a drug. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding

off-label

use, and if we or our collaborators do not market any of our drug candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for

off-label

marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. In addition, later discovery of previously unknown AEs or other problems with our drugs or their manufacturers or manufacturing processes, data integrity issues with regulatory filings, or failure to comply with regulatory requirements, may yield various results, including:

•

litigation involving patients taking our drug;

•

restrictions on such drugs, manufacturers or manufacturing processes;

•

restrictions on the labeling or marketing of a drug;

~~litigation involving patients taking our drug;~~

•

restrictions on drug distribution or use;

•

requirements to conduct post-marketing studies or clinical trials;

•

warning letters or untitled letters;

•

withdrawal of the drugs from the market;

•

refusal to approve pending applications or supplements to approved applications that we submit;

•

recall of drugs;

~~restrictions on such drugs, manufacturers or manufacturing processes;~~

•

fines, restitution or disgorgement of profits or revenues;

•

suspension or withdrawal of marketing approvals;

•

damage to relationships with any potential collaborators;

•

unfavorable press coverage and damage to our reputation;

•

refusal to permit the import or export of drugs;

•

drug seizure; or

~~restrictions on the labeling or marketing of a drug;~~

•

injunctions or the imposition of civil or criminal penalties.

~~Table of Contents~~

~~restrictions on drug distribution or use;~~

~~requirements to conduct post-marketing studies or clinical trials;~~

~~warning letters or untitled letters;~~

~~withdrawal of the drugs from the market;~~

~~refusal to approve pending applications or supplements to approved applications that we submit;~~

~~recall of drugs;~~

~~fines, restitution or disgorgement of profits or revenues;~~

~~suspension or withdrawal of marketing approvals;~~

~~damage to relationships with any potential collaborators;~~

~~unfavorable press coverage and damage to our reputation;~~

~~refusal to permit the import or export of drugs;~~

~~drug seizure; or~~

~~injunctions or the imposition of civil or criminal penalties.~~

Under the Cures Act and the Trump Administration’s regulatory reform initiatives, the FDA’s policies, regulations and guidance may be revised or revoked and that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue.

In December 2016, the ~~21st~~21^st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur ~~innovation, but its ultimate implementation is unclear.~~innovation. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the ~~United States~~U.S. or abroad. For example, certain policies of the Trump Administration may impact our business and industry. Namely, the Trump Administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. An under-resourced FDA could result in delays in the FDA’s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. In January 2017, President Trump issued an executive order, applicable to all executive agencies including the FDA, which requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the

~~“two-for-one”~~

“two-for-one” provisions. This executive order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the executive order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within ~~OMB~~the Office of Management and Budget in February 2017, the administration indicates that the

~~“two-for-one”~~

“two-for-one” provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February 24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a “Regulatory Reform Officer” and establish a “Regulatory Reform Task Force” to implement the

two-for-one

provisions and other previously issued executive orders relating to the review of federal regulations. In response to the COVID-19 pandemic, the Trump Administration is looking for additional ways to provide regulatory relief. It is difficult to predict how these various requirements will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.

With the recent passage of the CREATES Act, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved drug products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications.

On December 20, 2019, President Trump signed legislation intended to facilitate the development of generic and biosimilar products. The bill, previously known as the CREATES Act, authorizes sponsors of abbreviated new drug applications, or ANDAs, and 505(b)(2) applications to file lawsuits against companies holding NDAs that decline to provide sufficient quantities of an approved reference drug on commercially reasonable, market-based terms. Drug products on FDA’s drug shortage list are exempt from these new provisions unless the product has been on the list for more than six continuous months or the FDA determines that the supply of the product will help alleviate or prevent a shortage.

To bring an action under the statute, an ANDA or 505(b)(2) applicant must take certain steps to request the reference product, which, in the case of products covered by a risk evaluation and mitigation strategy with elements to assure safe use, include obtaining authorization from the FDA for the acquisition of the reference product. If the applicant does bring an action for failure to provide a reference product, there are certain affirmative defenses available to the NDA holder, which must be shown by a preponderance of evidence. If the applicant prevails in litigation, it is entitled to a court order directing the NDA holder to provide, without delay, sufficient quantities of the applicable product on commercially reasonable, market-based terms, plus reasonable attorney fees and costs.

Additionally, the new statutory provisions authorize a federal court to award the product developer an amount “sufficient to deter” the NDA holder from refusing to provide sufficient product quantities on commercially reasonable, market-based terms if the court finds, by a preponderance of the evidence, that the NDA holder did not have a legitimate business justification to delay providing the product or failed to comply with the court’s order. For the purposes of the statute, the term “commercially reasonable, market-based terms” is defined as (1) the nondiscriminatory price at or below the most recent wholesale acquisition cost for the product, (2) a delivery schedule that meets the statutorily defined timetable, and (3) no additional conditions on the sale.

Although we intend to comply fully with the terms of these new statutory provisions, we are still exposed to potential litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved drug products on commercially reasonable, market-based terms for testing in support of ANDAs and 505(b)(2) applications. Such litigation would subject us to additional litigation costs, damages and reputational harm, which could lead to lower revenues. The CREATES Act may enable generic competition with XPOVIO and any of our other drug candidates, if approved, which could impact our ability to maximize product revenue.

Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our drug candidates and affect the prices we, or they, may obtain.

In the ~~United States~~U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell or

~~Table of Contents~~

commercialize XPOVIO or any drug candidate for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved drugs.

Among the provisions of the Patient Protection and Affordable Care Act, or ACA, of potential importance to our business, including, without limitation, our ability to commercialize our drugs and the prices we may obtain for any of our drug candidates that are approved for sale, are the following:

•

an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;

•

an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;

~~an annual,~~

~~non-deductible~~

~~fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;~~

•

expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;

•

a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer’s outpatient drugs to be covered under Medicare Part D;

•

extension of manufacturers’ Medicaid rebate liability;

•

expansion of eligibility criteria for Medicaid programs;

•

expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;

•

new requirements to report certain financial arrangements with physicians and teaching hospitals;

•

a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and

~~an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;~~

•

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.

~~expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;~~

~~a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% starting January 1, 2019)~~

~~point-of-sale~~

~~discounts off negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer’s outpatient drugs to be covered under Medicare Part D;~~

~~extension of manufacturers’ Medicaid rebate liability;~~

~~expansion of eligibility criteria for Medicaid programs;~~

~~expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;~~

~~new requirements to report certain financial arrangements with physicians and teaching hospitals;~~

~~a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and~~

~~a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.~~

Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in April 2013 and, due to subsequent legislative amendments, will stay in effect through ~~2027~~2029 unless additional Congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The CARES Act, which was signed into law on March 27, 2020 and designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 to December 31, 2020 and extended the sequester by one year, through 2030, in order to offset the added expense of the 2020 cancellation. These ~~new~~ laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for XPOVIO and for any of our product candidates for which we may obtain regulatory approval or the frequency with which XPOVIO or any ~~such~~ product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.

We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for XPOVIO or any other approved product and/or the level of reimbursement physicians receive for administering XPOVIO or any other approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.

Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump Administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the ~~Tax Act,~~TCJA, includes a provision repealing, effective January 1, 2019, the

tax-based

shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. OnAdditionally, the 2020 federal spending package permanently eliminated, effective January ~~22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed~~1, 2020, the ~~implementation of certain~~

ACA-mandated

~~fees, including the~~

~~so-called~~

~~“Cadillac”~~ “Cadillac” tax on ~~certain high cost~~high-cost employer-sponsored ~~insurance plans, the annual fee imposed on certain~~ health ~~insurance providers~~

~~Table of Contents~~

~~based on market share,~~coverage and ~~the~~ medical device ~~excise~~ tax on

~~non-exempt~~

~~medical devices.~~and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018, among other things, ~~amends~~amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. In July 2018, the Centers for Medicare and Medicaid Services, or CMS, published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On

In addition, on December 14, 2018, a U.S. District Court ~~Judge~~judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because itthe mandate was repealed as part of the ~~Tax Act,~~TCJA, the remaining provisions of the ACA are invalid as well. The Trump administration and CMS have both stated that the ruling will have no immediate effect, and on December 30, 2018 the same judge issued an order staying the judgment pending appeal. The Trump Administration ~~has~~ recently represented to the Court of Appeals considering this judgment that it does not oppose the lower court’s ruling. On July 10, 2019, the Court of Appeals for the Fifth Circuit heard oral argument in this case. ~~In those arguments,~~On December 18, 2019, that court affirmed the lower court’s ruling that the individual mandate portion of the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. On January 21, 2020, the U.S. Supreme Court declined to review this decision on an expedited basis. On March 3, 2020, the Supreme Court agreed to hear this case. More recently, the Trump Administration ~~argued~~filed a brief in ~~support~~this case supporting the decision of ~~upholding~~ the ~~lower court decision.~~Court of Appeals. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.

The Trump Administration has also taken executive actions to undermine or delay implementation of the ACA. In January 2017, President Trump signed an executive order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, the President signed a second executive order allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through the ACA exchanges. At the same time, the Trump Administration announced that it will discontinue the payment of cost-sharing reduction, or CSR, payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of that bill is uncertain. Further, in July 2018 following a federal district court decision from New Mexico, the Administration announced that it would be freezing payments to insurers under the ACA to cover sicker patients until it or Congress can address the appropriate methodology for calculating and making such payments. It remains to be seen how this action will affect the implementation of the ACA.

We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business. It is possible that repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future legislation to repeal and replace ACA provisions is uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion provisions. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from XPOVIO or from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.

Further, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration’s budget proposal ~~for fiscal year 2019~~ contains further drug price control measures that could be enacted during the ~~2019~~ budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for

low-income

patients. Specifically, the Trump Administration’s 2021 budget proposal includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients and increase patient access to lower cost generic drugs and biosimilars. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.

Specifically, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example, on May 11, 2018, the current administration issued a plan to lower drug prices. Under this blueprint for action, the current administration indicated that the Department of Health and Human Services, or HHS, will take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies, advance biosimilars and generics to boost price competition, evaluate the inclusion of prices in drug makers’ ads to enhance price competition, speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug makers, avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and Medicaid, work to give Medicare Part D plan sponsors more negotiation power with drug makers, examine which Medicare Part B drug prices could be negotiated by Medicare Part D plans, improve the design of the Medicare Part B Competitive Acquisition Program, update Medicare’s drug-pricing dashboard to increase transparency, prohibit Medicare Part D contracts that include “gag rules” that prevent pharmacists from informing patients when they could pay less

out-of-pocket

by not using insurance,

~~Table of Contents~~

and require that Medicare Part D plan members be provided with an annual statement of plan payments,

out-of-pocket

spending, and drug price increases.Finally, the current presidential administration’s budget proposal for fiscal year 2021 includes a $135.0 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs.

More recently, on ~~January 31, 2019,~~July 24, 2020, President Trump issued four executive orders that are intended to lower the costs of prescription drug products. The first order would require all federally qualified health centers to pass on to patients the discounts the health centers receive on insulin and epinephrine through Medicare's 340B Drug Discount Program. The second order would establish an international pricing index that would set the price Medicare Part B pays for the costliest medications covered under the program to the lowest price in other economically advanced countries. The President has indicated that this order will be held until August 24, 2020, because the administration may not implement it. The third order is intended to reduce the costs of drugs by supporting the safe importation of prescription drugs. Specifically, the order calls upon the Department of Health and Human Services, or HHS, ~~Office~~to facilitate grants to individuals of ~~Inspector General~~waivers of the prohibition of importation of prescription drugs that would allow patients to import FDA-approved drug products from abroad, so long as doing so would result in lower costs. In addition, the order would allow wholesalers and pharmacies to re-import both biological drugs and insulin that were originally manufactured in the U.S. and then exported for international sale. This action follows the publication of a proposed ~~modifications~~rulemaking on December 23, 2020, that, if finalized, would allow states or certain other non-federal government entities to submit importation program proposals to the FDA for review and approval. Applicants would be required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers. At the same time, the FDA issued draft guidance that would allow manufacturers to import their own FDA-approved drugs that are authorized for sale in other countries (multi-market approved products). Finally, the fourth order would end drug rebates used by health plan sponsors, pharmacies or pharmacy benefit managers, or PBMs, in operating the Medicare Part D program. Specifically, the order directs HHS to exclude from safe harbor protections under the federal anti-kickback statute ~~discount~~retroactive price reductions that are not applied at the point-of-sale. Instead, the order requires HHS to establish new safe ~~harbor for the purpose of reducing the cost of drug products~~harbors that would allow health plan sponsors, pharmacies, and PBMs to pass on those discounts to consumers ~~which, among other things, if finalized,~~at point-of-sale in order to “lower the patient's out-of-pocket costs” and “permit the use of certain bona fide PBM service fees”. Each of these orders directs the federal government to implement the initiatives outlined in the orders, meaning they will ~~affect discounts paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations.~~

not have immediate effects.

At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.

Moreover, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us and any collaborators to more stringent drug labeling and post-marketing testing and other requirements.

Our relationships with healthcare providers and physicians and third-party payors ~~will be~~are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

Healthcare providers, physicians and third party payors ~~will~~ play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our ~~future~~ arrangements with third party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following:

•

Anti-Kickback Statute—the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;

•

False Claims Act—the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at a minimum of $11,181 and a maximum of $22,363 per false claim;

•

HIPAA—the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information;

~~Anti-Kickback Statute~~

—the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;

•

Transparency Requirements—federal laws require applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; and

•

Analogous State and Foreign Laws—analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to sales or marketing arrangements and claims involving healthcare items or services and are generally broad and are enforced by many different federal and state agencies as well as through private actions.

~~Table of Contents~~

~~False Claims Act~~

—the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant

~~per-claim~~

~~penalties, currently set at $5,500 to $11,000 per false claim;~~

~~HIPAA~~

—the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information;

~~Transparency Requirements~~

~~—federal laws require applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; and~~

~~Analogous State and Foreign Laws~~

—analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to sales or marketing arrangements and claims involving healthcare items or services and are generally broad and are enforced by many different federal and state agencies as well as through private actions.

Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not

pre-empted

by HIPAA, thus complicating compliance efforts.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we ~~expect to~~ do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.

Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.

The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain

~~Table of Contents~~

measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside of the European Union, including the ~~United States~~U.S. and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the ~~United States.~~U.S. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer

associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.

Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR’s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.

Similar actions are either in place or under way in the ~~United States.~~U.S. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy ~~Act—~~Act, which ~~goes~~went into effect ~~in 2020—~~on January 1, 2020, is creating similar risks and obligations as those created by GDPR, though the Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.

Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, including

non-compliance

with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.

We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of

non-U.S.

jurisdictions, including the GDPR. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.

~~Table of Contents~~

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain drug candidates outside of the ~~United States~~U.S. and require us to develop and implement costly compliance programs.

We are subject to numerous laws and regulations in each jurisdiction outside of the ~~United States~~U.S. in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.

The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the ~~United States~~U.S. to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The ~~Securities and Exchange Commission, or~~ SEC is involved with enforcement of the books and records provisions of the FCPA.

Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

Various laws, regulations and executive orders also restrict the use and dissemination outside of the ~~United States,~~U.S., or the sharing with certain

non-U.S.

nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the ~~United States,~~U.S., has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the ~~United States,~~U.S., which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions.

~~Table of Contents~~

Governments outside of the ~~United States~~U.S. tend to impose strict price controls, which may adversely affect our revenues from the sales of drugs, if any.

In some countries, including the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we or our existing and future collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.

Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, ~~including in recent months,~~ the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent protection for our drug candidates and other discoveries, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize drugs and other discoveries similar or identical to ours, and our ability to successfully commercialize our drug candidates and other discoveries may be adversely affected.

Our success depends in large part on our ability to obtain and maintain patent protection in the ~~United States~~U.S. and other countries with respect to our proprietary drug candidates and other discoveries. We seek to protect our proprietary position by filing patent applications in the ~~United States~~U.S. and abroad related to our novel drug candidates and other discoveries that are important to our business. ~~To date, 69~~As of July 15, 2020, 72 patents ~~have issued~~were in force that relate to XPO1 inhibitors, including composition of matter patents for selinexor, verdinexor and eltanexor in the ~~United States,~~U.S., and their use in targeted therapeutics. In addition, 1115 patents ~~have issued~~were in force that relate to our PAK4/NAMPT inhibitors, including two composition of matter patents for

KPT-9274

in the ~~United States~~U.S. and its use in targeted therapeutics. We cannot be certain that any other patents will issue with claims that cover any of our key drug candidates or other discoveries or drug candidates.

The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our drug candidates or other discoveries, or which effectively prevent others from commercializing competitive drugs and discoveries. Changes in either the patent laws or interpretation of the patent laws in the ~~United States~~U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.

The laws of foreign countries may not protect our rights to the same extent as the laws of the ~~United States.~~U.S. For example, in some foreign jurisdictions, our ability to secure patents based on our filings in the ~~United States~~U.S. may depend, in part, on our ability to timely obtain assignment of rights to the invention from the employees and consultants who invented the technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the ~~United States~~U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.

~~Table of Contents~~

Assuming the other requirements for patentability are met, prior to March 2013, in the ~~United States,~~U.S., the first to invent the claimed invention was entitled to the patent, while outside of the ~~United States,~~U.S., the first to file a patent application is entitled to the patent. In March 2013, the ~~United States~~U.S. transitioned to a

first-inventor-to-file

system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent. We may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, or post-grant or

inter partes

review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our discoveries or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights.

Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative discoveries or drugs in a

non-infringing

manner.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the ~~United States~~U.S. and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical discoveries and drugs, or limit the duration of the patent protection of our discoveries and drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Competitors or commercial supply companies or others may infringe our patents and other intellectual property rights. For example, we are aware of third parties selling a version of our lead product candidate for research purposes, which may infringe our intellectual property rights. To counter such infringement, we may advise such companies of our intellectual property rights, including, in some cases, intellectual property rights that provide protection for our lead product candidates, and demand that they stop infringing those rights. Such demand may provide such companies the opportunity to challenge the validity of certain of our intellectual property rights, or the opportunity to seek a finding that their activities do not infringe our intellectual property rights. We may also be required to file infringement actions, which can be expensive and time-consuming. In an infringement proceeding, a defendant may assert and a court may agree with a defendant that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the intellectual property at issue. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability and the ability of any current and future collaborators to develop, manufacture, market and sell XPOVIO and our drug candidates and use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates and technology, including interference proceedings before the ~~U.S. Patent and Trademark Office.~~USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. No litigation asserting such infringement claims is currently pending against us, and we have not been found by a court of competent jurisdiction to have infringed a third party’s intellectual property rights. If we are found to infringe or think there is a risk we may be found to infringe, a third party’s intellectual property rights, we could be required or choose to obtain a license from such third party to continue developing, marketing and selling our drugs, drug candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be

non-exclusive,

thereby giving our competitors access to the same intellectual property licensed to us. We could be forced, including by court order, to cease commercializing the infringing intellectual property or drug or to cease using the infringing technology. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

~~Table of Contents~~

We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or

know-how

of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for

non-compliance

with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the ~~United States Patent and Trademark Office, or~~ USPTO and various foreign patent offices at various points over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with such provisions, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which

non-compliance

can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.

If we do not successfully extend the term of patents covering our drug candidates under the Hatch-Waxman Amendments and similar foreign legislation, our business may be materially harmed.

Depending upon the timing, duration and conditions of FDA marketing approval, if any, of our drug candidates, one or more of our U.S. patents may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for one patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. The total patent term, including the extension period, may not exceed 14 years following FDA approval. Accordingly, the length of the extension, or the ability to even obtain an extension, depends on many factors.

In the ~~United States,~~U.S., only a single patent can be extended for each qualifying FDA approval, and any patent can be extended only once and only for a single product. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Because both selinexor and verdinexor are protected by a single family of patents and applications, we may not be able to secure patent term extensions for both of these drug candidates in all jurisdictions where these drug candidates are ~~approved, if ever.~~

approved.

If we are unable to obtain a patent term extension for a drug candidate or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that drug candidate, if any, in that jurisdiction will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue could be materially reduced.

~~Table of Contents~~

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for our drugs, drug candidates and other discoveries, we also rely on trade secrets, including unpatented

know-how,

technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into

non-disclosure

and confidentiality agreements with parties who have access to them, such as our employees, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. To the extent that we are unable to timely enter into confidentiality and invention or patent assignment agreements with our employees and consultants, our ability to protect our business through trade secrets and patents may be harmed. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the ~~United States~~U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. To the extent inventions are made by a third party under an agreement that does not grant us an assignment of their rights in inventions, we may choose or be required to obtain a license.

Not all of our trademarks are registered. Failure to secure those registrations could adversely affect our business.

As of ~~November 1, 2019, five of our trademarks, including XPOVIO, are registered~~July 15, 2020, we have trademark registrations in the ~~United States.~~U.S. for our name and logo, and a combination of the two, XPOVIO, and PORE for our online portal. We also have 9 pending

~~intent-to-use~~

applications in the ~~United States, six of which have been allowed, meaning that we can perfect~~U.S. to register two additional drug names (examination is currently suspended), and KARYFORWARD and a KARYFORWARD logo for our ~~registration when we have commenced use in commerce.~~financial aid and charitable services. Outside the ~~United States, we have registrations~~U.S., XPOVIO is registered or pending in the European Union for seven trademarks (potential drug names for selinexor) and pending applications for two others. Applications for the same nine trademarks were filed in 15 other jurisdictions, some of which have also proceeded to registration. Applications for one of those marks (XPOVIO) have been filed in 14thirty-seven additional jurisdictions, and ~~applications for three of those marks (NEXPOVIO, XPOVI and XPOVIE) have been filed in 20 additional jurisdictions. We have also filed trademark applications for XPOVIO~~is registered in Katakana in Japan, Hangul in South Korea, and Chinese characters in Taiwan. We also have registrations or applications for eight additional possible drug names in numerous foreign jurisdictions. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would, which could adversely affect our business. During trademark registration proceedings in the ~~United States~~U.S. and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.

In addition, any proprietary name we propose to use with our key drug candidates in the ~~United States~~U.S. must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed drug names, including an evaluation of potential for confusion with other drug names. If the FDA objects to any of our proposed proprietary drug names for any of our drug candidates, if approved, we may be required to expend significant additional resources in an effort to identify a suitable proprietary drug name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.

Risks Related to Employee Matters and Managing Growth

Our future success depends on our ability to retain our Chief Executive Officer, our President and Chief Scientific Officer and other key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on Michael Kauffman, M.D., Ph.D., our Chief Executive Officer, and Sharon Shacham, Ph.D., M.B.A., our President and Chief Scientific Officer, as well as the other principal members of our management and scientific teams. Although we have entered into formal employment agreements with Drs. Kauffman and Shacham, these agreements do not prevent them from terminating their employment with us at any time. We do not maintain “key person” insurance for any of our executives or other employees. The loss of the services of any of our key employees could impede the achievement of our research, development, commercialization and other business objectives.

Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

~~Table of Contents~~

Drs. Kauffman and Shacham are married to each other. The separation or divorce of the couple in the future could adversely affect our business.

Dr. Kauffman, our Chief Executive Officer and member of our board of directors, and Dr. Shacham, our President and Chief Scientific Officer, are married to each other. They are two of our executive officers and are a vital part of our operations. If they were to become separated or divorced or could otherwise not amicably work with each other, one or both of them may decide to cease his or her employment with us or it could negatively impact our working environment. Alternatively, their work performance may not be satisfactory if they become preoccupied with issues relating to their personal situation. In these cases, our business could be materially harmed.

We have expanded and expect to continue to expand our development, regulatory and sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

We have experienced and expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, regulatory affairs, sales, marketing and distribution. To manage our current and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing such growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

Our business and operations may be materially adversely affected in the event of computer system failures or security breaches, and the costs and consequences of implementing data protection measures could be significant.

Despite the implementation of security measures, our internal computer systems, and those of our contract research organizations and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber attacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our reputation or competitive position could be damaged, and the further development and commercialization of our drug candidates could be delayed or halted. We may also be vulnerable to cyber attacks by hackers, or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or result in legal proceedings. In addition, the cost and operational consequences of implementing further data protection measures could be significant. Moreover, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate security measures.

Risks Related to Our Common Stock

Our executive officers, directors and principal stockholders maintain the ability to control all matters submitted to stockholders for approval.

As of ~~September 30, 2019,~~July 15, 2020, our executive officers, directors and a small number of stockholders own more than a majority of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.

~~Table of Contents~~

Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

•

establish a classified board of directors such that not all members of the board are elected at one time;

•

allow the authorized number of our directors to be changed only by resolution of our board of directors;

~~establish a classified board of directors such that not all members of the board are elected at one time;~~

•

limit the manner in which stockholders can remove directors from the board;

•

establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;

•

require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;

•

limit who may call stockholder meetings;

•

authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and

•

require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.

~~allow the authorized number of our directors to be changed only by resolution of our board of directors;~~

~~limit the manner in which stockholders can remove directors from the board;~~

~~establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;~~

~~require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;~~

~~limit who may call stockholder meetings;~~

~~require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.~~

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

An active trading market for our common stock may not be sustained.

Although our common stock is listed on The Nasdaq Global Select Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for you to sell shares of our common stock without depressing the market price for the shares, or at all. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.

If securities analysts do not continue to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that analysts will provide favorable coverage or continue to cover us. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.

The price of our common stock has been and may be volatile in the future and fluctuate substantially.

Our stock price has been and is likely to be volatile and may fluctuate substantially. For example, since ~~January 1, 2015,~~July 15, 2019, our common stock has traded at prices per share as high as ~~$38.47~~$29.61 and as low as ~~$3.92.~~$7.55. On ~~October 29, 2019,~~July 31, 2020, the closing sale price of our common stock on The Nasdaq Global Select Market was ~~$11.52~~$16.05 per share. The stock market in general and the market for pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular ~~companies.~~companies, such as the recent response to the ongoing COVID-19 pandemic and related world-wide economic disruptions. The market price for our common stock may be influenced by many factors, including:

•

our success in commercializing XPOVIO;

•

the success of competitive drugs or technologies;

~~our success in launching and commercializing XPOVIO;~~

•

results of clinical trials of our drug candidates or those of our competitors;

•

our success in commercializing our drug candidates, if and when approved;

•

regulatory or legal developments in the U.S. and other countries;

•

developments or disputes concerning patent applications, issued patents or other proprietary rights;

•

the recruitment or departure of key personnel;

•

the level of expenses related to the commercialization of XPOVIO and clinical development programs for any of our drug candidates;

•

the results of our efforts to discover, develop, acquire or in-license additional drug candidates or drugs;

•

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

•

variations in our financial results or those of companies that are perceived to be similar to us;

•

changes in the structure of healthcare payment systems;

•

market conditions in the pharmaceutical and biotechnology sectors, including as the result of uncertainties due to the ongoing COVID-19 pandemic;

•

general economic, industry and market conditions; and

•

the other factors described in this “Risk Factors” section.

~~Table of Contents~~

~~the success of competitive drugs or technologies;~~

~~results of clinical trials of our drug candidates or those of our competitors;~~

~~our success in commercializing our drug candidates, if and when approved;~~

~~regulatory or legal developments in the United States and other countries;~~

~~developments or disputes concerning patent applications, issued patents or other proprietary rights;~~

~~the recruitment or departure of key personnel;~~

~~the level of expenses related to the commercial launch of XPOVIO and clinical development programs for any of our drug candidates;~~

~~the results of our efforts to discover, develop, acquire or~~

~~in-license~~

~~additional drug candidates or drugs;~~

~~actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;~~

~~variations in our financial results or those of companies that are perceived to be similar to us;~~

~~changes in the structure of healthcare payment systems;~~

~~market conditions in the pharmaceutical and biotechnology sectors;~~

~~general economic, industry and market conditions; and~~

~~the other factors described in this “Risk Factors” section.~~

Securities litigation or other litigation could result in substantial damages and may divert management’s time and attention from our business.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. We are a target of this type of litigation. See Part II, Item 1, “Legal Proceedings” in this Quarterly Report on Form

10-Q

for information concerning securities litigation recently initiated against us and certain of our executive officers and directors and certain other defendants. We may become the target of additional securities litigation in the future. For example, we may face additional securities class action litigation or other litigation if we fail to successfully ~~launch and~~ commercialize XPOVIO, or if we cannot obtain regulatory approvals for, or if we otherwise fail to successfully commercialize and launch, our drug candidates. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of such suits, and we may not prevail. Monitoring and defending against legal actions is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, we may incur substantial legal fees and costs in connection with any such litigation. We have not established any reserves for any potential liability relating to any such potential lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. We currently maintain insurance coverage for some of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be enough to cover damages awarded. In addition, certain types of damages may not be covered by insurance, and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future. A decision adverse to our interests on one or more legal matters or litigation could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our reputation, financial condition and results of operations.

We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.

Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our drug candidates. Pending their use to fund our operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.

We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.

As a public company, we incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management

~~Table of Contents~~

and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly especially since we are no longer an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, and are no longer able to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are “emerging growth companies” and that were applicable to us prior to January 1, 2019.

Section 404 of the Sarbanes-Oxley Act of 2002 requires us, on an annual basis, to review and evaluate our internal controls. To maintain compliance with Section 404, we are required to document and evaluate our internal control over financial reporting, which has been both costly and challenging. We will need to continue to dedicate internal resources, continue to engage outside consultants and follow a detailed work plan to continue to assess and document the adequacy of internal control over financial reporting, continue to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.

A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. We had 62,705,481 shares outstanding as of September 30, 2019. Of such shares, at least 7.8 million shares are eligible for sale in the public market under Rule 144 of the Securities Act of 1933, as amended, or the Securities Act, subject to the volume limitations and other conditions of Rule 144. The holders of these shares may at any time decide to sell their shares in the public market. We have also registered all shares of common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, to the extent applicable.

Our ability to use our net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations.

Under the provisions of the Internal Revenue Code of 1986, as amended, or the Code, our net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (and state tax authorities under relevant state tax rules). In addition, as ~~a result of~~described below in “Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,” the ~~Tax~~TCJA (as amended by the Coronavirus Aid, Relief, and Economic Security Act, ~~for~~or CARES Act) includes changes to U.S. federal ~~income~~ tax ~~purposes,~~rates and the ~~use of~~rules governing net operating loss carryforwards ~~arising in taxable years beginning after December 31, 2017 is limited~~that may significantly impact our ability to ~~80% of~~utilize our net operating losses to offset taxable income in ~~any future taxable year, although such losses may be carried forward indefinitely. It is uncertain how various states will respond to~~ the ~~Tax Act.~~future. Furthermore, the use of net operating loss and tax credit carryforwards may become subject to an annual limitation under Sections 382 and 383 of the Code, respectively, and similar state provisions in the event of certain cumulative changes in the ownership interest of significant shareholders in excess of 50 percent over a three-year period. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of a company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Our company has completed several financings since its inception which resulted in an ownership change under Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, some of which are outside of our control, could result in ownership changes in the future. For these reasons, we may not be able to use some or all of our net operating loss and tax credit carryforwards, even if we attain profitability.

~~The comprehensive~~

Changes in tax ~~reform bill could~~laws or in their implementation or interpretation may adversely affect our business and financial condition.

Recent changes in tax law may adversely affect our business or financial condition. The ~~Tax Act~~TCJA significantly revises the Internal Revenue Code of 1986, as amended. The ~~Tax Act,~~TCJA, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of ~~34%~~35% to a flat rate of 21%, limitation of the tax deduction for net interest expense to 30% of adjusted ~~earnings~~taxable income (except for certain small businesses),

~~Table of Contents~~

limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. ~~Notwithstanding~~

As part of Congress’ response to the ~~reduction in~~COVID-19 pandemic, the ~~corporate income~~Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, and the CARES Act was enacted on March 27, 2020. Both contain numerous tax ~~rate,~~provisions. In particular, the ~~overall impact~~CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of the ~~new federal~~80%-of-income limitation on the use of net operating losses, which was enacted as part of the TCJA. It also provides that net operating losses arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible to be carried back up to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax ~~law~~deductibility for net interest expense by increasing the limitation from 30% to 50% of adjusted taxable income.

Regulatory guidance under the TCJA, the FFCR Act and the CARES Act is ~~uncertain~~ and continues to be forthcoming, and such guidance could ultimately increase or lessen their impact on our business and financial ~~condition~~condition. It is also likely that Congress will enact additional legislation in connection with the COVID-19 pandemic, some of which could ~~be adversely affected.~~have an impact on us. In addition, it is uncertain ~~how~~if and to what extent various states will ~~respond~~conform to the ~~Tax~~TCJA, the FFCR Act or the CARES Act.

~~Table of Contents~~

Item 6. Exhibits.

Exhibit Number		Description of Exhibit

10.1†		Amendment to License Agreement, dated May 1, 2020, by and between Antengene Therapeutics Limited and the Registrant.

10.2		Amendment No. 1 to the Open Market Sale Agreement, by and between the Registrant and Jefferies LLC, dated May 5, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the Commission on May 5, 2020)

31.1*		Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2*		Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1**		Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		Inline XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH*		Inline XBRL Taxonomy Extension Schema Document.

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104*		Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

Exhibit
Number

Form

Incorporated by Reference

Provided
Herewith

Description of Exhibit
File Number

Date of Filing

Exhibit Number

10.1

Annual Bonus Plan of the Registrant.

8-K

001-36167

August 6, 2019

10.1

10.2*

Revenue Interest Financing Agreement, dated September 14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P.

X

31.1

Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

X

31.2

Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

X

32.1

Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

32.2

Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

101.INS

Inline XBRL Instance Document

The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document

101.SCH

Inline XBRL Schema Document

X

101.CAL

Inline XBRL Calculation Linkbase Document

X

101.DEF

Inline XBRL Definition Linkbase Document

X

101.LAB

Inline XBRL Label Linkbase Document

X

101.PRE

Inline XBRL Presentation Linkbase Document

X

104

Cover Page Interactive Data File

Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

†	Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

*	Filed herewith.

* Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

**	Furnished herewith.

~~Table of Contents~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	KARYOPHARM THERAPEUTICS INC.

Date: ~~November~~August 4, ~~2019~~ 2020	By:	/s/ MICHAEL KAUFFMAN
		Michael Kauffman, M.D., Ph.D.
		Chief Executive Officer
		(Principal executive officer)

Date: ~~November~~August 4, ~~2019~~ 2020	By:	/s/ MICHAEL MASON
		Michael Mason
		Senior Vice President, Chief Financial Officer and Treasurer
		(Principal financial and accounting officer)


	September 30, 2019				December 31, 2018
Assets
Current assets:
Cash and cash equivalents		$	168,004			$	118,021
Short-term investments			99,525				210,178
Accounts receivable			7,928				—
Inventory			100				—
Prepaid expenses and other current assets			5,310				6,413

Total current assets			280,867				334,612
Property and equipment, net			3,240				3,863
Operating lease right-of-use assets			10,904				—
Long-term investments			2,022				2,001
Restricted cash			712				716

Total assets		$	297,745			$	341,192

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	3,068			$	4,332
Accrued expenses			32,421				32,493
Deferred revenue			1,053				9,362
Operating lease liabilities			1,583				—
Deferred rent			—				390
Other current liabilities			1,077				327

Total current liabilities			39,202				46,904
Convertible senior notes			107,962				102,664
Deferred royalty obligation			73,589				—
Operating lease liabilities, net of current portion			13,643				—
Deferred revenue, net of current portion			3,479				4,532
Deferred rent, net of current portion			—				3,922

Total liabilities			237,875				158,022
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; NaN issued and outstanding			—				—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 62,705,481 shares issued and outstanding at September 30, 2019; 100,000,000 shares authorized; 60,829,308 shares issued and outstanding at December 31, 2018			6				6
Additional paid-in capital			884,585				857,156
Accumulated other comprehensive loss			(30	)			(244	)
Accumulated deficit			(824,691	)			(673,748	)

Total stockholders’ equity			59,870				183,170

Total liabilities and stockholders’ equity		$	297,745			$	341,192


	Three Months Ended, September 30,								Nine Months Ended September 30,
	2019				2018				2019				2018
Revenues:
Product revenue, net		$	12,821			$	—			$	12,821			$	—
License and other revenue			328				239				9,976				30,130

Total revenues			13,149				239				22,797				30,130
Operating expenses:
Cost of sales			1,013				—				1,013				—
Research and development			26,270				36,427				90,761				122,482
Selling, general and administrative			25,267				12,966				77,032				30,076

Total operating expenses			52,550				49,393				168,806				152,558

Loss from operations			(39,401	)			(49,154	)			(146,009	)			(122,428	)
Other income (expense):
Interest income			1,137				1,098				4,320				2,260
Interest expense			(3,093	)			—				(9,180	)			—
Other income (expense)			10				(13	)			(36	)			(20	)

Total other (expense) income, net			(1,946	)			1,085				(4,896	)			2,240

Loss before income taxes			(41,347	)			(48,069	)			(150,905	)			(120,188	)
Income tax provision			(20	)			(14	)			(38	)			(9	)
										��
Net loss		$	(41,367	)		$	(48,083	)		$	(150,943	)		$	(120,197	)

Net loss per share—basic and diluted		$	(0.67	)		$	(0.79	)		$	(2.46	)		$	(2.17	)

Weighted-average number of common shares outstanding used in net loss per share—basic and diluted			62,092,841				60,586,511				61,297,249				55,465,261


	Three Months Ended September 30,								Nine Months Ended September 30,
	2019				2018				2019				2018
Net loss		$	(41,367	)		$	(48,083	)		$	(150,943	)		$	(120,197	)

Comprehensive income (loss)
Unrealized (loss) gain on investments			(59	)			110				250				105
Foreign currency translation adjustments			(32	)			(3	)			(36	)			(41	)

Comprehensive loss		$	(41,458	)		$	(47,976	)		$	(150,729	)		$	(120,133	)


	January 1, 2019 Prior to ASC 842 Adoption			ASC 842 Adjustment				January 1, 2019 as Adjusted
Consolidated balance sheet data (in thousands):
Operating lease and right-of-use assets (1)		$	—		$	11,711			$	11,711
Deferred rent (2)		$	390		$	(390	)		$	—
Deferred rent non-current (2)		$	3,922		$	(3,922	)		$	—
Operating lease liabilities (3)		$	—		$	1,175			$	1,175
Non-current operating lease liabilities (3)		$	—		$	14,848			$	14,848


	Shares			Weighted- Average Exercise Price Per Share			Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		8,917,084			$	13.78		7.4		$	8,197
Granted		2,996,650				8.08
Exercised		(131,143	)			5.55
Canceled		(1,571,701	)			13.77

Outstanding at September 30, 2019		10,210,890				12.22		7.0		$	12,443

Exercisable at September 30, 2019		5,426,297			$	14.64		5.5		$	7,869


	Number of Shares Underlying RSUs			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2018		25,000			$	9.87
Granted		1,049,900				9.16
Forfeited		(230,300	)			9.24
Vested		(10,000	)			8.13

Unvested at September 30, 2019		834,600			$	9.18


Years end ing December 31,	Future Minimum Payments
2019		$	793
2020			3,200
2021			3,277
2022			3,447
2023 and thereafter			10,453

Total minimum lease payments		$	21,170
Less: present value adjustment			(5,944	)

Present value of minimum lease payments		$	15,226


	Nine Months Ended September 30, 2019
Contractual interest expense		$	3,882
Amortization of debt discount			5,045
Amortization of debt issuance costs			253

Total interest expense		$	9,180

Large accelerated filer

Accelerated filer

Non-accelerated
filer

Smaller reporting company

Emerging growth company